<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Convalescent plasma for people with COVID‐19: a living systematic review - Iannizzi, C - 2023 | Cochrane Library</title> <meta content="Convalescent plasma for people with COVID‐19: a living systematic review - Iannizzi, C - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Convalescent plasma for people with COVID‐19: a living systematic review - Iannizzi, C - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013600.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Convalescent plasma for people with COVID‐19: a living systematic review" name="citation_title"/> <meta content="Claire Iannizzi" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Khai Li Chai" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Vanessa Piechotta" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Sarah J Valk" name="citation_author"/> <meta content="Catherine Kimber" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Erica M Wood" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Abigail A Lamikanra" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="David J Roberts" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Zoe McQuilten" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Cynthia So-Osman" name="citation_author"/> <meta content="Aikaj Jindal" name="citation_author"/> <meta content="SPS Hospitals" name="citation_author_institution"/> <meta content="Lise J Estcourt" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="lise.estcourt@nhsbt.nhs.uk" name="citation_author_email"/> <meta content="Nina Kreuzberger&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Nicole Skoetz&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD013600.pub6" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/05/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*COVID-19 [therapy]; COVID-19 Serotherapy; Immunoglobulins; SARS-CoV-2; *Virus Diseases" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013600.pub6&amp;doi=10.1002/14651858.CD013600.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013600\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013600\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","th","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013600.pub6",title:"Convalescent plasma for people with COVID\\u201019: a living systematic review",firstPublishedDate:"May 10, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013600.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013600.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013600.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013600.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013600.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013600.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013600.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013600.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013600.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013600.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1931 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013600.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0158"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-sec-0142"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/appendices#CD013600-sec-0163"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/supinfo/CD013600-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/supinfo/CD013600-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2024 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Convalescent plasma for people with COVID‐19: a living systematic review</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0004">Claire Iannizzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0005">Khai Li Chai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0006">Vanessa Piechotta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0007">Sarah J Valk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0008">Catherine Kimber</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0009">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0010">Erica M Wood</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0011">Abigail A Lamikanra</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0012">David J Roberts</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0013">Zoe McQuilten</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0014">Cynthia So-Osman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0015">Aikaj Jindal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0016"><i class="icon corresponding-author fa fa-envelope"></i>Lise J Estcourt</a></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0017">Nina Kreuzberger</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information#CD013600-cr-0018">Nicole Skoetz</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information/en#CD013600-sec-0187">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 May 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013600.pub6">https://doi.org/10.1002/14651858.CD013600.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013600-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013600-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013600-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013600-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013600-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013600-abs-0004">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013600-abs-0001" lang="en"> <section id="CD013600-sec-0001"> <h3 class="title" id="CD013600-sec-0001">Background</h3> <p>Convalescent plasma may reduce mortality in patients with viral respiratory diseases, and is being investigated as a potential therapy for coronavirus disease 2019 (COVID‐19). A thorough understanding of the current body of evidence regarding benefits and risks of this intervention is required. </p> </section> <section id="CD013600-sec-0002"> <h3 class="title" id="CD013600-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of convalescent plasma transfusion in the treatment of people with COVID‐19; and to maintain the currency of the evidence using a living systematic review approach. </p> </section> <section id="CD013600-sec-0003"> <h3 class="title" id="CD013600-sec-0003">Search methods</h3> <p>To identify completed and ongoing studies, we searched the World Health Organization (WHO) COVID‐19 Global literature on coronavirus disease Research Database, MEDLINE, Embase, Cochrane COVID‐19 Study Register, and the Epistemonikos COVID‐19 L*OVE Platform. We searched monthly until 03 March 2022. </p> </section> <section id="CD013600-sec-0004"> <h3 class="title" id="CD013600-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) evaluating convalescent plasma for COVID‐19, irrespective of disease severity, age, gender or ethnicity. </p> <p>We excluded studies that included populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)), as well as studies evaluating standard immunoglobulin. </p> </section> <section id="CD013600-sec-0005"> <h3 class="title" id="CD013600-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology.</p> <p>To assess bias in included studies we used RoB 2. We used the GRADE approach to rate the certainty of evidence for the following outcomes: all‐cause mortality at up to day 28, worsening and improvement of clinical status (for individuals with moderate to severe disease), hospital admission or death, COVID‐19 symptoms resolution (for individuals with mild disease), quality of life, grade 3 or 4 adverse events, and serious adverse events. </p> </section> <section id="CD013600-sec-0006"> <h3 class="title" id="CD013600-sec-0006">Main results</h3> <p>In this fourth review update version, we included 33RCTs with 24,861 participants, of whom 11,432 received convalescent plasma. Of these, nine studies are single‐centre studies and 24 are multi‐centre studies. Fourteen studies took place in America, eight in Europe, three in South‐East Asia, two in Africa, two in western Pacific and three in eastern Mediterranean regions and one in multiple regions. We identified a further 49 ongoingstudies evaluating convalescent plasma, and 33 studies reporting as being completed. </p> <p><b>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</b> </p> <p>29 RCTs investigated the use of convalescent plasma for 22,728 participants with moderate to severe disease. 23 RCTs with 22,020 participants compared convalescent plasma to placebo or standard care alone, five compared to standard plasma and one compared to human immunoglobulin. We evaluate subgroups on detection of antibodies detection, symptom onset, country income groups and several co‐morbidities in the full text. </p> <p><i>Convalescent plasma versus placebo or standard care alone</i> </p> <p>Convalescent plasma does not reduce all‐cause mortality at up to day 28 (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.03; 220 per 1000; 21 RCTs, 19,021 participants; high‐certainty evidence). It has little to no impact on need for invasive mechanical ventilation, or death (RR 1.03, 95% CI 0.97 to 1.11; 296 per 1000; 6 RCTs, 14,477 participants; high‐certainty evidence) and has no impact on whether participants are discharged from hospital (RR 1.00, 95% CI 0.97 to 1.02; 665 per 1000; 6 RCTs, 12,721 participants; high‐certainty evidence). Convalescent plasma may have little to no impact on quality of life (MD 1.00, 95% CI −2.14 to 4.14; 1 RCT, 483 participants; low‐certainty evidence). Convalescent plasma may have little to no impact on the risk of grades 3 and 4 adverse events (RR 1.17, 95% CI 0.96 to 1.42; 212 per 1000; 6 RCTs, 2392 participants; low‐certainty evidence). It has probably little to no effect on the risk of serious adverse events (RR 1.14, 95% CI 0.91 to 1.44; 135 per 1000; 6 RCTs, 3901 participants; moderate‐certainty evidence). </p> <p><i>Convalescent plasma versus standard plasma</i> </p> <p>We are uncertain whether convalescent plasma reduces or increases all‐cause mortality at up to day 28 (RR 0.73, 95% CI 0.45 to 1.19; 129 per 1000; 4 RCTs, 484 participants; very low‐certainty evidence). We are uncertain whether convalescent plasma reduces or increases the need for invasive mechanical ventilation, or death (RR 5.59, 95% CI 0.29 to 108.38; 311 per 1000; 1 study, 34 participants; very low‐certainty evidence) and whether it reduces or increases the risk of serious adverse events (RR 0.80, 95% CI 0.55 to 1.15; 236 per 1000; 3 RCTs, 327 participants; very low‐certainty evidence). We did not identify any study reporting other key outcomes. </p> <p><i>Convalescent plasma versus human immunoglobulin</i> </p> <p>Convalescent plasma may have little to no effect on all‐cause mortality at up to day 28 (RR 1.07, 95% CI 0.76 to 1.50; 464 per 1000; 1 study, 190 participants; low‐certainty evidence). We did not identify any study reporting other key outcomes. </p> <p><b>Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and mild disease</b> </p> <p>We identified two RCTs reporting on 536 participants, comparing convalescent plasma to placebo or standard care alone, and two RCTs reporting on 1597 participants with mild disease, comparing convalescent plasma to standard plasma. </p> <p><i>Convalescent plasma versus placebo or standard care alone</i> </p> <p>We are uncertain whether convalescent plasma reduces all‐cause mortality at up to day 28 (odds ratio (OR) 0.36, 95% CI 0.09 to 1.46; 8 per 1000; 2 RCTs, 536 participants; very low‐certainty evidence). It may have little to no effect on admission to hospital or death within 28 days (RR 1.05, 95% CI 0.60 to 1.84; 117 per 1000; 1 RCT, 376 participants; low‐certainty evidence), on time to COVID‐19 symptom resolution (hazard ratio (HR) 1.05, 95% CI 0.85 to 1.30; 483 per 1000; 1 RCT, 376 participants; low‐certainty evidence), on the risk of grades 3 and 4 adverse events (RR 1.29, 95% CI 0.75 to 2.19; 144 per 1000; 1 RCT, 376 participants; low‐certainty evidence) and the risk of serious adverse events (RR 1.14, 95% CI 0.66 to 1.94; 133 per 1000; 1 RCT, 376 participants; low‐certainty evidence). We did not identify any study reporting other key outcomes. </p> <p><i>Convalescent plasma versus standard plasma</i> </p> <p>We are uncertain whether convalescent plasma reduces all‐cause mortality at up to day 28 (OR 0.30, 95% CI 0.05 to 1.75; 2 per 1000; 2 RCTs, 1597 participants; very low‐certainty evidence). It probably reduces admission to hospital or death within 28 days (RR 0.49, 95% CI 0.31 to 0.75; 36 per 1000; 2 RCTs, 1595 participants; moderate‐certainty evidence). Convalescent plasma may have little to no effect on initial symptom resolution at up to day 28 (RR 1.12, 95% CI 0.98 to 1.27; 1 RCT, 416 participants; low‐certainty evidence). We did not identify any study reporting other key outcomes. </p> <p>This is a living systematic review. We search monthly for new evidence and update the review when we identify relevant new evidence. </p> </section> <section id="CD013600-sec-0007"> <h3 class="title" id="CD013600-sec-0007">Authors' conclusions</h3> <p>For the comparison of convalescent plasma versus placebo or standard care alone, our certainty in the evidence that convalescent plasma for individuals with moderate to severe disease does not reduce mortality and has little to no impact on clinical improvement or worsening is high. It probably has little to no effect on SAEs. For individuals with mild disease, we have very‐low to low certainty evidence for most primary outcomes and moderate certainty for hospital admission or death. There are 49 ongoing studies, and 33 studies reported as complete in a trials registry. Publication of ongoing studies might resolve some of the uncertainties around convalescent plasma therapy for people with asymptomatic or mild disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013600-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013600-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013600-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013600-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013600-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013600-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013600-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD013600-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013600-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013600-abs-0002" lang="en"> <h3>Is plasma from the blood of people who have recovered from COVID‐19 an effective treatment for other people with COVID‐19? </h3> <p><b>Key messages</b> </p> <p>• We are very confident that plasma from the blood of people who have recovered from COVID‐19 (convalescent plasma) has no benefits for the treatment of people with moderate to severe COVID‐19. </p> <p>• Convalescent plasma may have little to no benefit for treating people with mild COVID‐19. </p> <p>• We found49 ongoing studies and 33 finished studies with unpublished results. We will update our review with evidence from these studies as soon as possible. New evidence may answer our remaining questions, especially for people with mild COVID‐19 or who have no symptoms. </p> <p><b>What is convalescent plasma?</b> </p> <p>The body produces antibodies as one of its defences against infection. Antibodies are found in part of the blood called plasma. Plasma from people who have recovered from the COVID‐19 virus contains COVID‐19 antibodies, and it can be used to make convalescent plasma, which is plasma that contains these antibodies. </p> <p>Convalescent plasma has been used successfully to treat some viruses. This treatment (given by a drip or injection) is generally well‐tolerated, but can cause unwanted effects. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out whether convalescent plasma is an effective treatment for people with confirmed COVID‐19. We looked at: </p> <p>• deaths from any cause after treatment with convalescent plasma;</p> <p>• worsening of patients’ condition, measured by the number of people who needed support from a ventilator (a machine that helps people breathe if they cannot breathe on their own) or died; and improvement of patients’ condition, measured by participants discharged from hospital; </p> <p>• quality of life; and</p> <p>• unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated convalescent plasma to treat people with COVID‐19. Studies could take place anywhere in the world and include people of any age, gender or ethnicity, with mild, moderate or severe COVID‐19. </p> <p>Where possible we pooled (added up) the studies’ results to analyse them. We rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 33 studies with 24,861 participants that investigated convalescent plasma. Among these, 29 studies included people with moderate to severe COVID‐19 and four studies included people with mild COVID‐19. Studies mainly took place in hospitals, in countries all over the world. The following findings apply to convalescent plasma compared with placebo (the same treatment but with no active ingredients) or standard care. </p> <p><b>People with moderate to severe COVID‐19</b> </p> <p>• Convalescent plasma makes no difference to <b>deaths from any cause</b> at up to 28 days after treatment, about 225 in 1000 people died, compared to 220 in 1000 people who had been given convalescent plasma (21 studies, 19,021 people). </p> <p>• Convalescent plasma makes little to no difference to <b>needing invasive mechanical ventilation or dying</b> . About 287 in 1000 people needed invasive mechanical ventilation support or died, compared to 296 in 1000 people given convalescent plasma (6 studies, 14,477 people). It makes no difference to<b>participants being discharged from hospital.</b> About 665 in 1000 people were discharged from hospital, compared to 665 in 1000 people given convalescent plasma (6 studies, 12,721 people). </p> <p>• Convalescent plasma probably makes no difference to <b>serious unwanted effects,</b> about 118 in 1000 people may be at risk to have serious unwanted effects compared to 133 in 1000 people given convalescent plasma (6 studies, 4901 people). </p> <p>• Convalescent plasma may result in no difference in <b>quality of life</b> (1 study, 483 people). </p> <p><b>People with mild COVID‐19</b> <br/>• Convalescent plasma may result in no difference to <b>deaths from any cause</b> up to 28 days after treatment. About 22 in 1000 people given placebo or standard care died, compared to 9 in 1000 people given convalescent plasma (2 studies, 536 people). </p> <p>• Convalescent plasma may result in no difference to <b>admission to hospital or death within 28 days</b> after treatment. About 112 in 1000 people given placebo or standard care were admitted to hospital or died, compared to 117 in 1000 people given convalescent plasma (1 study, 376 people). </p> <p>• Convalescent plasma may result in no difference in the <b>time until COVID‐19 symptoms resolved</b> (1 study, 376 people). </p> <p>• Convalescent plasma may result in no difference to <b>serious unwanted effects</b>. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>• We are very confident in the evidence for deaths from any cause, and worsening and improvement of patients’ condition in people with moderate to severe COVID‐19, as the results are consistent and are from many high‐quality studies. </p> <p>• Our confidence in the other evidence for people with moderate and severe, and mild COVID‐19 is still limited, as we could not identify enough consistent results from a lot of studies. </p> <p>• We still have little evidence on quality of life and for people with mild disease, and none for people without COVID‐19 symptoms. </p> <p><b>How up to date is this evidence?</b> </p> <p>This is the fifth version of our review. The evidence is up to date to 03 March 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013600-sec-0158" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013600-sec-0158"></div> <h3 class="title" id="CD013600-sec-0159">Implications for practice</h3> <section id="CD013600-sec-0159"> <p>We are very confident in the evidence that convalescent plasma for the treatment of individuals with moderate to severe disease does not reduce mortality and has little to no impact on the need for invasive mechanical ventilation or death (clinical worsening) and participants discharged from hospital (clinical improvement) when compared to placebo or standard care alone. Convalescent plasma probably has little to no effect on the risk of serious adverse events in such patients. Further, we identified very low‐ to low‐certainty evidence for the effects of convalescent plasma when compared to standard plasma in individuals with moderate to severe COVID‐19. Convalescent plasma therapy may result in little to no impact on serious adverse events, in such patients. For the same population, when compared to human immunoglobulin treatment, we identified low‐certainty evidence for mortality. </p> <p>For individuals with a diagnosis of SARS‐CoV‐2 infection and mild disease, we currently have low confidence in the evidence for the effects of convalescent plasma when compared to placebo or standard care alone. For the same comparison, convalescent plasma may result in a clinically relevant increased risk of grade 3 or 4 adverse events and serious adverse events. When compared to standard plasma, we have low‐ to moderate confidence in the evidence on the effects of convalescent plasma, in such patients. </p> </section> <h3 class="title" id="CD013600-sec-0160">Implications for research</h3> <section id="CD013600-sec-0160"> <p>For the fifth version of this living systematic review investigating the use of convalescent plasma for people with COVID‐19, we included data from 33 randomised controlled trials (RCTs) reporting on the effectiveness and safety of convalescent plasma, and in total considered the experience of 24,861 participants. Studies should more consistently report outcomes and, if relevant, consider the competing event of death. Further, studies should consider standard treatment changes during the pandemic to ensure and improve comparability in terms of co‐interventions administered in all study arms. Concerning adverse events, studies should try to blind at least outcome assessors, and report adverse events consistently, and for both the intervention and the control arm. </p> <p>Additional studies evaluating convalescent plasma treatment in asymptomatic participants would be of interest to assess whether the intervention is more effective if given earlier in the course of the disease. Additional data are needed for patients with any disease severity who are immune‐suppressed, as well as subgroup data for plasma from SARS‐CoV‐2 variants, and different ethnicities. Future studies should also report outcomes based on antibody titre in the donor plasma administered. </p> <p>There are 49 ongoing studies evaluating convalescent plasma and 30 studies reporting in a trials registry as being completed or terminated. We will also keep track of three platform trials. Publication of the results might resolve some of the uncertainties around convalescent plasma therapy for people with asymptomatic or mild disease and for certain subgroups. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013600-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013600-sec-0008"></div> <div class="table" id="CD013600-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with moderate to severe disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to placebo or standard care alone for individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> individualswith moderate to severe disease<br/><b>Setting:</b> inpatient <br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> placebo or standard care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or standard care alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28 ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b><br/>(207 to 232) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.92 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19021<br/>(21 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma does not reduce all‐cause mortality at up to day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b><br/>(278 to 319) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.97 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14477<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma has little to no impact on the need for invasive mechanical ventilation, or death at day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>665 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>665 per 1000</b><br/>(645 to 678) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.97 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12721<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma has no impact on whether participants are discharged from hospital.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with EQ‐5D‐5L‐questionnaire, at day 28 (0 indicates worst heath and 100 best health) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life, assessed with EQ‐5D‐5L‐questionnaire, at day 28 was <b>72</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1 higher</b><br/>(2.14 lower to 4.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on quality of life at up to day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b><br/>(174 to 257) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b><br/>(0.96 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2392<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on the risk of grades 3 and 4 adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ total<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b><br/>(108 to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.91 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3901<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma probably has little to no effect on the risk of serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423533352409190077" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423533352409190077</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because of few participants and wide confidence interval.<br/><sup>b</sup> Downgraded one level for serious indirectness, because some studies did not provide clear definitions of how the adverse events were measured and the number of events are inconsistent.<br/><sup>c</sup> Downgraded one level for publication bias, because safety outcomes were assessed and reported in most studies for convalescent plasma group only. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013600-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to standard plasma for individuals with moderate to severe disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to standard plasma for individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> individuals with moderate to severe disease<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> standard plasma </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard plasma</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><br/>(80 to 210) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73</b><br/>(0.45 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduces or increases all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>311 per 1000</b><br/>(16 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.59</b><br/>(0.29 to 108.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduces or increases the risk of need for invasive mechanical ventilation, or death at day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with standardised scales at longest follow‐up ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The identified study reported the number of participants experiencing any event of grade 3 (27/147 in CP group versus 17/72 in SP group), or grade 4 (26/147 in CP group versus 15/72 in SP group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduced or increases the risk for grades 3 and 4 adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b><br/>(162 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.55 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduces or increases the risk of serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575562054934976" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575562054934976</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for serious inconsistency, because direction of effect is not consistent in all the studies.<br/><sup>b</sup> Downgraded two levels for very serious imprecision, because of few participants and because optimal information size is not met at a power of 0.80.<br/><sup>c</sup> Downgraded three levels due to extreme imprecision, because of extremely few participants, extremely few events, very wide confidence interval and optimal information size is not met at a power of 0.80.<br/><sup>d</sup> Downgraded one level for serious indirectness, because definition of outcomes was different to the definition used in our review.<br/><sup>e</sup> Downgraded two levels for very serious imprecision, because of few participants, and few events.<br/><sup>f</sup> Downgraded two levels for very serious imprecision, because of few participants, and few events and optimal information size is not met at a power of 0.80.<br/><sup>g</sup> Downgraded one level for publication bias, because safety outcomes were assessed and reported in most studies for convalescent plasma group only. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013600-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to human immunoglobulin for individuals with moderate to severe disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to human immunoglobulin for individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> individuals with moderate to severe disease<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> human immunoglobulin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with human immunoglobulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b><br/>(329 to 650) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.76 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no effect on all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432005298021526745" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432005298021526745</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious imprecision, because of few events, few participants and because optimal information size is not met at a power of 0.90. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013600-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with mild disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to placebo or standard care alone for individuals with mild disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> outpatients withmild disease<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> placebo or standard care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or standard care alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(2 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.36</b><br/>(0.09 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not convalescent plasma reduces all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to hospital or death within 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(67 to 206) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.60 to 1.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on admission to hospital or death within 28 days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom resolution‐ all initial symptoms resolved ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Time to symptom resolution (absolute effect calculated for day 12)<br/>follow‐up: 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 1.05</b><br/>(0.85 to 1.30)<br/>[symptoms resolution ] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Convalescent plasma may have little to no impact on time to symptom resolution.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b><br/>(406 to 555) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with standardised scales at longest follow‐up ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/>(84 to 245) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b><br/>(0.75 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on the risk of grades 3 and 4 adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/>(77 to 227) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.66 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on the risk of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575913930302502" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575913930302502</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for serious indirectness, because outcome definition did not exactly match our definition (defined as death associated with COVID‐19).<br/><sup>b</sup> Downgraded two levels for very serious imprecision, because of few participants, few events, wide confidence intervals and because optimal information size is not met for a power of 0.90. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013600-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to standard plasma for outpatients with mild disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to standard plasma for outpatients withmild disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> outpatients withmild disease<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> standard plasma </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard plasma</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/>(0 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.30</b><br/>(0.05 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1597<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not convalescent plasma reduces all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to hospital or death within 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/>(23 to 55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b><br/>(0.31 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1595<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma probably reduces admission to hospital or death at up to day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom resolution‐ all initial symptoms resolved<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>657 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>736 per 1000</b><br/>(644 to 835) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.98 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>416<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no effect on symptom resolution at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to symptom resolution ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with standardised scales ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432020765287988004" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432020765287988004</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by three levels for extremely serious imprecision, because few events, extremely wide confidence intervals and because optimal information size is not met for a power of 0.90. <br/><sup>b</sup> Downgraded one level for serious imprecision, because optimal information size is not met for a power of 0.90.<br/><sup>c</sup> Downgraded by two levels for very serious imprecision, because few events, very wide confidence intervals and because optimal information size is not met for a power of 0.90. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013600-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013600-sec-0009"></div> <p>‐</p> <section id="CD013600-sec-0010"> <h3 class="title" id="CD013600-sec-0010">Description of the condition</h3> <p>The clinical syndrome coronavirus disease 2019 (COVID‐19) is a new, rapidly emerging zoonotic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; <a href="./references#CD013600-bbs2-0403" title="World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available from www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>). On 22 March 2020, the World Health Organization (WHO) declared the current COVID‐19 outbreak to be a pandemic, with the outbreak resulting in more than 535 million confirmed cases and over 6.3 million deaths worldwide as of June 2022 (<a href="./references#CD013600-bbs2-0404" title="World Health Organization (WHO). Rolling updates on coronavirus diseases (COVID‐19). Available from www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (accessed 22 March 2021).">WHO 2020b</a>; <a href="https://covid19.who.int/" target="_blank">WHO 2021a</a>). Although there are similarities with historic coronavirus epidemics, with severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) responsible for 813 and 858 deaths respectively, the scale and impact of the COVID‐19 pandemic present unprecedented challenges to health facilities and healthcare workers all over the world (<a href="./references#CD013600-bbs2-0401" title="World Health Organization (WHO). Cumulative number of reported probable cases of SARS. Available from www.who.int/csr/sars/country/2003_07_11/en/ (accessed 22 March 2021).">WHO 2007</a>; <a href="./references#CD013600-bbs2-0402" title="World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV). Available from www.who.int/emergencies/mers-cov/en/ (accessed 22 March 2021).">WHO 2019</a>). Concurrently, new SARS‐CoV‐2 variants emerged, potentially having an effect on the transmission and characteristics of the disease, the effectiveness of vaccines and treatments, or on public health and social measures (<a href="./references#CD013600-bbs2-0410" title="World Health Organization. Tracking SARS-CoV-2 variants. Awailable from www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed 17 October 2022).">WHO 2022b</a>). </p> <p>Early reports suggested case fatality rates between 0.7% and 4% (<a href="./references#CD013600-bbs2-0403" title="World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available from www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>; <a href="./references#CD013600-bbs2-0405" title="World Health Organization (WHO). Coronavirus disease (COVID-19) situation report-209; 16 August 2020. Available from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200816-covid-19-sitrep-209.pdf?sfvrsn=5dde1ca2_2 (accessed 22 March 2021).">WHO 2020c</a>). More recent reports estimate wide‐ranging case fatality rates, as low as 0. 1% in Singapore and up to 5.2% in Peru (<a href="./references#CD013600-bbs2-0353" title="Johns Hopkins University and Medicine. Mortality analyses. Available from https://coronavirus.jhu.edu/data/mortality (last accessed 21 September 2022).">Johns Hopkins 2022</a>). However, these numbers should be interpreted with great care due to testing availability, underreporting of cases and delays from confirmation of a case to time of death (<a href="./references#CD013600-bbs2-0356" title="Kim D-H, ChoeYJ , Jeong J-Y. Understanding and interpretation of case fatality rate of coronavirus disease 2019. Journal of Korean Medical Science2020;35(12):e137. [DOI: 10.3346/jkms.2020.35.e137]">Kim 2020</a>), ethnicity, underlying health conditions, access to health care, and socioeconomic status (<a href="./references#CD013600-bbs2-0411" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv [Preprint]2020. [DOI: doi.org/10.1101/2020.05.06.20092999]">Williamson 2020</a>). </p> <p>The median incubation period and time to symptom onset of SARS‐CoV‐2 was reported to be five days, with 97.5% of cases developing symptoms within 11.5 days of infection (<a href="./references#CD013600-bbs2-0319" title="BrandalLT , MacDonaldE , VenetiL , RavloT , LangeH , NaseerU , et al. Outbreak caused by the SARS-CoV-2 omicron variant in Norway, November to December 2021. European Surveillance2021;26(50):2101147. [DOI: 10.2807/1560-7917.ES.2021.26.50.2101147]">Brandal 2021</a>; <a href="./references#CD013600-bbs2-0360" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577-82. [DOI: 10.7326/M20-0504]">Lauer 2020</a>). However, the median incubation time depends on the virus variant and is estimated to be only three days (range: 0 to 8 days) in case of the Omicron variant, which is shorter compared to the estimate for the Delta variant, for instance, or other previous variants (<a href="./references#CD013600-bbs2-0319" title="BrandalLT , MacDonaldE , VenetiL , RavloT , LangeH , NaseerU , et al. Outbreak caused by the SARS-CoV-2 omicron variant in Norway, November to December 2021. European Surveillance2021;26(50):2101147. [DOI: 10.2807/1560-7917.ES.2021.26.50.2101147]">Brandal 2021</a>). Common signs and symptoms can include fever, dry cough, fatigue and sputum production (<a href="./references#CD013600-bbs2-0403" title="World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available from www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>). Postviral olfactory dysfunction is reported in 5% to 85% of cases, with loss of both smell and taste reported (<a href="./references#CD013600-bbs2-0351" title="Izquierdo-DominguezA , Rojas-LechugaMJ , MullolJ , AlobidI . Olfactory dysfunction in the COVID-19 outbreak. Journal of Investigational Allergology &amp; Clinical Immunology2020;30(5):317-26. [DOI: 10.18176/jiaci.0567]">Izquierdo‐Dominguez 2020</a>). Other less commonly reported signs and symptoms are shortness of breath, sore throat, headache, myalgia or arthralgia, chills, nausea or vomiting, nasal congestion, diarrhoea, haemoptysis and conjunctival congestion (<a href="./references#CD013600-bbs2-0403" title="World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available from www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>). Of the reported cases, 80% are estimated to have a mild or asymptomatic course of infection, and an estimated 5% of cases are admitted to the intensive care unit (ICU) with acute respiratory distress syndrome (ARDS), septic shock, multiple organ failure, or all three conditions (<a href="./references#CD013600-bbs2-0391" title="Team NCPERE. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China. China CDC Weekly2020;2(8):113-22. [DOI: 10.3760/cma.j.issn.0254-6450.2020.02.003]">Team 2020</a>; <a href="./references#CD013600-bbs2-0403" title="World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available from www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>). A risk factor for developing infection and progressing to severe disease is old age, with people aged over 80 years at highest risk of mortality. Other risk factors are cardiovascular disease, obesity, hypertension, diabetes, chronic respiratory disease, cancer and compromised immune status (<a href="./references#CD013600-bbs2-0324" title="ChenL , XiongJ , BaoL , ShiY . Convalescent plasma as a potential therapy for COVID-19. Lancet Infectious Diseases2020;20(4):398-400.">Chen 2020a</a>; <a href="./references#CD013600-bbs2-0349" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506. [DOI: 10.1016/S0140-6736(20)30183-5]">Huang 2020</a>; <a href="./references#CD013600-bbs2-0365" title="LiangW , GuanW , ChenR , WangW , LiJ , XuK , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology2020;21(3):335-7. [DOI: 10.1016/S1470-2045(20)30096-6]">Liang 2020</a>; <a href="./references#CD013600-bbs2-0403" title="World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available from www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 22 March 2021).">WHO 2020a</a>; <a href="./references#CD013600-bbs2-0412" title="WuC , ChenX , CaiY , XiaJ , ZhouX , XuS , et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine2020;180:934-43. [DOI: 10.1001/jamainternmed.2020.0994]">Wu 2020a</a>). Individuals who are immune‐compromised are at higher risk of adverse outcomes from COVID‐19, including people who have received recent chemotherapy and chemoimmunotherapy, recipients of solid organ and allogeneic transplants and individuals with haematological malignancies and solid organ cancer (<a href="./references#CD013600-bbs2-0323" title="Chavez-MacGregorM , LeiX , ZhaoH , ScheetP , GiordanoSH . Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncology2022;8(1):69-78. [DOI: 10.1001/jamaoncol.2021.5148]">Chavez‐MacGregor 2022</a>; <a href="./references#CD013600-bbs2-0337" title="FungM , BabikJM . COVID-19 in immunocompromised hosts: what we know so far. Clinical Infectious Diseases2020;72:340-50. [DOI: 10.1093/cid/ciaa863]">Fung 2020</a>). </p> <p>SARS‐CoV‐2 is a positive‐sense, single‐stranded ribonucleic acid (RNA) virus with a large genome. There are indications that the virus is capable of inducing an excessive immune reaction in the host, with highly activated but decreased numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T cells detected in the peripheral blood of people with COVID‐19 (<a href="./references#CD013600-bbs2-0414" title="XuZ , ShiL , WangY , ZhangJ , HuangL , ZhangC , et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Medicine2020;8(4):420-2. [DOI: 10.1016/S2213-2600(20)30076-X]">Xu 2020a</a>). Early reports also showed that people critically ill with COVID‐19 frequently exhibit a hypercoagulable state and endothelial inflammation, which is hypothesised to lead to the high burden of thromboembolic events seen in this population (<a href="./references#CD013600-bbs2-0329" title="DrigginE , MadhavanMV , BikdeliB , ChuichT , LaracyJ , Biondi-ZoccaiG , et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. Journal of the American College of Cardiology2020;75(18):2352-71.">Driggin 2020</a>). SARS‐CoV‐2 binds to the angiotensin‐converting enzyme 2 (ACE2). ACE2 is a protein that functions as the receptor, facilitating entry of SARS‐CoV‐2 into the host cell, and is most abundant on type II alveolar cells in the lungs (<a href="./references#CD013600-bbs2-0395" title="TolouianR , VahedSZ , GhiyasvandS , TolouianA , ArdalanM . COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. Journal of Renal Injury Prevention2020;9(2):e19. [DOI: 10.34172/jrip.2020.19]">Tolouian 2020</a>; <a href="./references#CD013600-bbs2-0398" title="Van de VeerdonkF , NeteaMG , Van DeurenM , Van der MeerJW , De MastQ , BruggemannRJ , et al. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints [Preprint]2020. [DOI: 10.20944/preprints202004.0023.v1]">Van de Veerdonk 2020</a>). </p> <p>Widespread availability of vaccines against SARS‐CoV‐2 has reduced infections and the risk of severe disease. However, individuals who are immunocompromised have reduced rates of seroconversion following vaccination and therefore remain susceptible to severe COVID‐19 and in need of effective therapies (<a href="./references#CD013600-bbs2-0361" title="LeeAR , WongSY , ChaiLY , LeeSC , LeeMX , MuthiahMD , et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ2022;376:e068632. [DOI: 2022;376:e068632]">Lee 2022</a>; <a href="./references#CD013600-bbs2-0392" title="TehJS , CoussementJ , NeohZC , SpelmanT , LazarakisS , SlavinMA , et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Advances2022;6(7):2014-34. [DOI: 10.1182/bloodadvances.2021006333]">Teh 2022</a>). </p> </section> <section id="CD013600-sec-0011"> <h3 class="title" id="CD013600-sec-0011">Description of the intervention</h3> <p>Convalescent plasma and convalescent serum prepared from convalescent plasma are interventions that have been used in the past to treat conditions when no vaccine or pharmacological interventions were available. Diphtheria, pneumococcal pneumonia, hepatitis A and B, mumps, polio, measles, and rabies are conditions where convalescent plasma has been shown to be effective (<a href="./references#CD013600-bbs2-0330" title="EiblMM . History of immunoglobulin replacement. Immunology and Allergy Clinics of North America2008;28(4):737-64. [DOI: 10.1016/j.iac.2008.06.004]">Eibl 2008</a>). </p> <p>A systematic review has shown that convalescent plasma may have clinical benefit for people with influenza and SARS (<a href="./references#CD013600-bbs2-0367" title="Mair-JenkinsJ , Saavedra-CamposM , BaillieJK , ClearyP , KhawFM , LimWS , et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. Journal of Infectious Diseases2015;211(1):80-90. [DOI: 10.1093/infdis/jiu396]">Mair‐Jenkins 2015</a>). This systematic review included observational studies and randomised controlled trials (RCTs) that investigated the use of convalescent plasma or serum for treating severe acute respiratory infections of laboratory‐confirmed or suspected viral aetiology, and included investigations with patients of any age and sex. Control interventions consisted of sham or placebo therapy and no therapy. Although the included studies were generally small and of low quality, with a moderate to high risk of bias, the review authors concluded that the use of convalescent plasma may reduce mortality, and appears safe (<a href="./references#CD013600-bbs2-0367" title="Mair-JenkinsJ , Saavedra-CamposM , BaillieJK , ClearyP , KhawFM , LimWS , et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. Journal of Infectious Diseases2015;211(1):80-90. [DOI: 10.1093/infdis/jiu396]">Mair‐Jenkins 2015</a>). The authors also suggested that the effectiveness of convalescent plasma in reducing hospital length of stay is dependent on early administration of the therapy, and use as prophylaxis is more likely to be beneficial than treating severe disease. However, the optimal timing and dosage of convalescent plasma therapy are unknown. </p> <p>There is conflicting evidence about the effect of convalescent plasma for treating severe acute respiratory infections. For instance, studies that investigated the effectiveness of immune plasma for influenza showed no benefit (<a href="./references#CD013600-bbs2-0315" title="BeigelJH , TebasP , Elie-TurenneMC , BajwaE , BellTE , CairnsB , et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respiratory Medicine2017;5(6):500-11. [DOI: 10.1016/S2213-2600(17)30174-1]">Beigel 2017</a>; <a href="./references#CD013600-bbs2-0316" title="BeigelJH , AgaE , Elie-Turenne M-C, ChoJ , TebasP , ClarkCL , et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine2019;7(11):941-50. [DOI: 10.1016/S2213-2600(19)30199-7]">Beigel 2019</a>). </p> <p>Although convalescent plasma is generally thought to be a well‐tolerated therapy, adverse events can occur. Limited information is available about specific adverse events related to convalescent plasma therapy, but symptoms that have been reported are similar to those for other types of plasma blood components, including fever or chills, allergic reactions, and transfusion‐related acute lung injury (TRALI; <a href="./references#CD013600-bbs2-0316" title="BeigelJH , AgaE , Elie-Turenne M-C, ChoJ , TebasP , ClarkCL , et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine2019;7(11):941-50. [DOI: 10.1016/S2213-2600(19)30199-7]">Beigel 2019</a>; <a href="./references#CD013600-bbs2-0325" title="ChunS , ChungCR , HaYE , HanTH , KiCS , KangES , et al. Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East respiratory syndrome. Annals of Laboratory Medicine2016;36(4):393-5. [DOI: 10.3343/alm.2016.36.4.393]">Chun 2016</a>; <a href="./references#CD013600-bbs2-0366" title="LukeTC , KilbaneEM , JacksonJL , HoffmanSL . Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?Annals of Internal Medicine2006;145(8):599-609.">Luke 2006</a>). Furthermore, the transfer of coagulation factors present in plasma products is potentially harmful for people with COVID‐19, who are already at an increased risk of thromboembolic events (<a href="./references#CD013600-bbs2-0329" title="DrigginE , MadhavanMV , BikdeliB , ChuichT , LaracyJ , Biondi-ZoccaiG , et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. Journal of the American College of Cardiology2020;75(18):2352-71.">Driggin 2020</a>). Plasma transfusions are also known to cause transfusion‐associated circulatory overload (TACO). TACO and TRALI are especially important to consider, because COVID‐19 patients with comorbidities, who might be eligible for experimental treatment with convalescent plasma therapy, are at an increased risk of these adverse events. Risk‐mitigation strategies can be implemented to prevent TRALI. These include limiting donations from female donors, especially those with a history of pregnancy, and screening donors for antibodies that are implicated in TRALI (<a href="./references#CD013600-bbs2-0375" title="OtrockZK , LiuC , GrossmanBJ . Transfusion‐related acute lung injury risk mitigation: an update. Vox Sanguinis2017;112(8):694-703.">Otrock 2017</a>). In addition to the aforementioned adverse events, transfusion‐transmitted infections, red blood cell allo‐immunisation and haemolytic transfusion reactions have also been described following plasma transfusion, although they are less common (<a href="./references#CD013600-bbs2-0376" title="PandeyS , VyasGN . Adverse effects of plasma transfusion. Transfusion2012;52 Suppl 1:65S-79S.">Pandey 2012</a>). Pathogen inactivation can be implemented to decrease the risk of transmitting infections by transfusion (<a href="./references#CD013600-bbs2-0384" title="RockG . A comparison of methods of pathogen inactivation of FFP. Vox Sanguinis2011;100(2):169-78.">Rock 2011</a>), with likely preservation of neutralising antibodies (<a href="./references#CD013600-bbs2-0336" title="FocosiD , FranchiniM . Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfusion Clinique et Biologique2021;28(2):132-4. [DOI: 10.1016/j.tracli.2021.02.005]">Focosi 2021</a>; <a href="./references#CD013600-bbs2-0358" title="KostinAI , LundgrenMN , BulanovAY , LadyginaEA , ChirkovaKS , GintsburgAL , et al. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. Vox Sang2021;116(6):665-72. [DOI: 10.1111/vox.13056]">Kostin 2021</a>; <a href="./references#CD013600-bbs2-0359" title="LarreaL , CastroE , NavarroL , VeraB , Francés-GómezC , Sánchez-SendraB , et al. Preservation of anti-SARS-CoV-2 neutralising antibodies in convalescent plasma after pathogen reduction with methylene blue and visible light. Blood Transfusion2022;20(3):206-12. [DOI: 10.2450/2021.0136-21]">Larrea 2022</a>). </p> <p>A theoretical risk related to virus‐specific antibodies, which are transferred with convalescent plasma administration, is antibody‐dependent enhancement of infection (<a href="./references#CD013600-bbs2-0372" title="MorensDM . Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clinical Infectious Diseases1994;19(3):500-12.">Morens 1994</a>). Here, virus‐binding antibodies facilitate the entry and replication of virus particles into monocytes, macrophages and granulocytic cells and thereby increase the risk of more severe disease in the infected host. Although antibody‐dependent enhancement has not been demonstrated in COVID‐19, it has been seen with previous coronavirus infections when the antibodies given targeted a different serotype of the virus (<a href="./references#CD013600-bbs2-0399" title="WanY , ShangJ , SunS , TaiW , ChenJ , GengQ , et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Journal of Virology2020;94(5):e02015-19.">Wan 2020</a>; <a href="./references#CD013600-bbs2-0400" title="Wang S-F, Tseng S-P, Yen C-H, Yang J-Y, Tsao C-H, Shen C-W, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochemical and Biophysical Research Communications2014;451(2):208-14.">Wang 2014</a>). A mechanism for antibody‐dependent enhancement in COVID‐19 has recently been proposed, with non‐neutralising antibodies to variable S domains potentially enabling an alternative infection pathway via Fc receptor‐mediated uptake (<a href="./references#CD013600-bbs2-0382" title="RickeD , MaloneR . Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE). Preprints [Preprint]2020. [DOI: 10.20944/preprints202003.0138.v1]">Ricke 2020</a>). Antibody‐dependent enhancement is therefore a potentially harmful consequence of convalescent plasma therapy for COVID‐19. </p> <p>In summary, the benefits of the intervention for convalescent plasma should be carefully considered in view of the risks of adverse events. </p> </section> <section id="CD013600-sec-0012"> <h3 class="title" id="CD013600-sec-0012">How the intervention might work</h3> <p>Convalescent plasma contains pathogen‐specific neutralising antibodies, which can neutralise viral particles and may confer passive immunity to recipients. The duration of conferred protection can differ depending on the timing of administration, ranging from weeks to months after treatment (<a href="./references#CD013600-bbs2-0320" title="CasadevallA , PirofskiL . The convalescent sera option for containing COVID-19. Journal of Clinical Investigation2020;130(4):1545-8.">Casadevall 2020</a>). </p> <p>By neutralising SARS‐CoV‐2 particles, early treatment with convalescent plasma is postulated to increase the patient’s own capacity to clear the initial inoculum (<a href="./references#CD013600-bbs2-0320" title="CasadevallA , PirofskiL . The convalescent sera option for containing COVID-19. Journal of Clinical Investigation2020;130(4):1545-8.">Casadevall 2020</a>; <a href="./references#CD013600-bbs2-0383" title="RobbinsJB , SchneersonR , SzuSC . Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. Journal of Infectious Diseases1995;171(6):1387-98.">Robbins 1995</a>). This could lead to a reduction in mortality and fewer hospitalised patients progressing to the ICU. Furthermore, convalescent plasma may reduce the length of ICU stay in critically ill patients (<a href="./references#CD013600-bbs2-0367" title="Mair-JenkinsJ , Saavedra-CamposM , BaillieJK , ClearyP , KhawFM , LimWS , et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. Journal of Infectious Diseases2015;211(1):80-90. [DOI: 10.1093/infdis/jiu396]">Mair‐Jenkins 2015</a>), thus helping to lift pressure from global healthcare systems and increasing ICU capacity. </p> <p>Although, initially re‐infection was not thought to be likely (<a href="./references#CD013600-bbs2-0313" title="BaoL , DengW , GaoH , XiaoC , LiuJ , XueJ , et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv [Preprint]2020. [DOI: 10.1101/2020.03.13.990226]">Bao 2020a</a>; <a href="./references#CD013600-bbs2-0413" title="WuF , WangA , LiuM , WangQ , ChenJ , XiaS , et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv [Preprint]2020. [DOI: 110.1101/2020.03.30.2004736]">Wu 2020b</a>), this has changed since the end of 2021 when Omicron variants of SARS‐CoV‐2 became dominant (<a href="./references#CD013600-bbs2-0374" title="Office for National Statistics (ONS). Coronavirus (COVID-19) Infection Survey, characteristics of people testing positive for COVID-19. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveycharacteristicsofpeopletestingpositiveforcovid19uk/21september2022#cite-this-statistical-bulletin 21 September 2022.">ONS 2022</a>). </p> <p>This implies that convalescent plasma from people who have recovered from SARS‐CoV‐2 infection may be capable of conferring passive immunity. Retrospective studies also observed a potential correlation between the level of antibody titres in convalescent plasma and recovery after treatment (<a href="./references#CD013600-bbs2-0355" title="JoynerMJ , CarterRE , SenefeldJW , KlassenSA , MillsJR , JohnsonPW , et al. Convalescent plasma antibody levels and the risk of death from COVID-19. New England Journal of Medicine2021;384:1015-27. [DOI: 10.1056/NEJMoa2031893]">Joyner 2021</a>; <a href="./references#CD013600-bbs2-0213" title="ShenC , WangZ , ZhaoF , YangY , LiJ , YuanJ , et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA2020;323(16):1582-9. [DOI: 10.1001/jama.2020.4783]">Shen 2020</a>). It is important to note, however, that research in other coronavirus species has shown that immunity may not be long‐lasting, with two to three years of protection estimated from work with SARS and MERS (<a href="./references#CD013600-bbs2-0370" title="MoH , ZengG , RenX , LiH , KeC , TanY , et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology2006;11(1):49-53. [DOI: 10.1111/j.1440-1843.2006.00783.x]">Mo 2006</a>; <a href="./references#CD013600-bbs2-0379" title="PayneDC , IblanI , RhaB , AlgasrawiS , HinA , Al NsourM , et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerging Infectious Disease Journal2016;22(10):1824-6. [DOI: 10.3201/eid2210.160706]">Payne 2016</a>). Furthermore, there are indications that the severity of infection has an impact on antibody titres, with less‐severe disease leading to lower neutralising antibody response in people with SARS and COVID‐19 (<a href="./references#CD013600-bbs2-0346" title="HoMS , ChenWJ , ChenHY , LinSF , WangMC , DiJ , et al. Neutralizing antibody response and SARS severity. Emerging Infectious Diseases2005;11(11):1730-7.">Ho 2005</a>; <a href="./references#CD013600-bbs2-0416" title="ZhaoJ , YuanQ , WangH , LiuW , LiaoX , SuY , et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medRxiv [Preprint]2020. [DOI: 10.1101/2020.03.02.20030189]">Zhao 2020</a>). It is unclear exactly how often reinfection occurs, with the burden of reinfection likely to be underestimated, while at the same time a number of case reports of severe reinfection have been published (<a href="./references#CD013600-bbs2-0350" title="Iwasaki Akiko. What reinfections mean for COVID-19. Lancet Infectious Diseases2021;21(1):3-5.">Iwasaki 2021</a>). </p> </section> <section id="CD013600-sec-0013"> <h3 class="title" id="CD013600-sec-0013">Why it is important to do this review</h3> <p>There is an ongoing need for information to guide clinical decision making for COVID‐19 patients. Pharmacological treatment options have been and are continuing to be investigated in many ongoing trials, with treatment guidelines updated accordingly (<a href="./references#CD013600-bbs2-0409" title="Therapeutics and COVID-19: living guideline. Available from www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4 (accessed 16 October 2022).">WHO 2022a</a>). Current treatments that have been shown to be effective in non‐severe COVID‐19 at risk of hospitalisation include nirmatrelvir‐ritonavir, remdesivir and molnupiravir (<a href="./references#CD013600-bbs2-0409" title="Therapeutics and COVID-19: living guideline. Available from www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4 (accessed 16 October 2022).">WHO 2022a</a>), and in severe or critical COVID‐19 systemic corticosteroids, interleukin‐6 receptor blockers (tocilizumab and sarilumab), and baracitinib (Janus kinase inhibitor) (<a href="./references#CD013600-bbs2-0317" title="BeigelJH , TomashekKM , DoddLE , MehtaAK , ZingmanBS , KalilAC , et al. Remdesivir for the treatment of COVID-19 — preliminary report. New England Journal of Medicine2020;383(10):992-4. [DOI: 10.1056/NEJMoa2007764]">Beigel 2020</a>; <a href="./references#CD013600-bbs2-0347" title="HorbyP , LimWS , EmbersonJ , MafhamM , BellJ , LinsellL , et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv [Preprint]2020. [DOI: doi.org/10.1101/2020.06.22.20137273]">Horby 2020</a>; <a href="./references#CD013600-bbs2-0348" title="HorbyPW , Pessoa-AmorimG , PetoL , BrightlingCE , SarkarR , ThomasK , et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.02.11.21249258]">Horby 2021a</a>; <a href="./references#CD013600-bbs2-0409" title="Therapeutics and COVID-19: living guideline. Available from www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.4 (accessed 16 October 2022).">WHO 2022a</a>). Current treatment also consists of supportive care with extracorporeal membrane oxygenation in severe cases and oxygen supply in less severe cases (<a href="./references#CD013600-bbs2-0321" title="Centers for Disease Control and Prevention (CDC). Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Available from www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html (accessed 22 March 2021).">CDC 2020</a>; <a href="./references#CD013600-bbs2-0406" title="World Health Organization (WHO). Clinical management of severe acute respiratory infection (SARI) when COVID19 disease is suspected: interim guidance. World Health Organization2020;WHO/2019-nCoV/clinical/2020.4.">WHO 2020d</a>). Although the risk of hospitalisation and death has decreased during the course of the pandemic with emergence of different variants including omicron (<a href="./references#CD013600-bbs2-0312" title="AdjeiS , HongK , MolinariNM , Bull-OttersonL , AjaniUA , GundlapalliAV , et al. Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods — United States, April 2020–June 2022. Morbidity and Mortality Weekly Report2022;71(37):1182–9. [DOI: 10.15585/mmwr.mm7137a4]">Adjei 2022</a>; <a href="./references#CD013600-bbs2-0373" title="NybergT , FergusonNM , NashSG , WebsterHH , FlaxmanS , AndrewsN , et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet2022;399:1303-12. [DOI: 10.1016/S0140-6736(22)00462-7]">Nyberg 2022</a>; <a href="./references#CD013600-bbs2-0396" title="UlloaAC , BuchanSA , DanemanN , BrownKA . Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada. JAMA2022;327(13):1286–8. [DOI: 10.1001/jama.2022.2274]">Ulloa 2022</a>), even with current therapies, patients with COVID‐19 remain at increased risk of mortality, particularly older individuals and those with comorbidities (<a href="./references#CD013600-bbs2-0312" title="AdjeiS , HongK , MolinariNM , Bull-OttersonL , AjaniUA , GundlapalliAV , et al. Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods — United States, April 2020–June 2022. Morbidity and Mortality Weekly Report2022;71(37):1182–9. [DOI: 10.15585/mmwr.mm7137a4]">Adjei 2022</a>). </p> <p>Currently approved and available COVID‐19 vaccines have been shown to be well‐tolerated and effective (<a href="./references#CD013600-bbs2-0322" title="Centers for Disease Control and Prevention. Vaccines for COVID-19. Available from https://www.cdc.gov/coronavirus/2019-ncov/vaccines (accessed 25 May 2022).">CDC 2022</a>). They can prevent transmission to those who are at risk for becoming seriously ill and reduce the risk for developing severe disease (<a href="./references#CD013600-bbs2-0322" title="Centers for Disease Control and Prevention. Vaccines for COVID-19. Available from https://www.cdc.gov/coronavirus/2019-ncov/vaccines (accessed 25 May 2022).">CDC 2022</a>). However, even with the available effective vaccines, not everyone can be effectively vaccinated; for example, people who are temporarily or permanently immune‐compromised. Convalescent plasma can be prepared and made rapidly available by blood banks and hospitals when enough potential donors have recovered from the infection, using readily available materials and methods (<a href="./references#CD013600-bbs2-0318" title="BlochEM , ShohamS , CasadevallA , SachaisBS , ShazB , WintersJL , et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation2020;130(6):2757-65.">Bloch 2020</a>). However, its safety and efficacy are not well‐characterised, and there are costs associated with pursuing the use of convalescent plasma for treatment of COVID‐19. </p> <p>A multitude of clinical trials investigating the safety and effectiveness of convalescent plasma have been announced, and their results will need to be interpreted with care. Thus, there needs to be a thorough understanding of the current body of evidence regarding the use of convalescent plasma for people with COVID‐19, and an extensive review of the available literature is required. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013600-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013600-sec-0014"></div> <p>To assess the effectiveness and safety of convalescent plasma transfusion in the treatment of people with COVID‐19; and to maintain the currency of the evidence using a living systematic review approach. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013600-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013600-sec-0015"></div> <section id="CD013600-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013600-sec-0017"> <h4 class="title">Types of studies</h4> <p>The main description of methods is based on a template from Cochrane Haematology and is in line with a series of Cochrane Reviews investigating treatments and therapies for COVID‐19. The protocol for this review was registered with the Center for Open Science on 17 April 2020 (<a href="./references#CD013600-bbs2-0418" title="PiechottaV , ValkSJ , ChaiKL , WoodEM , LamikanraA , KimberC , et al. Safety and effectiveness of convalescent plasma or hyperimmune globulin for people with COVID-19: a rapid review. available at: doi.org/10.17605/OSF.IO/DWF532020. [DOI: 10.17605/OSF.IO/DWF53]">Piechotta 2020a</a>). Amendments that have been made since are summarised in <a href="#CD013600-sec-0191">Differences between protocol and review</a> and <a href="#CD013600-tbl-0006">Table 1</a>. </p> <div class="table" id="CD013600-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of PICO development from protocol stage to current review version</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparators</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study designs</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Protocol</b> </p> <p><b>Piechotta 2020a</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 April 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0001"> <li> <p>Individuals with a confirmed diagnosis of COVID‐19</p> </li> <li> <p>No age, gender or ethnicity restrictions</p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0002"> <li> <p>Populations with other coronavirus diseases</p> </li> <li> <p>Populations with mixed virus diseases, unless the trial authors provide subgroup data for people with COVID‐19 </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0003"> <li> <p>Convalescent plasma</p> </li> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0004"> <li> <p>Standard care</p> </li> <li> <p>Placebo</p> </li> <li> <p>Control treatment (e.g. drug treatments)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients (<a href="./references#CD013600-bbs2-0326" title="Core outcome set developers’ response to COVID-19 (2nd April 2020). Available from www.comet-initiative.org/Studies/Details/1538 (accessed 9 April 2020).">COMET 2020</a>) </p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0005"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0006"> <li> <p>Improvement of clinical symptoms, assessed through need for respiratory support:</p> <ul id="CD013600-list-0007"> <li> <p>oxygen by mask or nasal prongs</p> </li> <li> <p>oxygen by NIV or high‐flow</p> </li> <li> <p>Intubation and MV</p> </li> <li> <p>MV</p> </li> <li> <p>ECMO</p> </li> </ul> </li> <li> <p>30‐day and 90‐day mortality</p> </li> <li> <p>Admission to the ICU</p> </li> <li> <p>Length of stay on the ICU</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Number of participants with grades 3 and grade 4 AEs</p> </li> <li> <p>Number of participants with SAEs</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned inclusion priority, determined by availability of sufficient evidence</b> </p> <p> <ol id="CD013600-list-0008"> <li> <p>RCTs</p> </li> <li> <p>Prospective controlled NRSIs, including quasi‐RCTs, CBA studies, and ITS studies</p> </li> <li> <p>Prospective observational studies with a control group</p> </li> <li> <p>Prospective non‐comparative study designs (e.g. case series)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 1</b> </p> <p><b>Valk 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0009"> <li> <p>Convalescent plasma</p> </li> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0010"> <li> <p>Studies on standard immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based onCOMET Initiative for COVID‐19 patients</p> <p>(COMET 2020)</p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0011"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0012"> <li> <p>Improvement of clinical symptoms, assessed through need for respiratory support:</p> <ul id="CD013600-list-0013"> <li> <p>oxygen by mask or nasal prongs</p> </li> <li> <p>oxygen by NIV or high‐flow</p> </li> <li> <p>intubation and MV</p> </li> <li> <p>MV plus high‐flow oxygen</p> </li> <li> <p>ECMO</p> </li> <li> <p>30‐day and 90‐day mortality</p> </li> </ul> </li> <li> <p>Admission to the intensive care unit</p> </li> <li> <p>Length of stay on the intensive care unit</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0014"> <li> <p>Prospective non‐comparative study designs (e.g. case series)</p> </li> </ul> </p> <p><b>No evidence available for</b> </p> <p> <ul id="CD013600-list-0015"> <li> <p>RCTs</p> </li> <li> <p>NRSIs</p> </li> <li> <p>Prospective observational studies with a control group</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added exclusion criteria</p> <p> <ul id="CD013600-list-0016"> <li> <p>For studies on standard immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Revised secondary outcome "Improvement of clinical symptoms, assessed through need for respiratory support": </p> <p> <ul id="CD013600-list-0017"> <li> <p>added to the fourth bullet point (MV) "plus high‐flow oxygen"</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 2</b> </p> <p><b>Piechotta 2020b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 July 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0018"> <li> <p>Standard care</p> </li> <li> <p>Placebo</p> </li> <li> <p>Control treatment (e.g. drug treatments, standard immunoglobulin)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients</p> <p>(COMET 2020)</p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0019"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0020"> <li> <p>Improvement of clinical symptoms, assessed through need for respiratory support:</p> <ul id="CD013600-list-0021"> <li> <p>Oxygen by mask or nasal prongs</p> </li> <li> <p>Oxygen by NIV or high flow</p> </li> <li> <p>Intubation and MV</p> </li> <li> <p>MV plus high‐flow oxygen</p> </li> <li> <p>ECMO</p> </li> </ul> </li> <li> <p>30‐day and 90‐day mortality</p> </li> <li> <p>Admission to the intensive care unit</p> </li> <li> <p>Length of stay on the intensive care unit</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0022"> <li> <p>RCTs</p> </li> <li> <p>Prospective controlled NRSIs</p> </li> </ul> </p> <p><b>Further inclusion</b> </p> <p> <ul id="CD013600-list-0023"> <li> <p>Prospective and retrospective controlled NRSIs</p> </li> <li> <p>Safety data of prospective and retrospective non‐comparative study designs</p> </li> </ul> </p> <p>According to originally planned inclusion priorities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added eligible control treatment</p> <p> <ul id="CD013600-list-0024"> <li> <p>Standard immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added a secondary outcome:</p> <p> <ul id="CD013600-list-0025"> <li> <p>Quality of life</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added inclusion criteria for safety data</p> <p> <ul id="CD013600-list-0026"> <li> <p>Retrospective controlled NRSIs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 3</b> </p> <p><b>Chai 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 October 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients (COMET 2020)</p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0027"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0028"> <li> <p>Improvement of clinical symptoms, assessed by need for respiratory support with standardised scales (e.g. WHO Clinical Progression Scale (WHO 2020e), WHO Ordinal Scale for Clinical Improvement (WHO 2020f)) </p> </li> <li> <p>30‐day and 90‐day mortality</p> </li> <li> <p>Admission to the intensive care unit</p> </li> <li> <p>Length of stay on the intensive care unit</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Virological response</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0029"> <li> <p>RCTs</p> </li> <li> <p>Prospective controlled NRSIs</p> </li> </ul> </p> <p><b>Further inclusion</b> </p> <p> <ul id="CD013600-list-0030"> <li> <p>Prospective and retrospective controlled NRSIs</p> </li> <li> <p>Safety data of prospective and retrospective non‐comparative study designs</p> </li> </ul> </p> <p>According to originally planned inclusion priorities</p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0031"> <li> <p>Unregistered non‐comparative studies (e.g. case series)</p> </li> <li> <p>Efficacy data of non‐comparative studies</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Revised and renamed secondary outcome “Improvement of clinical symptoms”</p> <p> <ul id="CD013600-list-0032"> <li> <p>Cut‐offs are no longer self‐set, but now based on standardised scales</p> </li> </ul> </p> <p>Added secondary outcome:</p> <p> <ul id="CD013600-list-0033"> <li> <p>Virological response</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added exclusion criteria:</p> <p> <ul id="CD013600-list-0034"> <li> <p>Unregistered non‐comparative studies (e.g. case series)</p> </li> <li> <p>Efficacy data of non‐comparative studies</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0420" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0035"> <li> <p>Individuals with a confirmed diagnosis of COVID‐19</p> </li> <li> <p>No age, gender or ethnicity restrictions</p> </li> <li> <p>Participants with any disease severity</p> </li> <li> <p>Separate analyses for populations with ambulatory mild disease and for hospitalised participants with moderate to severe disease<sup>c</sup> </p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0036"> <li> <p>Populations with other coronavirus diseases</p> </li> <li> <p>Populations with mixed virus diseases, unless the trial authors provide subgroup data for people with COVID‐19 </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0037"> <li> <p>Standard care</p> </li> <li> <p>Placebo (saline solution)</p> </li> <li> <p>Control treatment (e.g. drug treatments, standard immunoglobulin)</p> </li> <li> <p>Standard plasma</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients (COMET 2020), and outcomes prioritised by consumer representatives, referees of previous versions of this review, and the German guideline panel for inpatient therapy of people with COVID‐19. </p> <p><b>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</b>Effectiveness of convalescent plasma </p> <p><i>Prioritised outcomes</i> </p> <p> <ul id="CD013600-list-0038"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and at hospital discharge</p> </li> <li> <p>Clinical status at up to day 28, day 60, and up to longest follow‐up); including</p> <ul id="CD013600-list-0039"> <li> <p>Improvement of clinical status</p> <ul id="CD013600-list-0040"> <li> <p>Liberation from supplemental oxygen in surviving patients i.e. WHO ≤ 4 on the Clinical Progression Scale (WHO 2020e) (for the subgroup of participants requiring any supplemental oxygen or ventilator support at baseline, i.e. WHO ≥ 5); </p> </li> <li> <p>Weaning or liberation from invasive MV in surviving patients i.e. WHO ≤ 6 (for the subgroup of participants requiring invasive mechanical ventilation at baseline, i.e WHO ≥ 7); </p> </li> </ul> </li> <li> <p>Worsening of clinical status</p> <ul id="CD013600-list-0041"> <li> <p>Need for invasive MV i.e. WHO 7‐9 (for the subgroup of participants not requiring invasive MV at baseline, i.e. WHO ≤ 6) </p> </li> <li> <p>Need for non‐invasive MV or high flow i.e. WHO = 6 (for the subgroup of participants not requiring non‐invasive or non‐invasive MV, or high flow oxygen at baseline, i.e WHO ≤ 5); </p> </li> <li> <p>Need for oxygen by mask or nasal prongs i.e. WHO = 5 (for the subgroup of participants not requiring any supplemental oxygen or ventilator support at baseline, i.e WHO ≤ 4) </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 30 days, and longest follow‐up available </p> </li> </ul> </p> <p><i>Additional outcomes</i> </p> <p> <ul id="CD013600-list-0042"> <li> <p>Duration of hospitalisation, or time to discharge from hospital</p> </li> <li> <p>Admission to the intensive care unit (ICU)</p> </li> <li> <p>Length of stay on the ICU, or time to discharge from ICU</p> </li> <li> <p>Viral clearance at baseline, up to 3, 7, and 15 days</p> </li> <li> <p>Need for dialysis</p> </li> </ul> </p> <p>Safety of convalescent plasma </p> <p> <ul id="CD013600-list-0043"> <li> <p>Adverse events (any grade, grade 1‐2, grade 3‐4)</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> <p><b>Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease</b> </p> <p>Effectiveness of convalescent plasma </p> <p><i>Prioritised outcomes</i> </p> <p> <ul id="CD013600-list-0044"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and at longest follow‐up.</p> </li> <li> <p>Development of moderate to severe clinical COVID‐19 symptoms, defined as WHO Clinical Progression Scale ≥ 4 (WHO 2020e), up to longest follow‐up </p> <ul id="CD013600-list-0045"> <li> <p>Need for invasive MV, non‐invasive MV or high flow i.e. WHO ≥ 6, severe disease;</p> <ul id="CD013600-list-0046"> <li> <p>Need for invasive MV i.e. WHO 7‐9;</p> </li> <li> <p>Need for non‐invasive mechanical ventilation or high flow i.e. WHO = 6.</p> </li> </ul> </li> <li> <p>Need for hospitalisation with or without supplemental oxygen i.e. WHO = 4‐5, moderate disease; </p> <ul id="CD013600-list-0047"> <li> <p>Need for oxygen by mask or nasal prongs i.e. WHO = 5;</p> </li> <li> <p>Need for hospitalisation without oxygen therapy i.e. WHO = 4.</p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life at up to 7 days, up to 30 days, and longest follow‐up available</p> </li> </ul> </p> <p><i>Additional outcomes</i> </p> <p> <ul id="CD013600-list-0048"> <li> <p>Admission to hospital</p> </li> <li> <p>Time to symptom onset</p> </li> <li> <p>Length of hospital stay, for subgroup of participants hospitalised during course of disease </p> </li> <li> <p>Admission to the ICU</p> </li> <li> <p>Viral clearance at baseline, up to 3, 7, and 15 days</p> </li> </ul> </p> <p>Safety of convalescent plasma </p> <p> <ul id="CD013600-list-0049"> <li> <p>Adverse events (any grade, grade 1‐2, grade 3‐4)</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0050"> <li> <p>RCTs</p> </li> <li> <p>Prospectively registered single‐arm studies with inclusion of ≥ 500 participants, even if upcoming RCTs report safety data for both groups </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Introduced separate populations<sup>c</sup> </p> <p> <ul id="CD013600-list-0051"> <li> <p>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</p> </li> <li> <p>Individuals with with confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added eligible control treatment</p> <p> <ul id="CD013600-list-0052"> <li> <p>Standard plasma</p> </li> </ul> </p> <p>Added specifications on placebo treatment</p> <p> <ul id="CD013600-list-0053"> <li> <p>Saline solution</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed primary and secondary outcomes to prioritised (included in 'Summary of findings' table) and additional outcomes (not included in 'Summary of findings' table). </p> <p>Revised and specified outcomes per population.</p> <p>Individuals with moderate to severe disease</p> <p> <ul id="CD013600-list-0054"> <li> <p>Outcome measures for all‐cause mortality were summarised below one outcome</p> </li> <li> <p>Sub‐outcomes for clinical improvement, and clinical worsening were introduced</p> </li> <li> <p>'Need for dialysis' was added as additional outcome</p> </li> <li> <p>'Time to discharge from hospital' was renamed to 'duration of hospitalisation, or time to discharge from hospital' to clarify that we are interested in both, continuous and time‐to‐event data. </p> </li> <li> <p>'Virological response' was renamed to 'viral clearance' to clarify that we are interested in test‐negativity and not in changes of viral load. </p> </li> </ul> </p> <p>Added outcomes for individuals with asymptomatic or mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added inclusion criteria</p> <p> <ul id="CD013600-list-0055"> <li> <p>For prospectively registered single‐arm studies with inclusion of ≥ 500 participants, even if upcoming RCTs report safety data for both groups </p> </li> </ul> </p> <p>Added exclusion criteria</p> <p> <ul id="CD013600-list-0056"> <li> <p>Controlled studies not being truly randomised</p> </li> <li> <p>Studies comparing early versus deferred plasma</p> </li> <li> <p>Studies on plasma donors</p> </li> <li> <p>Pharmacokinetics studies</p> </li> <li> <p>Studies terminated early because the sponsor was changed</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Current version)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0057"> <li> <p>Convalescent plasma</p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0058"> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</b>Effectiveness of convalescent plasma </p> <p><i>Primary outcomes</i> </p> <p> <ul id="CD013600-list-0059"> <li> <p>All‐cause mortality at day 28, day 60, time to event, and during hospital stay;</p> </li> <li> <p>Clinical status, at day 28, day 60, and up to the longest follow‐up, including the following: </p> <ul id="CD013600-list-0060"> <li> <p>worsening of clinical status: participants with clinical deterioration (new need for IMV) or death; </p> </li> <li> <p>Improvement of clinical status: participants discharged from hospital. Participants should be discharged without clinical deterioration </p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100, a standardised scale for assessing quality of life) at up to 7 days, up to 28 days, and longest follow‐up available; </p> </li> <li> <p>AEs (any grade, grades 1‐2, grades 3‐4), defined as the number of participants with any event and including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions, headache, thromboembolic events); </p> </li> <li> <p>SAEs, defined as the number of participants with any event.</p> </li> </ul> </p> <p><i>Secondary outcomes</i> </p> <p> <ul id="CD013600-list-0061"> <li> <p>Improvement of clinical status, at day 28 and up to the longest follow‐up, including:</p> <ul id="CD013600-list-0062"> <li> <p>weaning or liberation from IMV in surviving participants;</p> </li> <li> <p>ventilator‐free days (defined as days alive and free from MV);</p> </li> <li> <p>liberation from supplemental oxygen in surviving participants;</p> </li> </ul> </li> <li> <p>Need for dialysis at up to 28 days;</p> </li> <li> <p>Admission to the ICU on day 28;</p> </li> <li> <p>Duration of hospitalisation;</p> </li> <li> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days. </p> </li> </ul> </p> <p><b>Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease</b> </p> <p>Effectiveness of convalescent plasma </p> <p><i>Primary outcomes</i> </p> <p> <ul id="CD013600-list-0063"> <li> <p>All‐cause mortality at day 28, day 60, time to event, and at the longest follow‐up;</p> </li> <li> <p>Admission to hospital or death within 28 days;</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD013600-list-0064"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14, day 28, and up to the longest follow‐up; </p> </li> <li> <p>time to symptom resolution.</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 28 days, and longest follow‐up available; </p> </li> <li> <p>AEs (any grade, grades 1‐2, grades 3‐4)</p> </li> <li> <p>SAEs, defined as the number of participants with any event.</p> </li> </ul> </p> <p><i>Secondary outcomes</i> </p> <p> <ul id="CD013600-list-0065"> <li> <p>Worsening of clinical status, at day 28 and up to the longest follow‐up, including (moderate to severe COVID‐19 symptoms): </p> <ul id="CD013600-list-0066"> <li> <p>need for hospitalisation with the need for oxygen by mask or nasal prongs, or death;</p> </li> <li> <p>Need for IMVor death</p> </li> </ul> </li> <li> <p>Viral clearance, assessed with RT‐PCR for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0067"> <li> <p>RCTs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Removed inclusion criteria:</p> <p> <ul id="CD013600-list-0068"> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We renamed 'Prioritised outcomes' to 'Primary outcomes' and 'Additional outcomes' to 'Secondary outcomes'. </p> <p>We revised and redefined outcomes for individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease: </p> <p> <ul id="CD013600-list-0069"> <li> <p>For the primary outcomes, we renamed the outcome 'all‐cause mortality at hospital discharge' to 'all‐cause mortality during hospital stay' </p> </li> <li> <p>We redefined the outcome of worsening of clinical status to 'new need for IMV or death' (including the competing event of death) and the outcome of improvement of clinical status to 'participants discharged alive'. </p> </li> <li> <p>We added the outcome: 'improvement of clinical status' with 3 sub‐outcomes (weaning or liberation from IMV in surviving participants; ventilator‐free days; and liberation from supplemental oxygen in surviving participants). </p> </li> <li> <p>We removed the secondary outcome 'Length of stay on the ICU or time to discharge from ICU'. </p> </li> </ul> </p> <p>We revised and redefined outcomes for individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease. </p> <p> <ul id="CD013600-list-0070"> <li> <p>We added the outcome</p> <ul id="CD013600-list-0071"> <li> <p>'admission to hospital or death' (including the competing event of death)</p> </li> <li> <p>'symptom resolution' with 2 sub‐outcomes (all initial symptoms resolved and time to symptom resolution) </p> </li> <li> <p>'need for hospitalisation with the need for oxygen by mask or nasal prongs, or death'</p> </li> <li> <p>'need for IMV or death' (including the competing event of death)</p> </li> </ul> </li> <li> <p>We removed the outcome</p> <ul id="CD013600-list-0072"> <li> <p>'development of moderate to severe clinical COVID‐19 symptoms' including all the sub‐outcomes</p> </li> <li> <p>'admission to hospital'</p> </li> <li> <p>'time to symptom onset'</p> </li> <li> <p>'length of hospital stay'</p> </li> <li> <p>'admission to the ICU'</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added exclusion criteria</p> <p> <ul id="CD013600-list-0073"> <li> <p>Prospectively registered single‐arm studies with inclusion of ≥ 500 participants</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>CBA:</b> controlled before‐and‐after; <b>COMET:</b> Core Outcome Measures in Effectiveness Trials; <b>ECMO:</b> extracorporeal membrane oxygenation; <b>ICU:</b> intensive care unit;<b>IMV:</b> invasive mechanical ventilation; <b>ITS:</b> interrupted time series; <b>MV:</b> mechanical ventilation; <b>NIV:</b> non‐invasive ventilation; <b>NRSI:</b> non‐randomised studies of interventions; <b>RCT:</b> randomised controlled trial; <b>RT‐PCR:</b> reverse‐transcription polymerase chain reaction; <b>SAE:</b> serious adverse event; <b>TACO:</b> transfusion‐associated circulatory overload;<b>TAD:</b> transfusion‐associated dyspnoea; <b>TRALI:</b> transfusion‐related acute lung injury; <b>WHO:</b> World Health Organization; <b>WHOQOL‐100:</b> World Health Organization quality‐of‐life scale </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Including changes in study designs and methodology.<br/><sup>b</sup>Changes in PICO compared to the previously published version.<br/><sup>c</sup>According to the latest WHO clinical progression score (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). </p> </div> </div> <p>To assess the benefits and safety of convalescent plasma therapy for the treatment of COVID‐19, we included RCTs, as such studies, if performed appropriately, give the best evidence for experimental therapies in highly controlled therapeutic settings. We used the methods recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0362" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022a</a>). If we had identified non‐standard RCT designs, such as cluster‐randomised trials and cross‐over trials, we would have considered only the results from the first cycle of cross‐over RCTs. </p> <p>We included full‐text publications, preprint articles, abstract publications, and results published in trials registries, if sufficient information was available on study design, characteristics of participants, interventions and outcomes. We did not apply any limitation with respect to the length of follow‐up. </p> </section> <section id="CD013600-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included individuals with a confirmed diagnosis of COVID‐19, with no age, gender or ethnicity restrictions. </p> <p>We included trials that included participants with any disease severity. We performed separate analyses for populations with ambulatory mild disease and for hospitalised participants with moderate to severe disease, according to the latest WHO clinical progression score (see <a href="#CD013600-tbl-0007">Table 2</a>; <a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). </p> <div class="table" id="CD013600-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">World Health Organization clinical progression scale a </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Patient state</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptor</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Score</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uninfected; no viral RNA detected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Ambulatory mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic; viral RNA detected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic; independent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic; assistance needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hospitalised: moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised; no oxygen therapy<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised; oxygen by mask or nasal prongs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hospitalised: severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised; oxygen by non‐invasive mechanical ventilation or high flow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubation and mechanical ventilation; pO<sub>2</sub>/FiO<sub>2</sub> ≥ 150 or SpO<sub>2</sub>/FiO<sub>2</sub> ≥ 200 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive mechanical ventilation; pO<sub>2</sub>/FiO<sub>2</sub> &lt; 150 (SpO<sub>2</sub>/FiO<sub>2</sub> &lt; 200) or vasopressors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive mechanical ventilation; pO<sub>2</sub>/FiO<sub>2</sub> &lt; 150 and vasopressors, dialysis or ECMO </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ECMO:</b> extracorporeal membrane oxygenation; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>pO<sub>2</sub> </b> : partial pressure of oxygen; <b>SpO<sub>2</sub>:</b> oxygen saturation </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>World Health Organization (WHO) clinical progression scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>).<br/><sup>b</sup>If hospitalised for isolation only, record status as for ambulatory patient. </p> </div> </div> <p>We excluded studies that included populations with other coronavirus diseases (SARS or MERS). We also excluded studies that included populations with mixed viral diseases (e.g. influenza), unless the trial authors provided subgroup data for people with COVID‐19. </p> </section> <section id="CD013600-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following intervention.</p> <p> <ul id="CD013600-list-0074"> <li> <p>Convalescent plasma from people who had recovered from SARS‐CoV‐2 infection</p> </li> </ul> </p> <p>We did not include studies on standard immunoglobulin as intervention.</p> <p>We included the following comparisons for the control arm.</p> <p> <ul id="CD013600-list-0075"> <li> <p>Convalescent plasma therapy versus control treatment, for example, drug treatments (including but not limited to hydroxychloroquine, remdesivir), standard immunoglobulin. Co‐interventions were allowed, but must have been comparable between intervention groups. </p> </li> <li> <p>Convalescent plasma versus standard care or placebo (i.e. saline solution)</p> </li> <li> <p>Convalescent plasma versus standard plasma (i.e. fresh frozen plasma)</p> </li> </ul> </p> </section> <section id="CD013600-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes as predefined by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for COVID‐19 patients (<a href="./references#CD013600-bbs2-0326" title="Core outcome set developers’ response to COVID-19 (2nd April 2020). Available from www.comet-initiative.org/Studies/Details/1538 (accessed 9 April 2020).">COMET 2020</a>), and additional outcomes that have been prioritised by consumer representatives, referees of previous versions of this review, and the German guideline panel for inpatient therapy of people with COVID‐19. </p> <p>We defined outcome sets for two populations: individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease, and individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease, according to the WHO clinical progression scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). </p> <p>We assessed disease severity with need for respiratory support according to the WHO clinical progression scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). </p> <section id="CD013600-sec-0021"> <h5 class="title">Timing of outcome measurement</h5> <p>For time‐to‐event outcomes, such as mortality, discharge from hospital, and improvement of clinical symptoms, we included outcome measures representing the longest follow‐up time available. </p> <p>We included all other outcome categories for the observational periods that the study publications reported. We included those adverse events occurring during active treatment and had planned to include long‐term adverse events as well. If sufficient data had been available, we planned to group the measurement time points of eligible outcomes, for example, adverse events and serious adverse events, into those measured directly after treatment (up to seven days after treatment), medium‐term outcomes (15 days after treatment) and longer‐term outcomes (over 30 days after treatment). </p> </section> <section id="CD013600-sec-0022"> <h5 class="title">Primary outcomes</h5> <p>These critical outcomes will be included in the summary of findings tables.</p> <section id="CD013600-sec-0023"> <h6 class="title">Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</h6> <p> <ul id="CD013600-list-0076"> <li> <p>All‐cause mortality at day 28, day 60, time to death and during hospital stay</p> </li> <li> <p>Clinical status, at day 28, day 60, and up to the longest follow‐up, including the following: </p> <ul id="CD013600-list-0077"> <li> <p>worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death; </p> </li> <li> <p>improvement of clinical status: participants discharged from hospital. Participants should be discharged without clinical deterioration </p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100, a standardised scale for assessing quality of life) at up to 7 days, up to 28 days, and longest follow‐up available </p> </li> <li> <p>Adverse events (any grade, grades 1‐2, grades 3‐4), defined as the number of participants with any event and including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, transfusion‐associated dyspnoea (TAD), acute transfusion reactions, headache, thromboembolic events) </p> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)) </p> </li> </ul> </p> </section> <section id="CD013600-sec-0024"> <h6 class="title">Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </h6> <p> <ul id="CD013600-list-0078"> <li> <p>All‐cause mortality at day 28, day 60, time to event, and at the longest follow‐up</p> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD013600-list-0079"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14, day 28, and up to the longest follow‐up; </p> </li> <li> <p>time to symptom resolution</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 28 days, and longest follow‐up available; </p> </li> <li> <p>Adverse events (any grade, grades 1‐2, grades 3‐4)</p> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)) </p> </li> </ul> </p> </section> </section> <section id="CD013600-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>These outcomes will not be included in the summary of findings tables.</p> <section id="CD013600-sec-0026"> <h6 class="title">Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</h6> <p> <ul id="CD013600-list-0080"> <li> <p>Improvement of clinical status, at day 28 and up to the longest follow‐up, including:</p> <ul id="CD013600-list-0081"> <li> <p>weaning or liberation from invasive mechanical ventilation in surviving participants;</p> </li> <li> <p>ventilator‐free days (defined as days alive and free from mechanical ventilation);</p> </li> <li> <p>liberation from supplemental oxygen in surviving participants</p> </li> </ul> </li> <li> <p>Need for dialysis at up to 28 days</p> </li> <li> <p>Admission to the ICU on day 28</p> </li> <li> <p>Duration of hospitalisation</p> </li> <li> <p>Viral clearance, assessed with reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, and up to 3, 7, and 14 days. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0027"> <h6 class="title">Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </h6> <p> <ul id="CD013600-list-0082"> <li> <p>Worsening of clinical status, at day 28 and up to the longest follow‐up, including (moderate to severe COVID‐19 symptoms): </p> <ul id="CD013600-list-0083"> <li> <p>need for hospitalisation with oxygen by mask or nasal prongs, or death;</p> </li> <li> <p>need for invasive mechanical ventilation, or death</p> </li> </ul> </li> <li> <p>Viral clearance, assessed with RT‐PCR for SARS‐CoV‐2 at baseline, and up to 3, 7, and 14 days </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD013600-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <p>We carried out weekly searches until 11 August 2021 and from August 2021 onwards, we carried out monthly searches for completed and ongoing studies. In order to limit language bias, studies reported in all languages were eligible. We checked review search methods and strategies approximately monthly to ensure they reflected any terminology changes in the topic area, or in the databases. We adapted the strategy where necessary. </p> <section id="CD013600-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We designed and tested search strategies for electronic databases according to methods suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0362" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022a</a>). One review author (CD) developed the original strategies and Cochrane Haematology's Information Specialist (IM) peer‐reviewed and revised them at various times, to reflect the current state of knowledge. In this emerging field, we expected that at least study abstracts would be in English. If studies were published in other languages than those our review team could accommodate (English, Dutch, German, French, Italian, Malay and Spanish), we involved <a href="https://taskexchange.cochrane.org/" target="_blank">Cochrane TaskExchange</a> to identify people within Cochrane to translate these studies. </p> <p>As publication bias might influence all subsequent analyses and conclusions, we searched all potentially relevant trials registries in detail to detect ongoing studies as well as studies that had been completed but not yet published. It is mandatory to provide trial results in the trials registry, so we planned to extract and analyse these data, in case results were not published elsewhere. However, no outcome data have yet been added to the trials registries. </p> <p>We searched the following databases and sources from 1 January 2019 to 03 March 2022.</p> <p> <ul id="CD013600-list-0084"> <li> <p>Databases of medical literature (<a href="./appendices#CD013600-sec-0164">Appendix 1</a>): </p> <ul id="CD013600-list-0085"> <li> <p>MEDLINE Ovid (1 January 2020 to 02 March 2022);</p> </li> <li> <p>Embase Ovid (1 January 2020 to 02 March 2022);</p> </li> <li> <p>Cochrane COVID‐19 Study Register (<a href="https://covid-19.cochrane.org/" target="_blank">covid-19.cochrane.org</a>; inception to 03 March 2022)* </p> </li> <li> <p>PubMed (for epublications ahead of print only; 1 January 2020 to 03 March 2022)</p> </li> <li> <p>World Health Organization COVID‐19 Global literature on coronavirus disease (<a href="https://bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov" target="_blank">bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov</a>; inception to 03 March 2022) without references of MEDLINE and PubMed) </p> </li> <li> <p>Epistemonikos, L*OVE List Coronavirus disease (COVID‐19) (<a href="https://app.iloveevidence.com/topics" target="_blank">app.iloveevidence.com</a>; inception to 03 March 2022) </p> </li> </ul> </li> </ul> </p> <p>*The Cochrane COVID‐19 Study Register is a specialised register built within the Cochrane Register of Studies (CRS) and is maintained by Cochrane Information Specialists. Complete data sources and search methods for the register are available at <a href="https://community.cochrane.org/about-covid-19-study-register" target="_blank">community.cochrane.org/about-covid-19-study-register</a>. The register contains study reports from several sources, including: </p> <p> <ul id="CD013600-list-0086"> <li> <p>weekly searches of PubMed;</p> </li> <li> <p>daily searches of ClinicalTrials.gov;</p> </li> <li> <p>weekly searches of Embase.com;</p> </li> <li> <p>weekly searches of the WHO International Clinical Trials Registry Platform (ICTRP);</p> </li> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL).</p> </li> </ul> </p> </section> <section id="CD013600-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of all identified studies, relevant review articles and current treatment guidelines for further literature. We also contacted experts in the field, drug manufacturers and regulatory agencies in order to retrieve information on unpublished studies. </p> </section> </section> <section id="CD013600-sec-0031"> <h3 class="title" id="CD013600-sec-0031">Data collection and analysis</h3> <section id="CD013600-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Using <a href="./references#CD013600-bbs2-0327" title="Covidence. Version accessed 20 April 2020. Melbourne, Australia: Veritas Health Innovation, 2020. Available at covidence.org.">Covidence</a> software, two review authors (from among SJV, KLC, VP, CK, CI and NS) independently screened the results of the search strategies for eligibility, by reading the abstracts. We coded the abstracts as either 'retrieve' or 'do not retrieve'. In the case of disagreement, or if it was unclear whether we should retrieve the abstract or not, we obtained the full‐text publication for further discussion. Two review authors assessed the full‐text articles of selected studies. If the two review authors were unable to reach a consensus, they consulted a third review author to reach a final decision. </p> <p>We documented the study selection process in a flow chart, as recommended in the PRISMA statement (<a href="./references#CD013600-bbs2-0371" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>), and show the total numbers of retrieved references and the numbers of included and excluded studies. We list all studies that we excluded after full‐text assessment and the reasons for their exclusion in the <a href="./references#CD013600-sec-0233" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD013600-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (from among CI, NK, and EA) independently assessed eligible studies obtained in the process of study selection (as described above) for methodological quality and risk of bias. If the review authors were unable to reach a consensus, we consulted a third review author. </p> <p>Two review authors (from among CI, NK, NC, and EA) extracted data using a customised data extraction form, developed in Microsoft Excel (<a href="./references#CD013600-bbs2-0369" title="Microsoft Excel. Microsoft Corporation, 2018. Available from office.microsoft.com/excel.">Microsoft Corporation 2018</a>). Another review author (CI, NK, or NS) verified the accuracy and (where applicable) the plausibility of extractions and assessment. We conducted data extraction according to the guidelines proposed by Cochrane (<a href="./references#CD013600-bbs2-0364" title="LiT , HigginsJP , DeeksJJ , editor(s). Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Li 2022</a>). If the review authors were unable to reach a consensus, we consulted a third review author. </p> <p>We collated multiple reports of one study so that the study, and not the report, is the unit of analysis. </p> <p>We extracted the following information.</p> <p> <ul id="CD013600-list-0087"> <li> <p>General information: author, title, source, publication date, country, language, duplicate publications </p> </li> <li> <p>Quality assessment: study design, bias arising from the randomisation process, due to deviations from the intended interventions, due to missing outcome data, in measurement of the outcome, and in selection of the reported results </p> </li> <li> <p>Study characteristics: trial design, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, treatment cross‐overs, compliance with assigned treatment, length of follow‐up </p> </li> <li> <p>Participant characteristics: age, sex, ethnicity, number of participants recruited/allocated/evaluated, disease, severity of disease, additional diagnoses, previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation), whether the donors were tested by nasal swabs or whether the plasma was tested </p> </li> <li> <p>Interventions: convalescent plasma therapy, concomitant therapy, duration of follow‐up, donors' disease severity, how donations were tested for neutralising antibody </p> <ul id="CD013600-list-0088"> <li> <p>For studies that included a control group: comparator (type)</p> </li> </ul> </li> <li> <p>Outcomes: as specified in <a href="#CD013600-sec-0020">Types of outcome measures</a> </p> </li> </ul> </p> </section> <section id="CD013600-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the RoB 2 to analyse the risk of bias in the underlying study results (<a href="./references#CD013600-bbs2-0390" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). Of interest for this review was the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect) and we performed all assessments with RoB 2 on this effect. The outcomes that we addressed are those specified for inclusion in Summary of findings table 1. Accordingly, the outcomes had been prioritised according to the COMET Initiative for COVID‐19 patients (<a href="./references#CD013600-bbs2-0326" title="Core outcome set developers’ response to COVID-19 (2nd April 2020). Available from www.comet-initiative.org/Studies/Details/1538 (accessed 9 April 2020).">COMET 2020</a>). </p> <p>Two review authors (from among CI, VP and EA) independently assessed the risk of bias for each study result. In case of discrepancies among their judgements or inability to reach consensus, we consulted a third review author to reach a final decision. We assessed the following types of bias as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0343" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook2022.">Higgins 2022a</a>). </p> <p> <ul id="CD013600-list-0089"> <li> <p>Bias arising from the randomisation process</p> </li> <li> <p>Bias due to deviations from the intended interventions</p> </li> <li> <p>Bias due to missing outcome data</p> </li> <li> <p>Bias in measurement of the outcome</p> </li> <li> <p>Bias in selection of the reported result</p> </li> </ul> </p> <p>For cluster‐RCTs, we had planned to add an additional domain to assess bias arising from the timing of identification and recruitment of participants in relation to timing of randomisation, as recommended in the archived RoB 2 guidance for cluster‐randomised trials (<a href="./references#CD013600-bbs2-0331" title="EldridgeS , CampbellM , CampbellM , DahotaA , GiraudeauB , HigginsJT , et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) additional considerations for cluster-randomized trials. Available from www.riskofbias.info/welcome/rob-2-0-tool/archive-rob-2-0-cluster-randomized-trials-2016 (accessed 22 March 2021).">Eldridge 2016</a>), and in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0344" title="HigginsJ , EldridgeS , LiT . Chapter 23: Including variants on randomised trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 202s). Cochrane, 2022. Available from training.cochrane.org/handbook2022.">Higgins 2022b</a>). </p> <p>To address these types of bias we used the signalling questions recommended in RoB 2 and made a judgement using the following options: </p> <p> <ul id="CD013600-list-0090"> <li> <p>'yes': if there is firm evidence that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question); </p> </li> <li> <p>'probably yes': a judgement has been made that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question); </p> </li> <li> <p>'no': if there is firm evidence that the question is unfulfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question); </p> </li> <li> <p>'probably no': a judgement has been made that the question is unfulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question); </p> </li> <li> <p>'no information': if the study report does not provide sufficient information to allow any judgement. </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias: </p> <p> <ul id="CD013600-list-0091"> <li> <p>low risk of bias;</p> </li> <li> <p>some concerns;</p> </li> <li> <p>high risk of bias.</p> </li> </ul> </p> <p>Subsequently, we derived a risk of bias rating for each prespecified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD013600-list-0092"> <li> <p>'Low risk of bias': we judged the trial to be at low risk of bias for all domains for this result. </p> </li> <li> <p>'Some concerns': we judged the trial to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain. </p> </li> <li> <p>'High risk of bias': we judged the trial to be at high risk of bias in at least one domain for the result or we judged the trial to have some concerns for multiple domains in a way that substantially lowers confidence in the results. </p> </li> </ul> </p> <p>We used the RoB 2 Excel tool to implement RoB 2 (available on the <a href="https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2" target="_blank">riskofbiasinfo.org</a> website), added our judgements to the analysis for each assessed study and outcome, and stored our detailed RoB 2 assessments as supplementary online material. We used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our GRADE decision on downgrading for risk of bias. </p> </section> <section id="CD013600-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes, we recorded the mean, standard deviation and total number of participants in both the treatment and control groups. For dichotomous outcomes, we recorded the number of events and total number of participants in both the treatment and control groups. </p> <p>For continuous outcomes using the same scale, we performed analyses using the mean difference (MD) with 95% confidence intervals (CIs). For continuous outcomes measured with different scales, we performed analyses using the standardised mean difference (SMD). For interpreting SMDs, we re‐expressed SMDs in the original units of a particular scale with the most clinical relevance and impact. </p> <p>If available, we extracted and reported hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to symptom resolution). If HRs were not available, we made every effort to estimate the HR as accurately as possible using the available data and a purpose‐built method based on the Parmar and Tierney approach (<a href="./references#CD013600-bbs2-0378" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>; <a href="./references#CD013600-bbs2-0394" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>). If sufficient studies provided HRs, we used HRs rather than risk ratios (RRs) or MDs in a meta‐analysis. </p> <p>For dichotomous outcomes, we planned to report the pooled RR with a 95% CI (<a href="./references#CD013600-bbs2-0328" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). If the number of observed events had been small (less than 5% of sample per group), and if studies had balanced treatment groups, we planned to report the Peto odds ratio (OR) with 95% CI (<a href="./references#CD013600-bbs2-0328" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). </p> </section> <section id="CD013600-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>As recommended in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0345" title="HigginsJP , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook2022.">Higgins 2022c</a>), for studies with multiple treatment groups, we planned to combine arms if they could be regarded as subtypes of the same intervention. </p> <p>When arms could not be pooled this way, we planned to compare each arm with the common comparator separately. For pair‐wise meta‐analysis, we planned to split the ‘shared’ group into two or more groups with smaller sample sizes, and include two or more (reasonably independent) comparisons. For this purpose, for dichotomous outcomes, both the number of events and the total number of participants would be divided up, and for continuous outcomes, the total number of participants would be divided up with unchanged means and standard deviations (SDs). </p> </section> <section id="CD013600-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> suggests a number of potential sources for missing data, which we needed to take into account: at study level, at outcome level and at summary data level (<a href="./references#CD013600-bbs2-0345" title="HigginsJP , LiT , DeeksJJ , editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook2022.">Higgins 2022c</a>). In the first instance, it is of the utmost importance to differentiate between data 'missing at random' and 'not missing at random'. </p> <p>We handled missing data by conducting an available‐case analysis and extracted all the available data. Further, we requested missing data from the study authors. For the previous update version, we contacted 11 principal investigators from included studies (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>). We received six responses: one each from <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a> and <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>, providing all requested information. For this current update version, we contacted another 11 principal investigators from included studies (<a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>). We received three responses (<a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>). </p> <p>We further contacted all principal investigators (where contact information was available) from ongoing studies, asking for their prospective completion dates, as well as completed or terminated studies without published results, and invited them to share their data with us for this update. We received a response from one study (<a href="./references#CD013600-bbs2-0247" title="NCT04374526. Early transfusIon of convalescent plasma in elderly COVID-19 patients to prevent disease progression. Available from clinicaltrials.gov/show/NCT04374526 (first received 5 May 2020). TeofiliL , LandolfiR , CingolaniA , AntinoriA , VecchietJ , SanguinettiM , et al. Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):875. [DOI: 10.1186/s13063-020-04821-1]">NCT04374526</a>), informing us that their trial was completed, but that the results will not be published soon and that they are willing to share their data for this update (no data were received from the investigators before submission of our review). </p> </section> <section id="CD013600-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials using a Chi<sup>2</sup> test with a significance level at P &lt; 0.1, and visual examination. We used the I<sup>2</sup> statistic (<a href="./references#CD013600-bbs2-0340" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), to quantify possible heterogeneity (I<sup>2</sup> &gt; 30% to signify moderate heterogeneity, I<sup>2</sup> &gt; 75% to signify considerable heterogeneity; <a href="./references#CD013600-bbs2-0328" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). If heterogeneity had been above 80%, we would have explored potential causes through sensitivity and subgroup analyses. If we had not found a reason for heterogeneity, we would not have performed a meta‐analysis, but would have only commented on results from all studies and presented these in tables. </p> </section> <section id="CD013600-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>As mentioned above, we searched trials registries to identify completed studies that have not been published elsewhere, to minimise or determine publication bias. We included studies irrespective of their publication status, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0368" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV , ThomasJ . Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook. Available from www.training.cochrane.org/handbook.">McKenzie 2022</a>). </p> <p>For meta‐analyses involving at least 10 studies, we intended to explore potential publication bias by generating a funnel plot and statistically testing this by conducting a linear regression test (<a href="./references#CD013600-bbs2-0390" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). We considered P &lt; 0.1 as significant for this test. </p> </section> <section id="CD013600-sec-0040"> <h4 class="title">Data synthesis</h4> <p>If the clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data in meta‐analysis. We performed separate analyses for populations with ambulatory mild disease and for hospitalised participants with moderate to severe disease, according to the latest WHO clinical progression score (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). We performed analyses according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0328" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). We did not conduct meta‐analyses that included different study designs. We conducted separate meta‐analyses for each comparison. </p> <p>We used <a href="./references#CD013600-bbs2-0381" title="Review Manager Web (RevMan Web). Version 4.21.1. The Cochrane Collaboration, 2022. Available from revman.cochrane.org.">RevMan Web 2022</a> software for analyses. One review author entered the data into the software, and a second review author checked the data for accuracy. </p> <p>We used the random‐effects model for all analyses, as we anticipated that true effects in included studies would be related but would not be the same. For binary outcomes, we based the estimation of the between‐study variance using the Mantel‐Haenszel method. We used the inverse variance method for continuous outcomes, outcomes that include data from cluster‐RCTs, or outcomes where HRs are available. We planned to explore heterogeneity above 80% with subgroup analyses. If we could not find a cause for the heterogeneity or if study outcomes were too clinically heterogeneous to be combined, we did not perform a meta‐analysis, but commented on the results in a narrative analysis, with the results from all studies presented in tables. </p> </section> <section id="CD013600-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses of the following characteristics for our prioritised outcomes, as specified in the Summary of findings section. </p> <p> <ul id="CD013600-list-0093"> <li> <p>Severity of condition for inpatients only (assessed with need for respiratory support according to WHO clinical progression scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>) are divided into: </p> <ul id="CD013600-list-0094"> <li> <p>moderate, when at least 90% of participants are WHO level 4 or higher, and below WHO level 6, </p> </li> <li> <p>severe disease, when at least 90% of participants are WHO level 6 or higher, and</p> </li> <li> <p>moderate to severe, when 90% of participants are in both the 'moderate' and severe' categories </p> </li> </ul> </li> <li> <p>Length of time since symptom onset (divided into up to and including 7 days and more than 7 days) </p> </li> <li> <p>Antibodies in recipients detected at baseline (divided into 'detected in a maximum of 20% of recipients' versus 'detected in at least 80% of recipients') </p> </li> <li> <p>Age of participants (divided into age groups: children, 18 to 64 years, 65 years and older) </p> </li> <li> <p>Pre‐existing conditions (diabetes, respiratory disease, hypertension, immunosuppression)</p> </li> <li> <p>Level of antibody titre in donors (divided into high and low titres, using the US Food and Drug Administration (FDA) definition for 'low' and 'high' titre using the definition provided by the study) </p> </li> <li> <p>Equity impact: sex (divided into female and male)</p> </li> <li> <p>Equity impact: country income groups, according to the World Bank definitions (divided into high‐ and low‐ or middle‐income countries; <a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>) </p> </li> </ul> </p> <p>We used the tests for interaction to test for differences between subgroup results.</p> <p>We had further planned to perform additional subgroup analyses of the following characteristics, but we did not find outcome data for: </p> <p> <ul id="CD013600-list-0095"> <li> <p>SARS‐CoV‐2 variants (e.g. B1.1.7, B.1.351, P.1, and other variants that may occur in the future) </p> </li> <li> <p>Equity impact: ethnicity</p> </li> </ul> </p> </section> <section id="CD013600-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses for the following.</p> <p> <ul id="CD013600-list-0096"> <li> <p>Risk of bias assessment components (studies with a low risk of bias or some concerns versus studies with a high risk of bias) </p> </li> <li> <p>Influence of completed, but not published studies (preprints)</p> </li> <li> <p>Influence of premature termination of studies</p> </li> </ul> </p> </section> <section id="CD013600-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of the evidence for the following outcomes. We prepared three summary of findings tables for the population of individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease, and two summary of findings tables for individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease. </p> <section id="CD013600-sec-0044"> <h5 class="title">Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</h5> <p> <ul id="CD013600-list-0097"> <li> <p>All‐cause mortality at day 28 and if not reported, all‐cause mortality at day 60, time‐to‐event estimate, or during hospital stay </p> </li> <li> <p>Clinical status, at day 28 and if not reported, clinical status at day 60, or up to the longest follow‐up, including the following: </p> <ul id="CD013600-list-0098"> <li> <p>worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death; </p> </li> <li> <p>improvement of clinical status: participants discharged from hospital. Participants should be discharged without clinical deterioration. </p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100, a standardised scale for assessing quality of life) at up to 7 days, up to 28 days, or longest follow‐up available </p> </li> <li> <p>Grade 3 or 4 adverse events, defined as the number of participants with any event and including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions, headache, thromboembolic events) </p> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)). </p> </li> </ul> </p> </section> <section id="CD013600-sec-0045"> <h5 class="title">Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </h5> <p> <ul id="CD013600-list-0099"> <li> <p>All‐cause mortality at day 28 and if not reported, all‐cause mortality at day 60, or time‐to‐event estimate </p> </li> <li> <p>Symptom resolution:</p> <ul id="CD013600-list-0100"> <li> <p>all initial symptoms resolved (asymptomatic) at day 28 and if not reported, at day 14 or up to the longest follow‐up; </p> </li> <li> <p>length of time to symptom resolution</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and functional independence; assessed with standardised scales (e.g. WHOQOL‐100) at longest follow‐up available </p> </li> <li> <p>Grade 3 or 4 adverse events</p> </li> <li> <p>Serious adverse events, defined as the number of participants with any serious adverse event (serious as defined according to CTCAE (Common Terminology Criteria for Adverse Events)) </p> </li> </ul> </p> <p>We followed the current GRADE guidance for these assessments in its entirety, as recommended in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0387" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). We used <a href="./references#CD013600-bbs2-0338" title="GRADEpro GDT. Version accessed 20 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a> software to create a summary of findings table (<a href="./references#CD013600-bbs2-0387" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). For RCTs, we used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our decision on downgrading for risk of bias. For time‐to‐event outcomes, we calculated absolute effects at specific time points, as recommended in the GRADE guidance 27 (<a href="./references#CD013600-bbs2-0388" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31.">Skoetz 2020</a>). We phrased the findings and certainty of the evidence as suggested in the informative statement guidance (<a href="./references#CD013600-bbs2-0385" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35.">Santesso 2020</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013600-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013600-sec-0046"></div> <section id="CD013600-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD013600-sec-0048"> <h4 class="title">Results of the search</h4> <p>As of 3 March 2022, we identified for this update 7625 new records, in addition to the 22,570 potentially relevant records from the previous versions (altogether 30,195 references). After removing duplicates, we screened 6455 new records for this update (altogether 22,267 records) based on their titles and abstracts, and we excluded 21,929 records that did not meet the prespecified inclusion criteria. We evaluated the remaining 338 records and screened the full texts, or, if these were not available, abstract publications or trial registry entries. See <a href="#CD013600-fig-0001">Figure 1</a> for the study flow diagram (<a href="./references#CD013600-bbs2-0371" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>). </p> <div class="figure" id="CD013600-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013600-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We identified 82 eligible studies within 108 citations: 33 included studies (60 records) (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>) and 49 ongoing studies (see 'Ongoing studies' below). </p> </section> <section id="CD013600-sec-0049"> <h4 class="title">Included studies</h4> <p>We included 33 studies reporting on 24,861 participants, of whom 11,432 received convalescent plasma (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>). </p> <section id="CD013600-sec-0050"> <h5 class="title">Design and sample size</h5> <p>All included studies were RCTs and their sample size ranged from 29 participants in <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a> to 11,558 participants in <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>. </p> <section id="CD013600-sec-0051"> <h6 class="title">Setting</h6> <p>The included studies differed considerably in their settings.</p> <p>Six studies were conducted in the USA (<a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>). Three were conducted in India (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>). Two were done in Brazil (<a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>), two in Spain (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>), two in Argentina (<a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>), and two in the Netherlands (<a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>). One was carried out in each of China (<a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>), Bahrain (<a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>), Belgium (<a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>), Ecuador (<a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>), Egypt (<a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>), Germany (<a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>), Iran (<a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>), Italy (<a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>), Mexico (<a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>), South Africa (<a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>), Sweden (<a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>), Uganda (<a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>), and the UK (<a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>). One study was conducted partly in Brazil, Canada, and the USA (<a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>), one was partly in Australia, Belgium, Canada, Croatia, Germany, Hungary, Ireland, Netherlands, New Zealand, Portugal, Romania, Spain, UK and the USA (<a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>), and one was conducted partly in the USA and partly in Brazil (<a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>). </p> <p>Nine studies are single‐centre studies (<a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>), and 24 are multi‐centre studies (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>), with a minimum of two centres for <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>, <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>, <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a> and <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a> and a maximum of 177 centres for <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>. </p> <p>Among the RCTs, 29 were performed in an inpatient setting (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>). Four studies were performed in an outpatient setting (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>). </p> </section> <section id="CD013600-sec-0052"> <h6 class="title">Participants</h6> <p>The RCTs by <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>, <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>, <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>, <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>, <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>, <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>, <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a> and <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a> included participants with moderate disease, and the RCTs by <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>, <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>, <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>, <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a> and <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a> included individuals with severe disease, according to the latest WHO clinical progression score (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). The RCTs by <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>, <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>, <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>, <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>, <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>, <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>, <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>, <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>, <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>, <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>, <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>, <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>, <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>, <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> and <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a> included individuals with both moderate and severe disease, according to the latest WHO clinical progression score (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). The RCTs by <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>, <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>, <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a> and <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a> included populations with mild disease. </p> </section> <section id="CD013600-sec-0053"> <h6 class="title">Interventions</h6> <p>Twenty‐five RCTs compared convalescent plasma with standard care, with or without placebo (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>), and seven RCTs compared convalescent plasma with standard plasma (<a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>). One RCT compared convalescent plasma with human immunoglobulin (<a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>). </p> <p>The dose and volume of plasma given in the studies that we evaluated for efficacy and safety varied. The total volume of convalescent plasma transfused varied between 200 mL and 600 mL of plasma, with participants receiving between one dose of plasma (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>), one to two doses of plasma (<a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>), and two or more doses of plasma (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>). </p> <section id="CD013600-sec-0054"> <p><b>Plasma donors</b></p> <p>All included RCTs determined antibody titres in donors, except one (<a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>). Twelve RCTs reported antibody titres in donors' plasma (<a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>), 12 RCTs reported neutralising antibody titres in donors' plasma (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>), and eight did not report antibody titre in donors (<a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>). </p> <p>Of the included studies, 30 RCTs reported the donors' eligibility criteria (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>). They also reported some descriptive information about donors, such as their age, gender and disease severity, and the time from disease recovery or RT‐PCR virus detection, or both. Among those RCTs reporting the sex of donors, in <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>, <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>, <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>, <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a> and <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>, most of the donors were male (94%, 88%, 91%, 96%, 59% and 65% respectively). In <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>, <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a> and <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>, all donors were male. </p> <p>Please refer to the <a href="./references#CD013600-sec-0232" title="">Characteristics of included studies</a> for more detailed information. </p> </section> </section> <section id="CD013600-sec-0055"> <h6 class="title">Outcomes</h6> <p>A list of outcomes and the applied method for which transformation of data and recalculations were made can be found in <a href="./appendices#CD013600-sec-0171">Appendix 2</a>. </p> <section id="CD013600-sec-0056"> <p><b>Efficacy outcomes</b></p> <p>We prioritised different efficacy outcomes, based on the setting and the disease severity in participants of the included RCTs (see <a href="#CD013600-sec-0020">Types of outcome measures</a>). </p> <p>Among the RCTs that included individuals with moderate to severe disease, 26 studies reported 28‐day mortality (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>) and five studies also reported all‐cause mortality during hospital stay (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>). Nine RCTs reported worsening of clinical status, assessed by the need for invasive mechanical ventilation or death (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>). Six RCTs reported improvement of clinical status, assessed by the number of participants discharged from hospital (<a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>). One of the included RCTs reported quality of life (<a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>). Nine RCTs reported the safety outcome, adverse event of any grade (<a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>); six RCTs reported the safety outcome, grade 3 or 4 adverse events (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>); and 10 RCTs reported serious adverse events (<a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>). </p> <p>Among the RCTs that included individuals with asymptomatic or mild disease, four reported 28‐day mortality (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>). Three RCTs reported admission to hospital or death within 28 days (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>). One RCT reported symptom resolution, assessed by 'all initial symptoms resolved' (<a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>), and one RCT reported time to symptom resolution (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). No RCTs for individuals with asymptomatic or mild disease reported quality of life. One RCT reported the safety outcomes, grade 3 or 4 adverse events and serious adverse events (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). </p> </section> <section id="CD013600-sec-0057"> <p><b>Safety outcomes</b></p> <p>Eighteen RCTs (<a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>; <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>; <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>; <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>; <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>; <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>; <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>; <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>; <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>; <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a>; <a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a>; <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>; <a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>), reported adverse events or serious adverse events, or both, for all the participants. From these 18 studies, we extracted safety data from 7953 participants, with safety data for 4913 participants who received convalescent plasma and 3040 participants who did not receive convalescent plasma. All the other included RCTs reported transfusion‐related adverse events for the participants receiving convalescent plasma (<a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a>; <a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a>; <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>; <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a>; <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>), and for the participants receiving standard plasma (<a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>; <a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>). From these studies, we extracted safety data from 7528 participants who received convalescent plasma only and 903 participants who received the standard plasma. </p> <p>Please refer to the <a href="./references#CD013600-sec-0232" title="">Characteristics of included studies</a> for more detailed information. </p> </section> </section> </section> <section id="CD013600-sec-0058"> <h5 class="title">Ongoing studies</h5> <p>Of the 49 ongoing studies, all are RCTs(see <a href="#CD013600-tbl-0008">Table 3</a>). Of the 49 RCTs, 16 were scheduled to be completed in 2020 and planned to evaluate between 15 and 480 participants, but according to the trial registry, five are not yet recruiting, and nine are still recruiting. Twenty‐three RCTs were expected to be completed in 2021, and planned to evaluate between 15 and 2400 participants. They were scheduled to be completed by the time of writing, but according to the trial registry, five are not yet recruiting, three are still recruiting and 15 are active, but not recruiting. Eight further RCTs are planned to be completed in 2022: <a href="./references#CD013600-bbs2-0269" title="CTRI/2020/05/025346. A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID-19 patients. Available from ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43005 (first received 5 May 2020). ">CTRI/2020/05/025346</a>, randomising 90 participants; <a href="./references#CD013600-bbs2-0271" title="EUCTR2020-001632-10. A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease. Available from www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE (first received 20 April 2020). JanssenM , SchakelU , Djuka FokouU , KrisamJ , StermannJ , KriegsmannK , et al. A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):828. ">EUCTR2020‐001632‐10</a> randomising 174 participants; <a href="./references#CD013600-bbs2-0275" title="SURCOVID trial: a randomized controlled trial using convalescent plasma early during moderate COVID-19 disease course in Suriname. Ongoing study. 1 June 2021. Contact author for more information.">ISRCTN49832318</a> randomising 210 participants, <a href="./references#CD013600-bbs2-0277" title="NCT04333251. Evaluating convalescent plasma to decrease coronavirus associated complications. A phase I study comparing the efficacy and safety of high-titer anti-Sars-CoV-2 plasma vs best supportive care in hospitalized patients with interstitial pneumonia due to COVID-19. Available from clinicaltrials.gov/show/NCT04333251 (first received 3 April 2020). ">NCT04333251</a>, randomising 115 participants; <a href="./references#CD013600-bbs2-0286" title="NCT04390503. Convalescent plasma for COVID-19 close contacts. Available from clinicaltrials.gov/ct2/show/NCT04390503 (first received 15 May 2020). ">NCT04390503</a>, randomising 150 participants; <a href="./references#CD013600-bbs2-0289" title="NCT04415086. Treatment of patients with COVID-19 with convalescent plasma. Available from clinicaltrials.gov/show/NCT04415086 (first received 4 June 2020). ">NCT04415086</a>, randomising 120 participants; <a href="./references#CD013600-bbs2-0299" title="MissetB , HosteE , DonneauAF , GrimaldiD , MeyfroidtG , MoutschenM , et al. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol. BMC Pulmonary Medicine2020;20(317). MissetB , HosteE , DonneauAF , GrimaldiD , MeyfroidtG , MoutschenM , et al. Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol. BMC Pulmonary Medicine July 2021;248. [DOI: https://doi.org/10.1186/s12890-021-01574-8]NCT04558476. Efficacy of convalescent plasma in patients with COVID-19 treated with mechanical ventilation. Available from clinicaltrials.gov/show/NCT04558476 (first received 22 September 2020). ">NCT04558476</a>, randomising 500 participants; <a href="./references#CD013600-bbs2-0305" title="NCT05077930. Convalescent plasma therapy for hospitalized patients with COVID-19. https://clinicaltrials.gov/ct2/show/NCT05077930. ">NCT05077930</a>, randomising 200 participants. </p> <div class="table" id="CD013600-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of ongoing convalescent plasma studies: design and planned completion date</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Title</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Link</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Planned number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Planned completion date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results available</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other study ID</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized, double‐blind, parallel‐controlled, trial to evaluate the efficacy and safety of anti‐SARS‐CoV‐2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID‐19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=49777 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID‐19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50059 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 April 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study on the application of convalescent plasma therapy in severe COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50727 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for the treatment of common COVID‐19: a prospective randomized controlled trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50537 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 August 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized, double‐blind, parallel‐controlled trial to evaluate the efficacy and safety of anti‐SARS‐CoV‐2 virus inactivated plasma in the treatment of severe novel </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50696 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTRI/2020/04/024915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID‐19 associated complications </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43332 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTRI/2020/05/025346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID‐19 patients </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43005 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 June 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTRI/2020/06/026123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma therapy in corona patients (severe COVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44667 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 December 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐001632‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized open label phase‐II clinical trial with or without infusion of plasma from subjects after convalescence of SARS‐CoV‐2 infection in high‐risk patients with confirmed severe SARS‐CoV‐2 disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐001632‐10/DE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04433910</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐001936‐86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A prospective, randomized, open label phase 2 clinical trial to evaluate superiority of anti‐SARS‐CoV‐2 convalescent plasma versus standard‐of‐care in hospitalized patients with mild COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐001936‐86/DE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐002122‐82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective open‐label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID‐19 convalescent plasma plus standard treatment vs. standard treatment alone of subjects with severe COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐002122‐82/DE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐005410‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre, randomized, double‐blind, placebo‐controlled, non‐commercial clinical trial to evaluate the efficacy and safety of specific anti‐SARS‐CoV‐2 immunoglobulin in the treatment of COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐005410‐18/PL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISRCTN49832318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SURCOVID trial: A randomized controlled trial using convalescent plasma early during moderate COVID‐19 disease course in Suriname </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN49832318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>01/04/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>jRCTs031200374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An open‐label, randomized, controlled trial to evaluate the efficacy of convalescent plasma therapy for COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-JPRN-jRCTs031200374" target="_blank">https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-JPRN-jRCTs031200374</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04333251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluating convalescent plasma to decrease coronavirus associated complications. A phase I study comparing the efficacy and safety of high‐titer anti‐SARS‐CoV‐2 plasma vs best supportive care in hospitalized patients with interstitial pneumonia due to COVID‐19. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04333251 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04345289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy and safety of novel treatment options for adults with COVID‐19 pneumonia (CCAP) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04345289 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐001367‐88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04372979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy of convalescent plasma therapy in the early care of COVID‐19 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04372979 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04374487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID‐19 associated complications </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04374487 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04376788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exchange transfusion versus plasma from convalescent patients with methylene blue in patients with COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04376788 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04380935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effectiveness and safety of convalescent plasma therapy on COVID‐19 patients with acute respiratory distress syndrome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04380935 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 August 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04385043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperimmune plasma in patients with COVID‐19 severe infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04385043 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04385186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactivated convalescent plasma as a therapeutic alternative in patients CoViD‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04385186 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 November 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04388410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety and efficacy of convalescent plasma transfusion for patients with SARS‐CoV‐2 infection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04388410 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04390503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for COVID‐19 close contacts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04390503 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 April 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04391101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for the treatment of severe SARS‐CoV‐2 (COVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04391101 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04403477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma therapy in severe COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04403477 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 October 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04415086</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment of patients with COVID‐19 with convalescent plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04415086 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 May 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04418518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A trial of convalescent plasma for hospitalized adults with acute COVID‐19 respiratory illness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04418518 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04425837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effectiveness and safety of convalescent plasma in patients with high‐risk COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04425837 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 February 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04438057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluating the efficacy of convalescent plasma in symptomatic outpatients infected with COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04438057 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 July 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04442191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as a possible treatment for COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04442191 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04452812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical and epidemiological study based on the use of convalescent plasma for the management of patients with COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04452812 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 April 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04456413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as treatment for subjects with early COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04456413 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 July 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04483960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australasian COVID‐19 trial (ASCOT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04483960 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 July 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACTRN12620000445976</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04521036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for COVID‐19 patients (CPCP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04521036 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 October 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04528368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for treating patients with COVID‐19 pneumonia without iIndication of ventilatory support </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04528368 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04558476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy of convalescent plasma in patients with COVID‐19 treated with mechanical ventilation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04558476 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 September 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04567173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as adjunctive therapy for hospitalized patients with COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04567173 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04634422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange (PLEX) and convalescent plasma (CCP) in COVID‐19 patients with multiorgan failure (COVID‐PLEX) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04634422 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04712344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessment of efficacy and safety of therapy with COVID‐19 convalescent plasma in subjects with severe COVID‐19 (IPCO) (IPCO) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04712344 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 September 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04730401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma in the treatment of COVID‐19 (CP_COVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04730401 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT04803370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy of Reinforcing Standard Therapy in COVID‐19 Patients With Repeated Transfusion of Convalescent Plasma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>https://clinicaltrials.gov/ct2/show/NCT04803370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 September 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT05077930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Convalescent Plasma Therapy for Hospitalized Patients With COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>https://clinicaltrials.gov/ct2/show/NCT05077930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL8633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non‐ICU patients with COVID‐19 infections </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.trialregister.nl/trial/8633 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PACTR202006760881890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lagos COVID‐19 convalescent plasma trial (LACCPT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 November 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PACTR202007653923168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clinical trial comparing use of convalescent plasma therapy plus standard treatment to standard treatment alone in patients with severe COVID‐19 infection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11047 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PER‐013‐20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as treatment for COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=013‐20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PER‐060‐20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomized phase 2 clinical trial to evaluate safety and efficacy of the use of plasma from convalescent plasma with the Coronavirus disease (COVID‐19) for the experimental treatment of patients hospitalized in the Centro Médico Naval "Cirujano Mayor Santiago Távara" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=060‐20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 March 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RBR‐7jqpnw</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effect of COVID‐19 convalescent plasma produced by HEMOPE: a randomized study, with a comparative group in several centers </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ensaiosclinicos.gov.br/rg/RBR‐7jqpnw/ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 July 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>RCT:</b> randomised controlled trial </p> </td> </tr> </tbody> </table> </div> <p>Please refer to Characteristics of ongoing studies (<a href="./references#CD013600-bbs1-0004" title="">Ongoing studies</a>) for more detailed information and <a href="#CD013600-tbl-0008">Table 3</a> for further details on the planned completed dates and planned number of participants per study. </p> </section> <section id="CD013600-sec-0059"> <h5 class="title">Studies awaiting assessment</h5> <p>In the process of finalising the review, two of our tracked ongoing studies were terminated early for futility and the trials stopped recruiting participants (<a href="./references#CD013600-bbs2-0245" title="NCT04361253. Evaluation of SARS-CoV-2 (COVID-19) antibody-containing plasma therapy. Available from clinicaltrials.gov/show/NCT04361253 (first received 24 April 2020). ">NCT04361253</a>, <a href="./references#CD013600-bbs2-0257" title="NCT04539275. COVID-19 (VA CURES-1). Available from clinicaltrials.gov/show/NCT04539275 (first received 04 September 2020). ">NCT04539275</a>). </p> <p>According to the trials registries, 28 RCTs have been completed, or had their recruitment completed, but no results have been published yet (<a href="./references#CD013600-bbs2-0230" title="CTRI/2020/05/025299. Convalescent plasma to limit coronavirus associated complications: an open label clinical study of anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19. Available from www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43752 (first received 21 May 2020). ">CTRI/2020/05/025299</a>; <a href="./references#CD013600-bbs2-0231" title="CTRI/2020/05/025328. Study to assess the safety and efficacy of convalescent plasma on outcome of COVID-19 associated complications. Available from ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43703 (first received 23 May 2020). ">CTRI/2020/05/025328</a>; <a href="./references#CD013600-bbs2-0232" title="CTRI/2020/06/025803. Effect of convalescent plasma in COVID-19 patients. Available from ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44478 (first received 11 June 2020). ">CTRI/2020/06/025803</a>; <a href="./references#CD013600-bbs2-0233" title="EUCTR2020-001860-27-GB. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. Available from https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first retrieved 14 June 2021). ">EUCTR2020‐001860‐27‐GB</a>; <a href="./references#CD013600-bbs2-0234" title="IRCT20120215009014N353. Effect of plasma of patients recovered from COVID-19 versus control group on treatment of COVID-19: a randomized clinical trial. Available from www.irct.ir/trial/47501 (first received 27 April 2020). ">IRCT20120215009014N353</a>; <a href="./references#CD013600-bbs2-0235" title="IRCT20150808023559N21. The effect of convalescent plasma therapy on patients with 19-COVID. Available from en.irct.ir/trial/47594 (first received 9 May 2020). ">IRCT20150808023559N21</a>; <a href="./references#CD013600-bbs2-0236" title="IRCT20200404046948N1. Efficacy and safety of convalescent plasma in the treatment of COVID-19. Available from en.irct.ir/trial/46973 (first received 15 April 2020). ">IRCT20200404046948N1</a>; <a href="./references#CD013600-bbs2-0237" title="IRCT20200413047056N1. Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19. Available from en.irct.ir/trial/47212 (first received 17 April 2020). ">IRCT20200413047056N1</a>; <a href="./references#CD013600-bbs2-0238" title="IRCT20200501047258N1. Effects of convalescent plasma in COVID-19. Available from en.irct.ir/trial/47629 (first received 04 May 2020). ">IRCT20200501047258N1</a>; <a href="./references#CD013600-bbs2-0239" title="IRCT20200503047281N1. Evaluation of convalescent plasma therapy for COVID-19 patients. Available from en.irct.ir/trial/47632 (first received 25 July 2020). ">IRCT20200503047281N1</a>; <a href="./references#CD013600-bbs2-0240" title="IRCT20201004048922N1. Evaluation of the effectiveness of intravenous infusion of human COVID-19 hyperimmune plasma with specific antibody titer in hospitalized patients with COVID-19: a randomized clinical trial. Available from www.irct.ir/trial/51443 (first received 19 July 2020). ">IRCT20201004048922N1</a>; <a href="./references#CD013600-bbs2-0242" title="NCT04332835. Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical study. Available from clinicaltrials.gov/show/NCT04332835 (first received 3 April 2020). ">NCT04332835</a>; <a href="./references#CD013600-bbs2-0243" title="NCT04345991. Efficacy of convalescent plasma to treat COVID-19 patients, a nested trial in the CORIMUNO-19 cohort. Available from clinicaltrials.gov/show/NCT04345991 (first received 15 April 2020). ">NCT04345991</a>; <a href="./references#CD013600-bbs2-0244" title="NCT04358783. Convalescent plasma compared to the best available therapy for the treatment of SARS-CoV-2 pneumonia. Available from clinicaltrials.gov/show/NCT04358783 (first received 24 April 2020). ">NCT04358783</a>; <a href="./references#CD013600-bbs2-0246" title="NCT04362176. Passive immunity trial of Nashville II. Available from clinicaltrials.gov/show/NCT04362176 (first received 24 April 2020). SelfWH , StewartTG , WheelerAP , AtrouniWE , Bistran-HallAJ , Casey JD et al. Passive immunity trial for our nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults (preprint). Available from www.researchsquare.com/article/rs-227796/v1 [Preprint]. [DOI: https://doi.org/10.21203/rs.3.rs-227796/v1]">NCT04362176</a>; <a href="./references#CD013600-bbs2-0247" title="NCT04374526. Early transfusIon of convalescent plasma in elderly COVID-19 patients to prevent disease progression. Available from clinicaltrials.gov/show/NCT04374526 (first received 5 May 2020). TeofiliL , LandolfiR , CingolaniA , AntinoriA , VecchietJ , SanguinettiM , et al. Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):875. [DOI: 10.1186/s13063-020-04821-1]">NCT04374526</a>; <a href="./references#CD013600-bbs2-0248" title="NCT04385199. Convalescent plasma for patients with COVID-19. Available from clinicaltrials.gov/show/NCT04385199 (first received 12 May 2020). ">NCT04385199</a>; <a href="./references#CD013600-bbs2-0249" title="NCT04405310. Convalescent plasma of COVID-19 to treat SARS-COV-2 a randomized double blind 2 center trial (CPC-SARS). Available from clinicaltrials.gov/show/NCT04405310 (first received 28 May 2020). ">NCT04405310</a>; <a href="./references#CD013600-bbs2-0250" title="NCT04425915. Efficacy of convalescent plasma therapy in patients with COVID-19. Available from clinicaltrials.gov/show/NCT04425915 (first received 11 June 2020). ">NCT04425915</a>; <a href="./references#CD013600-bbs2-0251" title="NCT04428021. Standard or convalescent plasma in patients with recent onset of COVID-19 respiratory failure. Available from clinicaltrials.gov/show/NCT04428021 (first received 11 June 2020). ">NCT04428021</a>; <a href="./references#CD013600-bbs2-0252" title="NCT04442958. Effectiveness of convalescent immune plasma therapy. Available from clinicaltrials.gov/show/NCT04442958 (first received 23 June 2020). ">NCT04442958</a>; <a href="./references#CD013600-bbs2-0253" title="NCT04468009. Treatment of critically ill patients with COVID-19 with convalescent plasma. Available from clinicaltrials.gov/show/NCT04468009 (first received 13 July 2020). ">NCT04468009</a>; <a href="./references#CD013600-bbs2-0254" title="NCT04497324. Peruconplasma: evaluating the use of convalescent plasma as management of COVID-19. Available from clinicaltrials.gov/ct2/show/NCT04497324 (first received 04 August 2020). PER-016-20. PERUCONPLASMA: Evaluating the use of convalescent plasma as managment of COVID-19. Available from www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=016-20 (first received 01 June 2020). SotoA , KrappF , VargasA , CabrejosL , ArgumanisE , Garcia PL , et al. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Trials2021;22:342. [DOI: https://doi.org/10.1186/s13063-021-05189-6]">NCT04497324</a>; <a href="./references#CD013600-bbs2-0256" title="AliS , LuxmiS , AnjumF , MuhayminSM , UddinSM , AliA , et al. Hyperimmune anti-COVID-19 IVIG (C-IVIG) therapy for passive immunization of severe and critically ill COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(905). SARS-CoV-2 antibodies based IVIG therapy for COVID-19 patients. Available from clinicaltrials.gov/ct2/show/NCT04521309 (first received 20 August 2020). ">NCT04521309</a>; <a href="./references#CD013600-bbs2-0258" title="NCT04542967. Study on the safety and efficacy of convalescent plasma in patients with severe COVID-19 disease. Available from clinicaltrials.gov/show/NCT04542967 (first received 09 September 2020). ">NCT04542967</a>; <a href="./references#CD013600-bbs2-0259" title="Ferrer RocaR , LlamasP , ManezR , GalbanC , QuintanaM , Sanchez-GarciaM , et al. Design of a study to evaluate the safety and efficacy of convalescent plasma to treat COVID-19 in critically ill patients. Intensive Care Medicine Experimental. Conference: 33rd European Society of Intensive Care Medicine Annual Congress, ESICM2020;8 Suppl 2. NCT04547127. A study to evaluate safety and efficacy of convalescent methylene blue treated (MBT) plasma from donors recovered from coronavirus disease 2019 (COVID-19). Available from clinicaltrials.gov/show/NCT04547127 (first received 14 September 2020). ">NCT04547127</a>; <a href="./references#CD013600-bbs2-0260" title="NCT04649879. Convalescent plasma for treatment of COVID-19: an open randomised controlled trial. Available from clinicaltrials.gov/show/NCT04649879 (first received 02 December 2020). ">NCT04649879</a>; <a href="./references#CD013600-bbs2-0261" title="KeitelV , JensenB , FeldtT , FischerJC , BodeJG , MatuschekC , et al. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Trials2021;22:343. [DOI: https://dx.doi.org/10.1186/s13063-021-05181-0]NCT04681430. Reconvalescent plasma/camostat mesylate early in SARS-CoV-2 Q-PCR (COVID-19) positive high-risk individuals (RES-Q-HR). Available from clinicaltrials.gov/ct2/show/NCT04681430 (first received 23 December 2020). ">NCT04681430</a>). For this reason, we have placed these studies in the category of '<a href="./references#CD013600-bbs1-0003" title="">Studies awaiting classification</a>'. </p> <p>Three studies are platform trials, A platform trial is an adaptive, multistage study design in which numerous interventions can be evaluated through interim analyses. These three trials do not currently include the convalescent plasma intervention, however, in a platform trial new study arms can be added within the study period to examine further interventions (<a href="./references#CD013600-bbs2-0377" title="ParkJJ , HarariO , DronL , LesterRT , ThorlundK , MillsEJ . An overview of platform trials with a checklist for clinical readers. Journal of Clinical Epidemiology2020;125:1-8.">Park 2020</a>). We are tracking these studies, in case they add an arm on convalescent plasma (<a href="./references#CD013600-bbs2-0255" title="NCT04501978. ACTIV-3: therapeutics for inpatients with COVID-19 (TICO). Available from clinicaltrials.gov/ct2/show/NCT04501978 (first received 6 August 2020). ">NCT04501978</a>; <a href="./references#CD013600-bbs2-0241" title="NCT04315948. Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy). Available from clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">NCT04315948</a>; <a href="./references#CD013600-bbs2-0262" title="NCT04801940. Helping alleviate the longer-term consequences of COVID-19 (HEAL-COVID). Available from clinicaltrials.gov/ct2/show/NCT04801940 (first retrieved 14 June 2021). ">NCT04801940</a>). </p> </section> </section> <section id="CD013600-sec-0060"> <h4 class="title">Excluded studies</h4> <p>We excluded in total 196 studies that did not match our inclusion criteria as follows.</p> <p>162 studies are excluded from the review based on unchanged exclusion criteria:</p> <p> <ul id="CD013600-list-0101"> <li> <p>76 studies were single‐arm studies with fewer than 500 participants receiving convalescent plasma (<a href="./references#CD013600-bbs2-0034" title="AbdullahHM , Hama-AliHH , AhmedSN , AliKM , KaradakhyKA , MahmoodSO , et al. A severe refractory COVID-19 patient responding to convalescent plasma; a case series. Annals of Medicine and Surgery2020;56:125-7. ">Abdullah 2020</a>; <a href="./references#CD013600-bbs2-0043" title="BradfuteSB , HurwitzI , YinglingAV , YeC , ChengQ , NoonanTP , et al. SARS-CoV-2 neutralizing antibody titers in convalescent plasma and recipients in New Mexico: an open treatment study in COVID-19 patients. Journal of Infectious Diseases2020;11:11. ">Bradfute 2020</a>; <a href="./references#CD013600-bbs2-0050" title="ChiCTR2000029850. Efficacy and safety of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study. Available from www.chictr.org.cn/showproj.aspx?proj=49533 (first received 15 February 2020). ">ChiCTR2000029850</a>; <a href="./references#CD013600-bbs2-0051" title="ChiCTR2000030039. Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19). Available from www.chictr.org.cn/showproj.aspx?proj=49544 (first received 21 February 2020). ">ChiCTR2000030039</a>; <a href="./references#CD013600-bbs2-0055" title="ChiCTR2000031501. The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study. Available from www.chictr.org.cn/showproj.aspx?proj=50254 (first received 2 April 2020). ">ChiCTR2000031501</a>; <a href="./references#CD013600-bbs2-0056" title="ChiCTR2000033798. The efficacy and safety of convalescent plasma therapy in novel coronavirus pneumonia (COVID-19): a medical records based retrospective cohort study. Available from www.chictr.org.cn/showproj.aspx?proj=55194 (first received 12 June 2020). ">ChiCTR2000033798</a>; <a href="./references#CD013600-bbs2-0058" title="CTRI/2020/04/024804. Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients. Available from ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42849 (first received 22 April 2020). ">CTRI/2020/04/024804</a>; <a href="./references#CD013600-bbs2-0059" title="CTRI/2020/08/027285. Safety of convalescent plasma (CVP) drawn from mild symptomatic COVID-19 patients. Available from www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45050 (first received 21 August 2020). ">CTRI/2020/08/027285</a>; <a href="./references#CD013600-bbs2-0065" title="DonatoM , ParkS , BakerM , KorngoldR , MorawskiA , GengX , et al. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study. medRxiv [Preprint]2020. [DOI: 10.1101/2020.07.20.20156398]">Donato 2020</a>; <a href="./references#CD013600-bbs2-0066" title="DuanK , LiuB , LiC , ZhangH , YuT , QuJ , et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America2020;117:9490-6. [DOI: 10.1073/pnas.2004168117]DuanK , LiuB , LiC , ZhangH , YuT , QuJ , et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv [Preprint]2020. [DOI: 10.1101/2020.03.16.20036145]">Duan 2020</a>; <a href="./references#CD013600-bbs2-0067" title="DulipsinghL , DanyalI , CrowellR , DiffenderferM , WilliamsK , LimaC , et al. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma. Transfus Apher Sci2020;59:102922. [DOI: https://doi.org/10.1016/j.transci.2020.102922]">Dulipsingh 2020</a>; <a href="./references#CD013600-bbs2-0078" title="IbrahimD , DulipsinghL , ZapatkaL , EadieR , CrowellR , WilliamsK , et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infectious Diseases and Therapy 2020 [Epub ahead of print];9:913–926. [DOI: 10.1007/s40121-020-00341-2]">Ibrahim 2020</a>; <a href="./references#CD013600-bbs2-0080" title="IRCT20151228025732N53. Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease. Available from en.irct.ir/trial/46931 (first received 10 April 2020). ">IRCT20151228025732N53</a>; <a href="./references#CD013600-bbs2-0081" title="IRCT20200406046968N2. Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients. Available from www.irct.ir/trial/47115 (first received 22 April 2020). ">IRCT20200406046968N2</a>; <a href="./references#CD013600-bbs2-0082" title="IRCT20200414047072N1. Use of convalescent plasma in the treatment of COVID-19. Available from en.irct.ir/trial/47163 (first received 28 April 2020). ">IRCT20200414047072N1</a>; <a href="./references#CD013600-bbs2-0083" title="IRCT20200416047099N1. Plasma therapy in patient with COVID-19. Available from en.irct.ir/trial/47266 (first received 21 April 2020). ">IRCT20200416047099N1</a>; <a href="./references#CD013600-bbs2-0090" title="JinC , GuJ , YuanY , LongQ , ZhangQ , ZhouH , et al. Treatment of 6 COVID-19 patients with convalescent plasma. medRxiv [Preprint]2020. [DOI: 10.1101/2020.05.21.20109512]">Jin 2020</a>; <a href="./references#CD013600-bbs2-0096" title="LiuST , LinHM , BaineI , WajnbergA , GumprechtJP , RahmanF , et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Medicine2020;26:1708–13. [DOI: https://doi.org/10.1038/s41591-020-1088-9]">Liu 2020a</a>; <a href="./references#CD013600-bbs2-0098" title="MadariagaML , GuthmillerJ , SchrantzS , JansenM , ChristensonC , KumarM , et al. Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. medRxiv [Preprint]2020. [DOI: 10.1101/2020.06.21.20132944]MadariagaML , SchrantzS , JansenMO , ChristensenC , KumarM , ProchaskaM , et al. Integrated COVID-19 convalescent plasma treatment and antibody research program at a single academic medical center. SSRN [Preprint]2020. [DOI: 10.2139/ssrn.3605131]">Madariaga 2020</a>; <a href="./references#CD013600-bbs2-0104" title="ChiCTR2000030841. Treatment of acute severe COVID-19 with immunoglobulin from cured COVID-19 patients. Available from www.chictr.org.cn/showproj.aspx?proj=51072 (first received 15 March 2020). NCT04264858. An exploratory clinical study on the treatment of acute severe 2019-nCoV pneumonia with immunoglobulin from cured 2019-nCoV pneumonia patients. Available from clinicaltrials.gov/show/NCT04264858 (first received 11 February 2020). ">NCT04264858</a>; <a href="./references#CD013600-bbs2-0105" title="NCT04292340. The efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19): an observational study. Available from clinicaltrials.gov/show/NCT04292340 (first received 3 March 2020). ">NCT04292340</a>; <a href="./references#CD013600-bbs2-0106" title="NCT04321421. Hyperimmune plasma for critical patients with COVID-19. Available from clinicaltrials.gov/ct2/show/NCT04321421 (first received 28 May 2020). ">NCT04321421</a>; <a href="./references#CD013600-bbs2-0109" title="NCT04327349. Investigating effect of convalescent plasma on COVID-19 patients outcome: a clinical trial. Available from clinicaltrials.gov/show/NCT04327349 (first received 31 March 2020). ">NCT04327349</a>; <a href="./references#CD013600-bbs2-0110" title="NCT04332380. Convalescent plasma for patients with COVID-19: a pilot study. Available from clinicaltrials.gov/show/NCT04332380 (first received 2 April 2020). ">NCT04332380</a>; <a href="./references#CD013600-bbs2-0111" title="NCT04333355. Phase 1 study to evaluate the safety of convalescent plasma as an adjuvant therapy in patients with SARS-CoV-2 infection. Available from clinicaltrials.gov/show/NCT04333355 (first received 3 April 2020). ">NCT04333355</a>; <a href="./references#CD013600-bbs2-0116" title="NCT04345679. Anti COVID-19 convalescent plasma therapy. Available from clinicaltrials.gov/show/NCT04345679 (first received 14 April 2020). ">NCT04345679</a>; <a href="./references#CD013600-bbs2-0117" title="NCT04346589. Convalescent antibodies infusion in critically ill COVID 19 patients. Available from clinicaltrials.gov/ct2/show/NCT04346589 (first received 15 April 2020). ">NCT04346589</a>; <a href="./references#CD013600-bbs2-0119" title="NCT04348877. Plasma rich antibodies from recovered patients from COVID19. Available from clinicaltrials.gov/show/NCT04348877 (first received 16 April 2020). ">NCT04348877</a>; <a href="./references#CD013600-bbs2-0122" title="NCT04353206. Convalescent plasma in ICU patients with COVID-19-induced respiratory failure. Available from clinicaltrials.gov/show/NCT04353206 (first received 20 April 2020). ">NCT04353206</a>; <a href="./references#CD013600-bbs2-0123" title="NCT04354831. A study evaluating the efficacy and safety of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19 infection. Available from clinicaltrials.gov/ct2/show/NCT04354831 (first received 21 April 2020). ">NCT04354831</a>; <a href="./references#CD013600-bbs2-0124" title="NCT04355897. COVID-19 plasma in treatment of COVID-19 patients. Available from clinicaltrials.gov/ct2/show/NCT04355897 (first received 21 April 2020). ">NCT04355897</a>; <a href="./references#CD013600-bbs2-0125" title="NCT04356482. Convalescent plasma for ill patients by COVID-19. Available from clinicaltrials.gov/show/NCT04356482 (first received 22 April 2020). ">NCT04356482</a>; <a href="./references#CD013600-bbs2-0130" title="NCT04365439. Convalescent plasma for COVID-19. Available from clinicaltrials.gov/show/NCT04365439 (first received 28 April 2020). ">NCT04365439</a>; <a href="./references#CD013600-bbs2-0135" title="NCT04374565. Convalescent plasma for treatment of COVID-19 patients with pneumonia. Available from clinicaltrials.gov/show/NCT04374565 (first received 5 May 2020). ">NCT04374565</a>; <a href="./references#CD013600-bbs2-0136" title="NCT04376034. Convalescent plasma collection and treatment in pediatrics and adults. Available from clinicaltrials.gov/show/NCT04376034 (first received 6 May 2020). ">NCT04376034</a>; <a href="./references#CD013600-bbs2-0138" title="NCT04377672. Human convalescent plasma for high-risk children exposed or infected with SARS-CoV-2. Available from clinicaltrials.gov/show/NCT04377672 (first received 6 May 2020). ">NCT04377672</a>; <a href="./references#CD013600-bbs2-0139" title="NCT04383548. Clinical study for efficacy of anti-corona VS2 immunoglobulins prepared from COVID19 convalescent plasma prepared by VIPS mini-pool IVIG medical devices in prevention of SARS-CoV-2 infection in high risk groups as well as treatment of early cases of COVID. Available from clinicaltrials.gov/show/NCT04383548 (first received 12 May 2020). ">NCT04383548</a>; <a href="./references#CD013600-bbs2-0140" title="NCT04384497. Convalescent plasma for treatment of COVID-19: an exploratory dose identifying study. Available from clinicaltrials.gov/ct2/show/NCT04384497 (first received 12 May 2020). ">NCT04384497</a>; <a href="./references#CD013600-bbs2-0142" title="NCT04388527. COVID-19 convalescent plasma for mechanically ventilated population. Available from clinicaltrials.gov/show/NCT04388527 (first received 14 May 2020). ">NCT04388527</a>; <a href="./references#CD013600-bbs2-0143" title="NCT04389710. Convalescent plasma for the treatment of COVID-19. Available from clinicaltrials.gov/show/NCT04389710 (first received 15 May 2020). ">NCT04389710</a>; <a href="./references#CD013600-bbs2-0144" title="NCT04389944. Amotosalen-ultraviolet a pathogen-inactivated convalescent plasma in addition to best supportive care and antiviral therapy on clinical deterioration in adults presenting with moderate to severe COVID-19. Available from clinicaltrials.gov/show/NCT04389944 (first received 15 May 2020). ">NCT04389944</a>; <a href="./references#CD013600-bbs2-0145" title="NCT04390178. Convalescent plasma as treatment for acute coronavirus disease (COVID-19). Available from clinicaltrials.gov/show/NCT04390178 (first received 15 May 2020). ">NCT04390178</a>; <a href="./references#CD013600-bbs2-0146" title="NCT04392232. A phase 2 study of COVID 19 convalescent plasma in high risk patients with COVID 19 infection. Available from clinicaltrials.gov/show/NCT04392232 (first received 18 May 2020). ">NCT04392232</a>; <a href="./references#CD013600-bbs2-0149" title="NCT04397523. Efficacy and safety of COVID-19 convalescent plasma. Available from clinicaltrials.gov/show/NCT04397523 (first received 21 May 2020). ">NCT04397523</a>; <a href="./references#CD013600-bbs2-0150" title="NCT04407208. Convalescent plasma therapy in patients with COVID-19. Available from clinicaltrials.gov/show/NCT04407208 (first received 29 May 2020). ">NCT04407208</a>; <a href="./references#CD013600-bbs2-0152" title="NCT04408209. Convalescent plasma for the treatment of patients with severe COVID-19 infection. Available from clinicaltrials.gov/show/NCT04408209 (first received 29 May 2020). ">NCT04408209</a>; <a href="./references#CD013600-bbs2-0153" title="NCT04411602. Feasibility study of anti-SARS-CoV-2 plasma transfusions in COVID-19 patients with SRD. Available from clinicaltrials.gov/show/NCT04411602 (first received 2 June 2020). ">NCT04411602</a>; <a href="./references#CD013600-bbs2-0154" title="NCT04412486. COVID-19 convalescent plasma (CCP) transfusion. Available from clinicaltrials.gov/show/NCT04412486 (first received 2 June 2020). ">NCT04412486</a>; <a href="./references#CD013600-bbs2-0155" title="NCT04418531. Convalescent antibodies infusion in COVID 19 patients. Available from clinicaltrials.gov/show/NCT04418531 (first received 5 June 2020). ">NCT04418531</a>; <a href="./references#CD013600-bbs2-0157" title="NCT04432103. Treatment of severe and critical COVID-19 pneumonia with convalescent plasma. Available from clinicaltrials.gov/show/NCT04432103 (first received 16 June 2020). ">NCT04432103</a>; <a href="./references#CD013600-bbs2-0159" title="NCT04438694. Use of convalescent plasma for treatment of patients with COVID-19 infection. Available from clinicaltrials.gov/show/NCT04438694 (first received 19 June 2020). ">NCT04438694</a>; <a href="./references#CD013600-bbs2-0161" title="NCT04458363. Convalescent plasma in pediatric COVID-19. Available from clinicaltrials.gov/ct2/show/NCT04458363 (first received 07 July 2020). ">NCT04458363</a>; <a href="./references#CD013600-bbs2-0162" title="NCT04462848. COVID-19 convalescent plasma as prevention and treatment for children with underlying medical conditions. Available from clinicaltrials.gov/show/NCT04462848 (first received 8 July 2020). ">NCT04462848</a>; <a href="./references#CD013600-bbs2-0167" title="NCT04471051. An observational cohort trial of outcomes and antibody responses following treatment with COVID19 convalescent plasma in hospitalized COVID-19 patients. Available from clinicaltrials.gov/show/NCT04471051 (first received 14 July 2020). ">NCT04471051</a>; <a href="./references#CD013600-bbs2-0169" title="NCT04474340. COVID-19 convalescent plasma treatment in SARS-CoV-2 infected patients: multicenter interventional study. Available from clinicaltrials.gov/show/NCT04474340 (first received 16 July 2020). ">NCT04474340</a>; <a href="./references#CD013600-bbs2-0170" title="NCT04476888. Convalescent plasma treatment in COVID-19. Available from clinicaltrials.gov/show/NCT04476888 (first received 20 July 2020). ">NCT04476888</a>; <a href="./references#CD013600-bbs2-0173" title="NCT04502472. Open-label treatment of severe coronavirus disease 2019 (COVID-19) with convalescent plasma. Available from clinicaltrials.gov/show/NCT04502472 (first received 06 August 2020). ">NCT04502472</a>; <a href="./references#CD013600-bbs2-0174" title="NCT04513158. Convalescent plasma in the early treatment of high-risk patients with SARS-CoV-2 (COVID-19) infection. Available from clinicaltrials.gov/show/NCT04513158 (first received 14 August 2020). ">NCT04513158</a>; <a href="./references#CD013600-bbs2-0176" title="NCT04516954. Convalescent plasma for COVID-19 patients. Available from clinicaltrials.gov/show/NCT04516954 (first received 18 August 2020). ">NCT04516954</a>; <a href="./references#CD013600-bbs2-0178" title="NCT04535063. Convalescent plasma as potential therapy for severe COVID-19 pneumonia. Available from clinicaltrials.gov/show/NCT04535063 (first received 01 September 2020). ">NCT04535063</a>; <a href="./references#CD013600-bbs2-0181" title="NCT04554992. Convalescent plasma for the treatment of COVID-19. Available from clinicaltrials.gov/show/NCT04554992 (first received 18 September 2020). ">NCT04554992</a>; <a href="./references#CD013600-bbs2-0184" title="NCT04565197. Convalescent plasma therapy for COVID-19 patients. Available from clinicaltrials.gov/show/NCT04565197 (first received 25 September 20209. ">NCT04565197</a>; <a href="./references#CD013600-bbs2-0185" title="NCT04569188. Convalescent plasma in COVID-19 elderly patients. Available from clinicaltrials.gov/show/NCT04569188 (first received 29 September 2020). ">NCT04569188</a>; <a href="./references#CD013600-bbs2-0186" title="NCT04570982. Clinical protocol for convalescent plasma and remdesivir therapy in Nepal. Available from clinicaltrials.gov/show/NCT04570982 (first received 30 September 2020). ">NCT04570982</a>; <a href="./references#CD013600-bbs2-0190" title="NCT04614012. Hyperimmune plasma for patients with COVID-19. Available from clinicaltrials.gov/show/NCT04614012 (first received 03 November 2020). ">NCT04614012</a>; <a href="./references#CD013600-bbs2-0191" title="NCT04616976. COVID-19 with convalescent plasma. Available from clinicaltrials.gov/show/NCT04616976 (first received 05 November 2020). ">NCT04616976</a>; <a href="./references#CD013600-bbs2-0192" title="NCT04622826. plasmApuane CoV-2: efficacy and safety of immune COVID-19 plasma in COVID-19 pneumonia in non ITU patients. Available from clinicaltrials.gov/show/NCT04622826 (first received 10 November 2020). ">NCT04622826</a>; <a href="./references#CD013600-bbs2-0195" title="NCT04644198. Convalescent plasma transfusion in severe COVID-19 patients in Jamaica. Available from clinicaltrials.gov/ct2/show/NCT04644198 (first received 25 November 2020). ">NCT04644198</a>; <a href="./references#CD013600-bbs2-0200" title="Olivares-GazcaJC , Priesca-MarinJM , Ojeda-LagunaM , Garces-EiseleJ , Soto-OlveraS , Palacios-AlonsoA , et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Revista de Investigation Clinica2020;72(3):159-64. ">Olivares‐Gazca 2020</a>; <a href="./references#CD013600-bbs2-0203" title="PER-031-20. Phase 2 Study of efficacy and safety of plasma from convalescent patients with COVID-19 in patients with moderate disease (AUNA 20-01). https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=031-20 (first received 06 July 2020). ">PER‐031‐20</a>; <a href="./references#CD013600-bbs2-0204" title="PerottiC , BaldantiF , BrunoR , Del FanteC , SeminariE , CasariS , et al. Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 2020 July 23 [Epub ahead of print];105:2834-40. PerottiC , BaldantiF , BrunoR , DelfanteC , SeminariE , CasariS , et al. Mortality reduction in 46 severe COVID-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. medRxiv [Preprint]2020. [DOI: 10.1101/2020.05.26.20113373]PerottiC , Del FanteC , BaldantiF , FranchiniM , PercivalleE , Vecchio NepitaE , et al. Plasma from donors recovered from the new coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. Internal and Emergency Medicine2020;15(5):819-24. [DOI: 10.1007/s11739-020-02384-2]">Perotti 2020</a>; <a href="./references#CD013600-bbs2-0207" title="RBR-4vm3yy. Effect of convalescent plasma in patients with severe COVID-19. www.ensaiosclinicos.gov.br/rg/RBR-4vm3yy/ (first received 11 May 2020). ">RBR‐4vm3yy</a>; <a href="./references#CD013600-bbs2-0210" title="RPCEC00000323. Plasma treatment to asymptomatic patient with COVID-19 infection. rpcec.sld.cu/en/trials/RPCEC00000323-En (first received 03 July 2020). ">RPCEC00000323</a>; <a href="./references#CD013600-bbs2-0211" title="SalazarE , ChristensenPA , GravissEA , NguyenDT , CastilloB , ChenJ , et al. Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality. American Journal of Pathology2020;11:11. ">Salazar 2020a</a>; <a href="./references#CD013600-bbs2-0221" title="XiaX , LiK , WuL , WangZ , ZhuM , HuangB , et al. Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood2020;23:23. ">Xia 2020</a>; <a href="./references#CD013600-bbs2-0226" title="ZengQL , YuZJ , GouJJ , LiGM , MaSH , ZhangGF , et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. Journal of Infectious Diseases2020;222(1):38-43. [DOI: 10.1093/infdis/jiaa228]">Zeng 2020</a>); </p> </li> <li> <p>37 studies were single‐arm studies or case series that had not been pre‐registered in a clinical trials registry (<a href="./references#CD013600-bbs2-0036" title="AhnJY , SohnY , LeeSH , ChoY , HyunJH , BaekYJ , et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science2020;35(14):e149. ">Ahn 2020</a>; <a href="./references#CD013600-bbs2-0038" title="AndersonJ , SchauerJ , BryantS , GravesCR . The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Reports in Women's Health2020;27:e00221. [DOI: 10.1016/j.crwh.2020.e00221]">Anderson 2020</a>; <a href="./references#CD013600-bbs2-0041" title="BaoY , LinSY , ChengZH , XiaJ , SunYP , ZhaoQ , et al. Clinical features of COVID-19 in a young man with massive cerebral hemorrhage—case report. SN Comprehensive Clinical Medicine 2020 May 23 [Epub ahead of print];2:703–9. [DOI: 10.1007/s42399-020-00315-y]">Bao 2020b</a>; <a href="./references#CD013600-bbs2-0042" title="BobekI , GopcsaL , RetiM , BekoG , HanczL , LakatosB , et al. Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases. Orvosi Hetilap2020;161(27):1111-21. ">Bobek 2020</a>; <a href="./references#CD013600-bbs2-0046" title="CantoreI , ValenteP . Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report. Transfusion and Apheresis Science 2020 Jun 10 [Epub ahead of print];59(5):102848. [DOI: 10.1016/j.transci.2020.102848]">Cantore 2020</a>; <a href="./references#CD013600-bbs2-0062" title="ÇınarOE , SayınalpB , KarakulakEA , KarataşAA , VeletM , İnkaya AÇ, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfusion and Apheresis Science2020;59(5):102821. [DOI: 10.1016/j.transci.2020.102821]">Çınar 2020</a>; <a href="./references#CD013600-bbs2-0057" title="ClarkE , GuilpainP , FilipL , PansuN , Le BihanC , CartronG , et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. British Journal of Haematology2020;27:27. ">Clark 2020</a>; <a href="./references#CD013600-bbs2-0068" title="EnzmannMO , EricksonMP , GrindelandCJ , LopezSM , HooverSE , LeedahlDD . Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas. Epidemiology and Infection2020;148:e124. ">Enzmann 2020</a>; <a href="./references#CD013600-bbs2-0069" title="ErkurtMA , SariciA , BerberI , KukuI , KayaE , OzgulM . Life-saving effect of convalescent plasma treatment in COVID-19 disease: clinical trial from eastern Anatolia. Transfusion and Apheresis Science 2020 Jun 27 [Epub ahead of print];59(5):102867. [DOI: 10.1016/j.transci.2020.102867]">Erkurt 2020</a>; <a href="./references#CD013600-bbs2-0071" title="FanO , QiangF , ShuhongG , HaibingY , XiangyangL , MinT , et al. Recovery from critical COVID-19 despite delays in diagnosis and respiratory treatment: a cautionary tale. Signa Vitae2020;16(1):193-8. ">Fan 2020</a>; <a href="./references#CD013600-bbs2-0072" title="FiglerowiczM , ManiaA , LubarskiK , LewandowskaZ , SluzewskiW , DerwichK , et al. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia. Transfusion and Apheresis Science 2020 July 1 [Epub ahead of print];59(5):102866. [DOI: 10.1016/j.transci.2020.102866]">Figlerowicz 2020</a>; <a href="./references#CD013600-bbs2-0075" title="GrisoliaG , FranchiniM , GlinganiC , IngleseF , GarutiM , BeccariaM , et al. Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review. American Journal of Obstetrics and Gynecology2020;2(3):100174. ">Grisolia 2020</a>; <a href="./references#CD013600-bbs2-0079" title="ImJH , NahmCH , BaekJH , KwonHY , LeeJS . Convalescent plasma therapy in coronavirus disease 2019: a case report and suggestions to overcome obstacles. Journal of Korean Medical Science2020;35(26):e239. ">Im 2020</a>; <a href="./references#CD013600-bbs2-0087" title="JamousF , MeyerN , BuusD , AteeliH , TaggartK , HansonT , et al. Critical illness due to COVID-19: a description of the surge in a single center in Sioux Falls. South Dakota Medicine2020;73(7):312-7. ">Jamous 2020</a>; <a href="./references#CD013600-bbs2-0088" title="JiangJ , MiaoY , ZhaoY , LuX , ZhouP , ZhouX , et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestation and complex complications. Clinical Transplantation 2020 Jun 30 [Epub ahead of print];34:e14025. [DOI: 10.1111/ctr.14025] [PMID: 32602952]">Jiang 2020a</a>; <a href="./references#CD013600-bbs2-0093" title="KaratasA , InkayaAC , DemirogluH , AksuS , HaziyevT , CinarOE , et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfusion and Apheresis Science 2020 October [Epub ahead of print ];59(5):102871. [DOI: 10.1016/j.transci.2020.102871]">Karatas 2020</a>; <a href="./references#CD013600-bbs2-0094" title="KongY , CaiC , LingL , ZengL , WuM , WuY , et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. Transfusion and Apheresis Science 2020 May 21 [Epub ahead of print];59:102820. [DOI: 10.1016/j.transci.2020.102820]">Kong 2020</a>; <a href="./references#CD013600-bbs2-0097" title="LiuM , ChenZ , DaiMY , YangJH , ChenXB , ChenD , et al. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with COVID-19. Transfusion 2020 Aug 8 [Epub ahead of print];60:2210-16. [DOI: 10.1111/trf.15975] [MEDLINE: mdl-32770691]">Liu 2020b</a>; <a href="./references#CD013600-bbs2-0099" title="Martinez-ResendezMF , Castilleja-LealF , Torres-QuintanillaA , Rojas-MartinezA , Garcia-RivasG , Ortiz-LopezR , et al. Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. medRxiv [Preprint]2020. [DOI: 10.1101/2020.07.14.20144469]">Martinez‐Resendez 2020</a>; <a href="./references#CD013600-bbs2-0100" title="McCuddyM , KelkarP , ZhaoY , WicklundD . Acute demyelinating encephalomyelitis (ADEM) in COVID-19 infection: a case series. medRxiv [Preprint]2020. [DOI: 10.1101/2020.07.15.20126730]">McCuddy 2020</a>; <a href="./references#CD013600-bbs2-0102" title="MiraE , YarceOA , OrtegaC , FernándezS , PascualN , GómezC , et al. Rapid recovery of a SARS-CoV-2 infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. Journal of Allergy and Clinical Immunology: In Practice2020;8(8):2793-5. ">Mira 2020</a>; <a href="./references#CD013600-bbs2-0199" title="NiuA , McDougalA , NingB , SafaF , LukA , MushattDM , et al. COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. Bone Marrow Transplantation2020;15:15. ">Niu 2020</a>; <a href="./references#CD013600-bbs2-0201" title="PeiS , YuanX , ZhiminZZ , RunYR , XieY , MinxueSM , et al. Convalescent plasma to treat COVID-19: Chinese strategy and experiences. medRxiv [Preprint]2020. [DOI: 10.1101/2020.04.07.20056440]">Pei 2020</a>; <a href="./references#CD013600-bbs2-0202" title="PengH , GongT , HuangX , SunX , LuoH , WangW , et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Research and Therapy2020;11(1):291. ">Peng 2020</a>; <a href="./references#CD013600-bbs2-0212" title="SalazarE , PerezKK , AshrafM , ChenJ , CastilloB , ChristensenPA , et al. Treatment of COVID-19 patients with convalescent plasma in Houston, Texas. medRxiv [Preprint]2020. [DOI: 10.1101/2020.05.08.20095471]SalazarE , PerezKK , AshrafM , ChenJ , CastilloB , ChristensenPA , et al. Treatment of COVID-19 patients with convalescent plasma. American Journal of Pathology 2020 May 27 [Epub ahead of print];190:1680-90. [DOI: 10.1016/j.ajpath.2020.05.014]">Salazar 2020b</a>; <a href="./references#CD013600-bbs2-0213" title="ShenC , WangZ , ZhaoF , YangY , LiJ , YuanJ , et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA2020;323(16):1582-9. [DOI: 10.1001/jama.2020.4783]">Shen 2020</a>; <a href="./references#CD013600-bbs2-0215" title="SoleimaniZ , SoleimaniA . ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids. Journal of Maternal-Fetal &amp; Neonatal Medicine 2020 Jul 26 [Epub ahead of print];26:1-4. [DOI: 10.1080/14767058.2020.1797669]">Soleimani 2020</a>; <a href="./references#CD013600-bbs2-0216" title="TaherA , AlalwanAA , NaserN , AlsegaiO , AlaradiA . Acute kidney injury in COVID-19 pneumonia: a single-center experience in Bahrain. Cureus2020;12(8):e9693. ">Taher 2020</a>; <a href="./references#CD013600-bbs2-0217" title="TanL , KangX , ZhangB , ZhengS , LiuB , YuT , et al. A special case of COVID-19 with long duration of viral shedding for 49 days. medRxiv [Preprint]2020. [DOI: 10.1101/2020.03.22.20040071]">Tan 2020</a>; <a href="./references#CD013600-bbs2-0219" title="WangY , ZhangY , YuQ , ZhuK . Convalescent plasma coupled with medications for the treatment of a severe COVID-19 patient: drugs analysis and pharmaceutical care based on the newly established guidelines for COVID-19 remedy. Frontiers in Pharmacology2020;11:966. [DOI: 10.3389/fphar.2020.00966]">Wang 2020</a>; <a href="./references#CD013600-bbs2-0220" title="WrightZ , BersabeA , EdenR , CapA . Successful use of COVID-19 convalescent plasma in a patient recently treated for follicular lymphoma. Clinical Lymphoma, Myeloma and Leukemia 2020 Jun 25 [Epub ahead of print];21(1):66-8. [DOI: 10.1016/j.clml.2020.06.012]">Wright 2020</a>; <a href="./references#CD013600-bbs2-0223" title="XuTM , LinB , ChenC , LiuLG , XueY . Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report. Virology Journal2020;17(1):80. ">Xu 2020b</a>; <a href="./references#CD013600-bbs2-0224" title="YangX , SuiY , LiuF , KangZ , WuS , ZhaoJ , et al. Clinical characteristics and convalescent plasma therapy in severe and critically ill COVID-19 patients. Social Science Research Network 2020 May 5 [Preprint]. [DOI: 10.2139/ssrn.3576894]">Yang 2020</a>; <a href="./references#CD013600-bbs2-0225" title="YeM , FuD , RenY , WangF , WangD , ZhangF , et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology 2020 April 15 [Epub ahead of print];92:1890-901. [DOI: 10.1002/jmv.25882]">Ye 2020</a>; <a href="./references#CD013600-bbs2-0227" title="ZhangB , LiuS , TanT , HuangW , DongY , ChenL , et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest2020;158(1):e9-e13. ">Zhang 2020a</a>; <a href="./references#CD013600-bbs2-0228" title="ZhangB , LiuS , TanT , HuangW , DongY , ChenL , et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020 Mar 31 [Epub ahead of print];158:e9-e13. [DOI: 10.1016/j.chest.2020.03.039]">Zhang 2020b</a>; <a href="./references#CD013600-bbs2-0229" title="ZhangL , PangR , XueX , BaoJ , YeS , DaiY , et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging 2020 Apr 22 [Epub ahead of print];12:6536–42. [DOI: 10.18632/aging.103102]">Zhang 2020c</a>); </p> </li> <li> <p>17 studies were performed with an intervention other than convalescent plasma (<a href="./references#CD013600-bbs2-0047" title="CaoW , LiuX , BaiT , FanH , HongK , SongH , et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infectious Diseases2020;7(3):ofaa102. ">Cao 2020a</a>; <a href="./references#CD013600-bbs2-0048" title="ChenX , LiY , WangJ , CaiH , CaoH , ShengJ . Pregnant women complicated with COVID-19: a clinical analysis of 3 cases. Zhejiang da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences2020;49(2):240-4. ">Chen 2020b</a>; <a href="./references#CD013600-bbs2-0049" title="ChenQ , QuanB , LiX , GaoG , ZhengW , ZhangJ , et al. A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019. Journal of Medical Virology2020;92(6):683-7. ">Chen 2020c</a>; <a href="./references#CD013600-bbs2-0064" title="DíezJM , RomeroC , GajardoR . Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy 2020 May 13 [Epub];12:571-6. [DOI: 10.2217/imt-2020-0095]">Díez 2020</a>; <a href="./references#CD013600-bbs2-0077" title="HuH , MaF , WeiX , FangY . Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. European Heart Journal2020;16:16. ">Hu 2020</a>; <a href="./references#CD013600-bbs2-0086" title="ISRCTN86534580. A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above. Available from www.isrctn.com/ISRCTN86534580 (first received 20 March 2020). ">ISRCTN86534580</a>; <a href="./references#CD013600-bbs2-0089" title="JiangY , HeS , ZhangC , WangX , ChenX , JinY , et al. Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China. Annals of Translational Medicine2020;8(8):547. ">Jiang 2020b</a>; <a href="./references#CD013600-bbs2-0095" title="LinJH , ChenYC , LuCL , HsuYN , WangWJ . Application of plasma exchange in association with higher dose CVVH in cytokine storm complicating COVID-19. Journal of the Formosan Medical Association2020;119(6):1116-8. [DOI: 10.1016/j.jfma.2020.04.023]">Lin 2020</a>; <a href="./references#CD013600-bbs2-0103" title="NCT04261426. The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia. Available from clinicaltrials.gov/ct2/show/NCT04261426 (first received 23 April 2020). ">NCT04261426</a>; <a href="./references#CD013600-bbs2-0114" title="NCT04344379. Prevention of SARS-CoV-2 in hospital workers exposed to the virus. Available from clinicaltrials.gov/show/NCT04344379 (first received 14 April 2020). ">NCT04344379</a>; <a href="./references#CD013600-bbs2-0120" title="NCT04350580. Polyvalent immunoglobulin in COVID-19 related ARDS. Available from clinicaltrials.gov/show/NCT04350580 (first received 17 April 2020). ">NCT04350580</a>; <a href="./references#CD013600-bbs2-0132" title="NCT04368013. Host-pathogen interactions, immune response, and clinical prognosis at COVID-19 - the CoVUm trial. Available from clinicaltrials.gov/show/NCT04368013 (first received 20 April 2020). ">NCT04368013</a>; <a href="./references#CD013600-bbs2-0209" title="RobbianiDF , GaeblerC , MueckschF , CetruloLJ , WangZ , ChoA , et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv [Preprint]2020. [DOI: 10.1101/2020.05.13.092619]">Robbiani 2020</a>; <a href="./references#CD013600-bbs2-0214" title="ShiH , ZhouC , HeP , HuangS , DuanY , WangX , et al. Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection. International Journal of Antimicrobial Agents2020;56(2):105974. [DOI: 10.1016/j.ijantimicag.2020.105974]">Shi 2020</a>; <a href="./references#CD013600-bbs2-0222" title="XieY , CaoS , LiQ , ChenE , DongH , ZhangW , et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. Journal of Infection2020;81(2):318-56. [DOI: 10.1016/j.jinf.2020.03.044]">Xie 2020</a>; <a href="./references#CD013600-bbs2-0063" title="deAssisRR , JainA , NakajimaR , JasinskasA , FelgnerJ , ObieroJM , et al. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent plasma using a coronavirus antigen microarray. bioRxiv [Preprint]2020. [DOI: 10.1101/2020.04.15.043364]">de Assis 2020</a>; <a href="./references#CD013600-bbs2-0061" title="CTRI/2020/10/028547. IND02 for prevention against SARS-CoV-2 infection: a randomized controlled study in moderate to high risk population. Available from ctri.nic.in/Clinicaltrials/showallp.php?mid1=48708&amp;EncHid=&amp;userName=2020/10/028547. ">CTRI/2020/10/028547</a>); </p> </li> <li> <p>five studies pertained to feasibility of collection of convalescent plasma only (<a href="./references#CD013600-bbs2-0045" title="BudhaiA , WuAA , HallL , StraussD , ParadisoS , AlberigoJ , et al. How did we rapidly implement a convalescent plasma program?Transfusion 2020 May 25 [Epub ahead of print];60:1348-55. [DOI: 10.1111/trf.15910]">Budhai 2020</a>; <a href="./references#CD013600-bbs2-0076" title="HashimHT . Convalescent plasma to treat COVID-19: its challenges in Iraq situation. Ethics, Medicine and Public Health 2020 Jul 16 [Epub ahead of print];15:100564. [DOI: 10.1016/j.jemep.2020.100564]">Hashim 2020</a>; <a href="./references#CD013600-bbs2-0113" title="NCT04344015. COVID-19 plasma collection. Available from clinicaltrials.gov/show/NCT04344015 (first received 23 April 2020). ">NCT04344015</a>; <a href="./references#CD013600-bbs2-0115" title="NCT04344977. COVID-19 plasma collection. Available from clinicaltrials.gov/ct2/show/NCT04344977 (first received 14 April 2020). ">NCT04344977</a>; <a href="./references#CD013600-bbs2-0127" title="NCT04360278. Plasma collection from convalescent and/or immunized donors for the treatment of COVID-19. Available from clinicaltrials.gov/show/NCT04360278 (first received 24 April 2020). ">NCT04360278</a>); </p> </li> <li> <p>five studies were cancelled by the investigator before recruiting participants into the study (<a href="./references#CD013600-bbs2-0052" title="ChiCTR2000030312. Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&amp; [A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient]. Available from www.chictr.org.cn/showproj.aspx?proj=50258 (first received 23 April 2020). ">ChiCTR2000030312</a>; <a href="./references#CD013600-bbs2-0053" title="ChiCTR2000030381. Cancelled by investigator. A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient [A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient]. Available from www.chictr.org.cn/showproj.aspx?proj=50290 (first received 23 April 2020). ">ChiCTR2000030381</a>; <a href="./references#CD013600-bbs2-0054" title="ChiCTR2000030442. Combination of tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19). Available from www.chictr.org.cn/showproj.aspx?proj=50380 (first received 23 April 2020). ">ChiCTR2000030442</a>; <a href="./references#CD013600-bbs2-0108" title="NCT04325672. Convalescent plasma to limit coronavirus associated complications: an open label, phase 2A study of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19. Available from clinicaltrials.gov/show/NCT04325672 (first received 23 April 2020). ">NCT04325672</a>; <a href="./references#CD013600-bbs2-0164" title="NCT04467151. Administration of anti-SARS-CoV-2 convalescent plasma in hospitalized, non-ICU patients with COVID-19. Available from clinicaltrials.gov/show/NCT04467151 (first received 10 July 2020). ">NCT04467151</a>); </p> </li> <li> <p>three studies reported standard operating procedure related to plasma donation (<a href="./references#CD013600-bbs2-0044" title="Brasil Ministério da Saúde, Secretaria de Ciência. NA [Tratamento farmacológico para casos internados com SARS-COV-2, do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo]. Available from fi-admin.bvsalud.org/document/view/27t7v (accessed 25 June 2020). ">Brasil Ministerio 2020</a>; <a href="./references#CD013600-bbs2-0073" title="FranchiniM , MaranoG , VelatiC , PatiI , PupellaS , LiumbrunoGM . Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sanguinis2021;116(1):136-7. [DOI: 10.1111/vox.12940]">Franchini 2020</a>; <a href="./references#CD013600-bbs2-0101" title="Ministerio de Salud - Instituto Nacional de Salud. NA [Lineamientos técnicos para uso de plasma convaleciente en pacientes con COVID-19]. Available from fi-admin.bvsalud.org/document/view/nruba2020;1:20. ">Ministerio de Salud 2020</a>); </p> </li> <li> <p>Two references were in Chinese (<a href="./references#CD013600-bbs2-0205" title="QiuT , WangJ , ZhouJ , ZouJ , ChenZ , MaX , et al. The report of two cases infection with novel coronavirus (2019-NCcoV) after kidney transplantation and the association literature analyzation. Chinese Journal of Organ Transplantation2020;41(0):E004. ">Qiu 2020</a>; <a href="./references#CD013600-bbs2-0218" title="TuY , WuX , LiuF , WangJ , LuoY , CaiZ , et al. Two clinical cases of novel coronavirus pneumonia (NCP) in renal transplant recipients. Chinese Journal of Organ Transplantation2020;41(0):E005. ">Tu 2020</a>); both were translated and assessed by Rujan Shrestha and Ya‐Ying Wang via Cochrane TaskExchange. The papers reported on a generalised collection of information about the COVID‐19 infection of two participants relating to aetiology, pathology, symptoms, clinical presentation and some generalised pharmacological treatment methods; </p> </li> <li> <p>five studies were controlled, non‐randomised studies with fewer than 500 participants receiving convalescent plasma (<a href="./references#CD013600-bbs2-0035" title="AbolghasemiH , EshghiP , CheraghaliAM , Imani FooladiAA , Bolouki MoghaddamF , ImanizadehS , et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfusion and Apheresis Science 2020 July 15 [Epub ahead of print];59(5):102875. [DOI: 10.1016/j.transci.2020.102875]">Abolghasemi 2020</a>; <a href="./references#CD013600-bbs2-0118" title="AlbalawiM , ZaidiSZ , AlShehryN , AlAskarA , ZaidiAR , AbdallahRN , et al. Safety and efficacy of convalescent plasma to treat severe COVID-19: protocol for the Saudi collaborative multi-center phase II study. JMIR Research Protocol2020;9(10):e23543. NCT04347681. Potential efficacy of convalescent plasma to treat severe COVID-19 and patients at high risk of developing severe COVID-19. Available from clinicaltrials.gov/show/NCT04347681 (first received 15 April 2020). ">NCT04347681</a>; <a href="./references#CD013600-bbs2-0141" title="NCT04384588. COVID19-convalescent plasma for treating patients with active symptomatic COVID 19 infection (FALP-COVID). Available from clinicaltrials.gov/show/NCT04384588 (first received 12 May 2020). ">NCT04384588</a>; <a href="./references#CD013600-bbs2-0037" title="AllahyariA , Seddigh-ShamsiM , MahmoudiM , Amel JamehdarS , AminiM , MozdourianM , et al. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome. International Immunopharmacology2021;93:107239. [DOI: https://doi.org/10.1016/j.intimp.2020.107239]IRCT20200409047007N1. Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS. Available from en.irct.ir/trial/47058 (first received 12 April 2020). ">Allahyari 2021</a>; <a href="./references#CD013600-bbs2-0085" title="IRCT20200525047562N1. Treatment of COVID-19 patients with convalescent plasma. Available from en.irct.ir/trial/48493 (first received 14 June 2020). ">IRCT20200525047562N1</a>); </p> </li> <li> <p>two studies were controlled studies, but probably not truly randomised (<a href="./references#CD013600-bbs2-0039" title="BaklaushevVP , AveryanovAV , SotnikovaAG , PerkinaAS , IvanovAV , YusubalievaGM , et al. Safety and efficacy of convalescent plasma for COVID-19: the preliminary results of a clinical trial. Journal of Clinical Practice2020;11(2):38-50. ">Baklaushev 2020</a>; <a href="./references#CD013600-bbs2-0206" title="RasheedAM , FatakDF , HashimHA , MauloodMF , KabahKK , AlmusawiYA , et al. The therapeutic effectiveness of convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv [Preprint]2020. [DOI: 10.1101/2020.06.24.20121905]">Rasheed 2020</a>); </p> </li> <li> <p>two studies were pharmacokinetics studies (<a href="./references#CD013600-bbs2-0193" title="NCT04638634. Pharmacokinetics, safety, and tolerability of CSL760, an anti- COVID-19 hyperimmune intravenous immunoglobulin, in healthy adult subjects. Available from clinicaltrials.gov/ct2/show/NCT04638634 (first received 20 November 2020). ">NCT04638634</a>; <a href="./references#CD013600-bbs2-0196" title="NCT04661839. Phase 1 study to evaluate safety and pharmacokinetics of COVID-HIGIV administered as a single dose or a repeat dose in healthy adults. Available from clinicaltrials.gov/show/NCT04661839 (first received 10 December 2020). ">NCT04661839</a>); </p> </li> <li> <p>two studies were withdrawn or suspended (<a href="./references#CD013600-bbs2-0137" title="NCT04377568. Efficacy of human coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children. Available from clinicaltrials.gov/show/NCT04377568 (first received 6 May 2020). ">NCT04377568</a>; <a href="./references#CD013600-bbs2-0208" title="RBR-5r8gv8p. Clinical trial with convalescent plasma for COVID-19 therapy. REBEC (ensaiosclinicos.gov.br) (first received 07 July 2020). ">RBR‐5r8gv8p</a>); </p> </li> <li> <p>one study included an irrelevant participant population (participants exposed to COVID‐19; <a href="./references#CD013600-bbs2-0107" title="NCT04323800. Convalescent plasma to stem coronavirus: a randomized, blinded phase 2 study comparing the efficacy and safety human coronavirus immune plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among adults exposed to COVID-19. Available from clinicaltrials.gov/show/NCT04323800 (first received 23 April 2020). ">NCT04323800</a>); </p> </li> <li> <p>one study was a single‐arm study with fewer than 500 participants receiving hyperimmune immunoglobulin (<a href="./references#CD013600-bbs2-0198" title="NCT04721236. Early use of hyperimmune plasma in COVID-19 (COV-II-PLA). Available from clinicaltrials.gov/ct2/show/NCT04721236 (first received 22 January 2021). ">NCT04721236</a>); </p> </li> <li> <p>one study compared early to deferred convalescent plasma (<a href="./references#CD013600-bbs2-0040" title="BalcellsME , RojasL , Le CorreN , Martínez-ValdebenitoC , CeballosME , FerrésM , et al. Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.17.20196212]">Balcells 2020</a>); </p> </li> <li> <p>one study was on plasma donors (<a href="./references#CD013600-bbs2-0182" title="NCT04555109. Convalescent plasma for COVID-19 research donor study. Available from clinicaltrials.gov/show/NCT04555109 (first received 18 September 2020). ">NCT04555109</a>); </p> </li> <li> <p>one study was terminated early and stopped because the sponsor was changed and a new study on convalescent plasma sponsored by the Italian Medicines Agency <i>(</i>AIFA) was started in Italy (<a href="./references#CD013600-bbs2-0147" title="NCT04393727. Transfusion of convalescent plasma for the early treatment of pneumonIa due to SARSCoV2. Available from clinicaltrials.gov/show/NCT04393727 (first received 19 May 2020). ">NCT04393727</a>); </p> </li> <li> <p>one study is a completed platform trial that did not include a convalescent plasma arm (<a href="./references#CD013600-bbs2-0188" title="NCT04593940. Immune modulators for treating COVID-19 (ACTIV-1 IM). Available from clinicaltrials.gov/ct2/show/NCT04593940 (first retrieved 14 June 2021). ">NCT04593940</a>). </p> </li> </ul> </p> <p>We excluded 34 more studies based on the updated exclusion criteria for this review version (update 4): </p> <p> <ul id="CD013600-list-0102"> <li> <p>14 studies included hyperimmune immunoblogulin as intervention, which is being investigated in a separate review (<a href="./references#CD013600-bbs2-0060" title="CTRI/2020/09/027903. Testing the efficacy and safety of a blood product COVID-19 hyper-immuneglobulin (human) solution in participants with active COVID-19. Available from ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47147 (first received 18 September 2020). ">CTRI/2020/09/027903</a>; <a href="./references#CD013600-bbs2-0092" title="jRCT2031200174. An international multicenter, adaptive, randomized double-blind, placebo-controlled trial of the safety, tolerability and efficacy of anti-coronavirus hyperimmune intravenous immunoglobulin for the treatment of adult hospitalized patients at onset of clinical progression of COVID-19. Available from who.int/trialsearch/Trial2.aspx?TrialID=JPRN-jRCT2031200174 (first received 26 October 2020). ">jRCT2031200174</a>; <a href="./references#CD013600-bbs2-0084" title="IRCT20200508047346N1. Evaluation of the effectiveness of rabbit antibody against coronavirus in patients. Available from www.irct.ir/trial/47953 (first received 13 May 2020). ">IRCT20200508047346N1</a>; <a href="./references#CD013600-bbs2-0131" title="NCT04366245. Clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection. Available from clinicaltrials.gov/show/NCT04366245 (first received 28 April 2020). ">NCT04366245</a>; <a href="./references#CD013600-bbs2-0148" title="NCT04395170. Convalescent plasma compared to anti-COVID-19 human immunoglobulin and standard treatment (TE) in hospitalized patients. Available from clinicaltrials.gov/show/NCT04395170 (first received 20 May 2020). ">NCT04395170</a>; <a href="./references#CD013600-bbs2-0165" title="NCT04468958. Safety, tolerability, and pharmacokinetics of SAB-185 in healthy participants. Available from clinicaltrials.gov/ct2/show/NCT04468958 (first received 13 July 2020). ">NCT04468958</a>; <a href="./references#CD013600-bbs2-0166" title="NCT04469179. Safety, tolerability, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19. Available from clinicaltrials.gov/show/NCT04469179 (first received 13 July 2020). ">NCT04469179</a>; <a href="./references#CD013600-bbs2-0175" title="NCT04514302. Safety and efficacy of anti-SARS-CoV-2 equine antibody fragments (INOSARS) for hospitalized patients with COVID-19. Available from clinicaltrials.gov/show/NCT04514302 (first received 14 August 2020). ">NCT04514302</a>; <a href="./references#CD013600-bbs2-0180" title="EUCTR2020-002542-16-GR. Treatment of patients with coronavirus infection with immunoglobulin. Available from who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002542-16-GR (first received 14 September 2020). NCT04546581. Inpatient treatment with anti-coronavirus immunoglobulin (ITAC). Available from clinicaltrials.gov/show/NCT04546581 (first received 14 September 2020). ">NCT04546581</a>; <a href="./references#CD013600-bbs2-0183" title="NCT04555148. COVIDIG (COVID-19 Hyper-ImmunoGlobulin). Available from clinicaltrials.gov/show/NCT04555148 (first received 18 September 2020). ">NCT04555148</a>; <a href="./references#CD013600-bbs2-0187" title="NCT04573855 - unclear. Treatment with anti-SARS-CoV-2 immunoglobulin in patients with COVID-19. Available from clinicaltrials.gov/show/NCT04573855 (first received 05 October 2020). ">NCT04573855</a>; <a href="./references#CD013600-bbs2-0074" title="EUCTR202000257427. A randomized, double-blind, placebo-controlled phase 2a and 2b study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia. Available from www.clinicaltrialsregister.eu/ctr-search/trial/2020-002574-27/FR (first received 01 July 2020). GaboritB , VanhoveB , Vibet MA , Le ThuautA , LacombeK , DubeeV , et al. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Trials2021;22(199). [DOI: 10.1186/s13063-021-05132-9]NCT04453384. Study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia. Available from clinicaltrials.gov/show/NCT04453384 (first received 01 July 2020). ">Gaborit 2021</a>; <a href="./references#CD013600-bbs2-0189" title="NCT04610502. Efficacy and safety of two hyperimmune equine anti Sars-CoV-2 in COVID-19 patients. Available from clinicaltrials.gov/show/NCT04610502 (first received 30 October 2020). ">NCT04610502</a>; <a href="./references#CD013600-bbs2-0070" title="EUCTR2020-005979-12-GR. Efficacy and safety of XAV-19 for the treatment of moderate to severe COVID-19. Available from https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-005979-12/GR (first received 08 March 2021). ">EUCTR2020‐005979‐12‐GR</a>); </p> </li> <li> <p>10 studies are expanded access studies from the USA (<a href="./references#CD013600-bbs2-0091" title="JoynerMJ , BrunoKA , KlassenSA , KunzeKL , JohnsonPW , LesserER , et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clinical Proceedings2020;95(9):1888-97. ">Joyner 2020</a>; <a href="./references#CD013600-bbs2-0112" title="NCT04338360. Expanded access to convalescent plasma for the treatment of patients with COVID-19. Available from clinicaltrials.gov/show/NCT04338360 (first received 8 April 2020). ">NCT04338360</a>; <a href="./references#CD013600-bbs2-0128" title="NCT04360486. Treatment of COVID-19 with anti-SARS-CoV-2 convalescent plasma (ASCoV2CP). Available from clinicaltrials.gov/show/NCT04360486 (first received 24 April 2020). ">NCT04360486</a>; <a href="./references#CD013600-bbs2-0129" title="NCT04363034. Arkansas expanded access COVID-19 convalescent plasma treatment program. Available from clinicaltrials.gov/ct2/show/NCT04363034 (first received 27 April 2020). ">NCT04363034</a>; <a href="./references#CD013600-bbs2-0134" title="NCT04374370. SARSCoV2 (COVID-19) convalescent plasma (CP) expanded access protocol (EAP). Available from clinicaltrials.gov/show/NCT04374370 (first received 5 May 2020). ">NCT04374370</a>; <a href="./references#CD013600-bbs2-0156" title="Investigational COVID-19 convalescent plasma infusion for severely or life-threateningly ill COVID-19 patients. Available from clinicaltrials.gov/ct2/show/NCT04420988 (first received 09 June 2020). ">NCT04420988</a>; <a href="./references#CD013600-bbs2-0160" title="Experimental expanded access treatment with convalescent plasma for the treatment of patients with COVID-19. Available from clinicaltrials.gov/ct2/show/NCT04445207 (first received 24 June 2020). ">NCT04445207</a>; <a href="./references#CD013600-bbs2-0168" title="NCT04472572. Expanded access to convalescent plasma for treatment of COVID-19. Available from clinicaltrials.gov/show/NCT04472572 (first received 15 July 2020). ">NCT04472572</a>; <a href="./references#CD013600-bbs2-0126" title="NCT04358211. Expanded access to convalescent plasma to treat and prevent pulmonary complications associated with COVID-19. Available from clinicaltrials.gov/show/NCT04358211 (first received 24 April 2020). ">NCT04358211</a>; <a href="./references#CD013600-bbs2-0133" title="NCT04372368. Convalescent plasma for the treatment of patients with COVID-19. Available from clinicaltrials.gov/show/NCT04372368 (first received 04 May 2020). ">NCT04372368</a>). These studies are non‐RCTs, and the expanded access programme is an FDA‐initiated, national, multicentre programme providing access to convalescent plasma for patients with serious or life‐threatening COVID‐19 disease, for investigations outside clinical trials when no alternative therapy options are available (<a href="./references#CD013600-bbs2-0397" title="Convalescent plasma COVID-19 (coronavirus) treatment. Available from www.uscovidplasma.org (accessed 22 September 2022).">US Covid Plasma 2022</a>); </p> </li> <li> <p>three studies were non‐randomised studies, excluded regardless of their sample size (<a href="./references#CD013600-bbs2-0171" title="Investigational treatments for COVID-19 in tertiary care hospital of Pakistan. Available from clinicaltrials.gov/ct2/show/NCT04492501 (first received 30 July 2020). ">NCT04492501</a>; <a href="./references#CD013600-bbs2-0151" title="Use of convalescent plasma for COVID-19. Available from clinicaltrials.gov/ct2/show/NCT04408040 (first received 29 May 2020). ">NCT04408040</a>; <a href="./references#CD013600-bbs2-0158" title="NCT04432272. Antibody-level based analysis of COVID convalescent serum (ABACCuS). Available from clinicaltrials.gov/ct2/show/NCT04432272 (first received 16 June 2020). ">NCT04432272</a>); </p> </li> <li> <p>two studies were single‐arm studies studies, excluded regardless of their sample size (<a href="./references#CD013600-bbs2-0121" title="NCT04352751. Experimental use of convalescent plasma for passive immunization in current COVID-19 pandemic in Pakistan in 2020. Available from clinicaltrials.gov/show/NCT04352751 (first received 20 April 2020). ">NCT04352751</a>; <a href="./references#CD013600-bbs2-0194" title="NCT04642014. Application of convalescent plasma in the treatment of SARS CoV-2 disease (COVID-19) with evaluation of therapy effectiveness. Available from clinicaltrials.gov/show/NCT04642014 (first received 24 November 2020). ">NCT04642014</a>); </p> </li> <li> <p>two studies were observational cohort studies (<a href="./references#CD013600-bbs2-0172" title="Evaluation of coronavirus disease 19 (COVID-19) convalescent plasma. Available from clinicaltrials.gov/ct2/show/NCT04497779 (first received 04 August 2020). ">NCT04497779</a>; <a href="./references#CD013600-bbs2-0179" title="NCT04545047. Observational study of convalescent plasma for treatment of veterans with COVID-19. Available from clinicaltrials.gov/show/NCT04545047 (first received 10 September 2020). ">NCT04545047</a>) and two were prospective case‐only studies (<a href="./references#CD013600-bbs2-0163" title='"NORPLASMA" COVID-19 convalescent plasma treatment monitoring study. Available from clinicaltrials.gov/ct2/show/NCT04463823 (first received 09 July 2020). '>NCT04463823</a>; <a href="./references#CD013600-bbs2-0197" title="NCT04669990. Remdesivir and convalescent plasma therapy for treatment of COVID-19 infection in Nepal: a registry study. Available from clinicaltrials.gov/ct2/show/NCT04669990 (first received 17 December 2020). ">NCT04669990</a>), excluded regardless of their sample size; </p> </li> <li> <p>one study compared high‐titre convalescent plasma to low‐titre convalescent plasma (<a href="./references#CD013600-bbs2-0177" title="NCT04524507. COVID-19 antibody plasma research study in hospitalized patients (UNC CCP RCT). Available from clinicaltrials.gov/show/NCT04524507 (first received 24 August 2020). ">NCT04524507</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013600-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed methodological quality and risk of bias for all 33 included RCTs using RoB 2, recommended in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013600-bbs2-0343" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook2022.">Higgins 2022a</a>). The completed RoB 2 tool with responses to all assessed signalling questions is available online at <a href="https://zenodo.org/record/6685234#.Y3JjvuzP3OR" target="_blank">zenodo.org/record/6685234#.YrMlYEZByHs</a>. </p> <section id="CD013600-sec-0062"> <h4 class="title">Overall judgements for studies that included individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease </h4> <section id="CD013600-sec-0063"> <h5 class="title">All‐cause mortality</h5> <p>Among those studies reporting a mortality outcome, we rated the overall risk of bias to be of some concern in <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>, <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>, <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>, <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>, <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a>, <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>, <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>, <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a> and <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a>. We assessed this outcome on a study level at day 28, day 60 and time to event. For <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, there were some inconsistencies in the adherence to the allocated interventions, which could be due to awareness of the intervention in this open‐label trial (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD013600-tblf-0124" title="">Risk of bias table for Analysis 1.4</a>). In <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>, the outcome analysed was not in accordance with the prespecified analysis plan, as the time point of the mortality outcome was not specified in the study protocol (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>). <a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a> provided no information on the concealment of the allocation sequence (see <a href="./references#CD013600-tblf-0139" title="">Risk of bias table for Analysis 2.1</a>; <a href="./references#CD013600-tblf-0140" title="">Risk of bias table for Analysis 2.2</a>). In one study (<a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>), information on whether the allocation sequence was concealed is missing (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD013600-tblf-0123" title="">Risk of bias table for Analysis 1.3</a>). Also, <a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a> and <a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a> provide no information on the concealment of the allocation sequence (see <a href="./references#CD013600-tblf-0145" title="">Risk of bias table for Analysis 3.1</a>; <a href="./references#CD013600-tblf-0146" title="">Risk of bias table for Analysis 3.2</a>; <a href="./references#CD013600-tblf-0147" title="">Risk of bias table for Analysis 3.3</a>; and see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD013600-tblf-0122" title="">Risk of bias table for Analysis 1.2</a>; <a href="./references#CD013600-tblf-0123" title="">Risk of bias table for Analysis 1.3</a>). <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a> provided insufficient information on whether co‐interventions were balanced across arms (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD013600-tblf-0123" title="">Risk of bias table for Analysis 1.3</a>; <a href="./references#CD013600-tblf-0124" title="">Risk of bias table for Analysis 1.4</a>). For one study (<a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>), the time point of measurement is not consistent with the time point indicated in the trial registry (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>). <a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a> did not publish a protocol and the data that produced this result were not mentioned as predefined outcomes in the trial registration (see <a href="./references#CD013600-tblf-0122" title="">Risk of bias table for Analysis 1.2</a>). <a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a> did not provide enough information on the randomisation process and allocation concealment, and the trial registry only indicates concealment through "Case Record Numbers" (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD013600-tblf-0123" title="">Risk of bias table for Analysis 1.3</a>). </p> <p>We rated the overall risk of bias to be high in <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>, because of baseline differences in hospitalisation between the groups (see <a href="./references#CD013600-tblf-0121" title="">Risk of bias table for Analysis 1.1</a>). </p> <p>We also assessed with a funnel plot the potential risk of publication bias for the outcome all‐cause mortality up to day 28, and there is no indication for publication bias, see <a href="#CD013600-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD013600-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD013600-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD013600-sec-0064"> <h5 class="title">Clinical status</h5> <p>Among those studies reporting at least one of the two outcomes addressing clinical status, we rated the overall risk of bias to be of some concern for <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a> and <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>. We assessed clinical status on a study level, including both improvement of clinical status by the number of participants discharged from hospital and worsening of clinical status by need for invasive mechanical ventilation or death. For <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>, we judged the risk of bias for need for invasive mechanical ventilation or death to be of some concern, as the study provided insufficient information on whether co‐interventions were balanced across arms (see <a href="./references#CD013600-tblf-0126" title="">Risk of bias table for Analysis 1.6</a>). For <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, we judged the risk of bias for participants discharged from hospital to be of some concern, because of some inconsistencies in adherence to the allocated interventions, which could be due to awareness of the intervention in this open‐label trial, as well as because the outcome analysed was not prespecified in the trials registry and a study protocol was not available (see <a href="./references#CD013600-tblf-0125" title="">Risk of bias table for Analysis 1.5</a>). </p> <p>In <a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>, we rated the overall risk of bias to be high. There are some baseline differences in hospitalisation between the two groups (see <a href="./references#CD013600-tblf-0125" title="">Risk of bias table for Analysis 1.5</a>). </p> </section> <section id="CD013600-sec-0065"> <h5 class="title">Quality of life</h5> <p>Only one study reported a quality‐of‐life outcome (<a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>). In this study, we rated the overall risk of bias to be of some concern, because the assessors were aware of the intervention received and it is possible that the assessment could have been influenced by knowledge of intervention received (see <a href="./references#CD013600-tblf-0127" title="">Risk of bias table for Analysis 1.7</a>). </p> </section> <section id="CD013600-sec-0066"> <h5 class="title">Safety</h5> <p>Among those studies that reported at least one of the safety outcomes, we rated the overall risk of bias to be of some concern for <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>, <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a>, <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>, <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>, <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>, <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>, <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a>, <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a>, <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a>, <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>, <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> and <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>. We assessed safety outcomes on a study level and included any adverse events, grade 1 or 2 adverse events, grade 3 to 4 adverse events and serious adverse events. </p> <p>For <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a>, we judged the risk of bias for grade 3 to 4 adverse events to be of some concern, because of some inconsistencies in the adherence to the allocated interventions, which could be due to awareness of the intervention in this open‐label trial. For <a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a> and <a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a>, the safety data were provided at our request by the study authors, and it is not clear whether data for this outcome were collected from all, or nearly all the participants randomised. There is also no information available on how safety was measured (see <a href="./references#CD013600-tblf-0130" title="">Risk of bias table for Analysis 1.10</a>). <a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a> gave no information on whether the allocation sequence was concealed and the outcome assessors were aware of the intervention received (see <a href="./references#CD013600-tblf-0131" title="">Risk of bias table for Analysis 1.11</a>). In <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>, too, the outcome assessors were aware of the interventions received, but external monitoring was performed at all sites to assess protocol adherence, reporting of adverse events and accuracy of data entry (see <a href="./references#CD013600-tblf-0130" title="">Risk of bias table for Analysis 1.10</a>; <a href="./references#CD013600-tblf-0131" title="">Risk of bias table for Analysis 1.11</a>). There is not enough information available in <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a> to evaluate the measurement of the outcome and the outcome is not predefined in the registry of supplemental material (see <a href="./references#CD013600-tblf-0144" title="">Risk of bias table for Analysis 2.6</a>). <a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a> and <a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a>did not blind the assessor, so the assessment could have been influenced by knowledge of the intervention received (see <a href="./references#CD013600-tblf-0131" title="">Risk of bias table for Analysis 1.11</a>). <a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a> did not predefine the outcome in the clinical trials registry and there is no protocol available (see <a href="./references#CD013600-tblf-0128" title="">Risk of bias table for Analysis 1.8</a>). <a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a> did not clearly indicate whether all the participants were included in the analysis and the assessors were aware of the intervention allocation (see <a href="./references#CD013600-tblf-0128" title="">Risk of bias table for Analysis 1.8</a>). In <a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a> and in <a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a>, the assessment of the outcome could have been influenced by knowledge of intervention received (see <a href="./references#CD013600-tblf-0128" title="">Risk of bias table for Analysis 1.8</a>; <a href="./references#CD013600-tblf-0130" title="">Risk of bias table for Analysis 1.10</a>; <a href="./references#CD013600-tblf-0131" title="">Risk of bias table for Analysis 1.11</a>). <a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> did not provide information on whether the outcome measure was appropriate and the outcome assessors were not blinded (see <a href="./references#CD013600-tblf-0128" title="">Risk of bias table for Analysis 1.8</a>; <a href="./references#CD013600-tblf-0129" title="">Risk of bias table for Analysis 1.9</a>; <a href="./references#CD013600-tblf-0130" title="">Risk of bias table for Analysis 1.10</a>). <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a> did not blind the assessors either, the data that produced this result were not analysed in accordance with the predefined outcomes stated in the trials registry and the protocol was not available (see <a href="./references#CD013600-tblf-0128" title="">Risk of bias table for Analysis 1.8</a>). </p> </section> </section> <section id="CD013600-sec-0067"> <h4 class="title">Overall judgements for studies that included individuals with a confirmed diagnosis of COVID‐19 and mild disease </h4> <section id="CD013600-sec-0068"> <h5 class="title">All‐cause mortality</h5> <p>Among those studies reporting a mortality outcome, we rated the overall risk of bias to be of some concern for <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>. There is not enough information available on the allocation sequence concealment, as the full‐text article is not published yet. In addition, the trials registry does not provide enough information on missing data (see <a href="./references#CD013600-tblf-0157" title="">Risk of bias table for Analysis 5.1</a>). </p> </section> <section id="CD013600-sec-0069"> <h5 class="title">Admission to hospital or death</h5> <p>Among those studies reporting admission to hospital or death, we rated the overall risk of bias to be of some concern for <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>. The trials registry did not provide enough information on the allocation sequence concealment and there are not enough information on missing data and the measurement of the outcome (see <a href="./references#CD013600-tblf-0158" title="">Risk of bias table for Analysis 5.2</a>). </p> </section> <section id="CD013600-sec-0070"> <h5 class="title">Symptom resolution</h5> <p>We assessed symptom resolution on a study level, including symptom resolution by all initial symptoms resolved (asymptomatic) at day 14, day 28, and at longest follow‐up available, and time to symptom resolution. We rated the overall risk of bias to be of some concern for <a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a> for the outcome all initial symptoms resolved (asymptomatic) at day 14 and day 28. There is not enough information available yet on the allocation sequence concealment, as the full‐text article has not yet been published. In addition, the trials registry does not provide enough information on missing data (see <a href="./references#CD013600-tblf-0160" title="">Risk of bias table for Analysis 5.4</a>; <a href="./references#CD013600-tblf-0159" title="">Risk of bias table for Analysis 5.3</a>) </p> </section> <section id="CD013600-sec-0071"> <h5 class="title">Quality of life</h5> <p>None of the studies that included individuals with a confirmed diagnosis of COVID‐19 and mild disease examined quality‐of‐life outcomes. </p> </section> <section id="CD013600-sec-0072"> <h5 class="title">Safety</h5> <p>Among those studies reporting at least one of the safety outcomes, we rated the overall risk of bias to be of some concern for <a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>. This study does not provide enough information to judge whether the outcome was measured appropriately (see <a href="./references#CD013600-tblf-0155" title="">Risk of bias table for Analysis 4.8</a>; <a href="./references#CD013600-tblf-0156" title="">Risk of bias table for Analysis 4.9</a>). </p> </section> </section> </section> <section id="CD013600-sec-0073"> <h3 class="title" id="CD013600-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD013600-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with moderate to severe disease</a>; <a href="./full#CD013600-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Convalescent plasma compared to standard plasma for individuals with moderate to severe disease</a>; <a href="./full#CD013600-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ Convalescent plasma compared to human immunoglobulin for individuals with moderate to severe disease</a>; <a href="./full#CD013600-tbl-0004"><b>Summary of findings 4</b> Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with mild disease</a>; <a href="./full#CD013600-tbl-0005"><b>Summary of findings 5</b> Summary of findings table ‐ Convalescent plasma compared to standard plasma for outpatients with mild disease</a> </p> <section id="CD013600-sec-0074"> <h4 class="title">Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</h4> <p>We present the summary of findings and the certainty of the evidence for our prioritised outcomes for individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease in <a href="./full#CD013600-tbl-0001">summary of findings Table 1</a> (convalescent plasma versus placebo or standard care alone), <a href="./full#CD013600-tbl-0002">summary of findings Table 2</a> (convalescent plasma versus standard plasma) and <a href="./full#CD013600-tbl-0003">summary of findings Table 3</a> (convalescent plasma versus human immunoglobulin). We assessed disease severity with the need for respiratory support according to the WHO clinical progression scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). </p> <section id="CD013600-sec-0075"> <h5 class="title">Convalescent plasma versus placebo or standard care alone</h5> <section id="CD013600-sec-0076"> <h6 class="title">Primary outcomes (included in the summary of findings table)</h6> <section id="CD013600-sec-0077"> <p><b>All‐cause mortality</b></p> <p>We assessed all‐cause mortality at day 28, day 60, by time until death and during hospital stay. </p> <p>Twenty‐one studies reported all‐cause mortality for 19,021 participants. Considering the reported event rates across studies, we estimated that 225 of 1000 participants die at up to 28 days when treated with placebo or standard care alone. Treatment with convalescent plasma does not reduce all‐cause mortality at up to day 28 (RR 0.98, 95% CI 0.92 to 1.03; 220 per 1000; 21 studies, 19,021 participants; I² = 1%; high‐certainty evidence; <a href="./references#CD013600-fig-0003" title="">Analysis 1.1</a>); at day 60 (RR 0.74, 95% CI 0.49 to 1.12; 3 studies, 272 participants; I² = 0%; <a href="./references#CD013600-fig-0004" title="">Analysis 1.2</a>); when measured over time (HR 0.98, 95% CI 0.92 to 1.04; 16 studies, 17,070 participants; I² = 0%; <a href="./references#CD013600-fig-0005" title="">Analysis 1.3</a>); or during hospital stay (RR 0.97, 95% CI 0.87 to 1.08; 4 studies, 2556 participants; I² = 0%; <a href="./references#CD013600-fig-0006" title="">Analysis 1.4</a>). </p> <p> <ul id="CD013600-list-0103"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0104"> <li> <p><b>Severity of disease:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to all‐cause mortality for people with moderate disease (WHO score 4 and 5) or severe disease (WHO score ≥ 6), according to the WHO Clinical Progression Scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD013600-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD013600-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD013600-fig-0006" title="">Analysis 1.4</a>). </p> </li> <li> <p><b>Antibodies in recipients detected at baseline:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the detection of antibodies in the recipients at baseline (<a href="./references#CD013600-fig-0047" title="">Analysis 6.1</a>). </p> </li> <li> <p><b>Length of time since symptom onset:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the length of time since symptom onset(<a href="./references#CD013600-fig-0051" title="">Analysis 7.1</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the pre‐existing condition of immunosuppression at baseline (<a href="./references#CD013600-fig-0059" title="">Analysis 10.1</a>); diabetes at baseline (<a href="./references#CD013600-fig-0064" title="">Analysis 12.1</a>); respiratory disease at baseline (<a href="./references#CD013600-fig-0070" title="">Analysis 14.1</a>); or hypertension at baseline (<a href="./references#CD013600-fig-0073" title="">Analysis 15.1</a>); participants' age (<a href="./references#CD013600-fig-0075" title="">Analysis 16.1</a>), sex (<a href="./references#CD013600-fig-0081" title="">Analysis 18.1</a>), or country income groups according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0087" title="">Analysis 20.1</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard placebo or standard care alone and the outcome all‐cause mortality. </p> </li> </ul> </li> <li> <p><b>Sensitivity analyses</b> </p> <ul id="CD013600-list-0105"> <li> <p>We summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0009">Table 4</a>. Reported effects of our main analysis were robust when we removed studies at high risk of bias or studies that were terminated early. We did not include any preprint articles in the main analysis of this outcome. </p> </li> </ul> </li> </ul> </p> <div class="table" id="CD013600-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses for the comparison of convalescent plasma versus placebo or standard care alone for the population of individuals with moderate to severe disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Main analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias (excluding studies<sup>a</sup> at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Publication status (excluding preprints<sup>b</sup>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study termination (excluding studies terminated early<sup>c</sup>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.92 to 1.03); including 19,021 participants from 21 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.93 to 1.03); including 18,510 participants from 20 studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.92 to 1.03); including 19,021 participants from 21 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.93 to 1.03); including 17,460 participants from 16 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation (for the subgroup of participants not requiring invasive mechanical ventilation at baseline, i.e. WHO ≤ 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (95% CI 0.97 to 1.11); including 14,477 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (95% CI 0.97 to 1.07); including 13,966 participants from 5 studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (95% CI 0.97 to 1.11); including 14,477 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (95% CI 0.96 to 1.09); including 13,556 participants from 5 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12,721 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12,721 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12.,21 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12,534 participants from 4 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (95% CI 0.96 to 1.42); including <br/>2392 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (95% CI 0.96 to 1.42); including <br/>2392 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (95% CI 0.96 to 1.42); including <br/>2392 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18 (95% CI 0.77 to 1.80); including 1471 participants from 5 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (95% CI 0.91 to 1.44) including <br/>3901 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (95% CI 0.91 to 1.44) including <br/>3901 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (95% CI 0.91 to 1.44) including <br/>3901 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95% CI 0.81 to 1.50); including 2980 participants from 5 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NR:</b> not reported; <b>RR:</b> risk ratio; <b>WHO:</b> World Health Organization </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Excluded studies with high risk of bias (<a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>).<br/><sup>b</sup>Excluded preprints: no study.<br/><sup>c</sup>Excluded studies with premature termination (<a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>). </p> </div> </div> </section> <section id="CD013600-sec-0078"> <p><b>Clinical status</b></p> <p>We assessed the clinical status of participants by the need for invasive mechanical ventilation or death (worsening of clinical status) and by participants discharged from hospital (improvement of clinical status) up to day 28, day 60, and up to longest follow‐up. </p> <p> <ul id="CD013600-list-0106"> <li> <p><b>Worsening of clinical status:</b> six studies reported the need for invasive mechanical ventilation or death for 14,477 participants. Considering the reported event rates within the study, we estimated that 287 of 1000 participants not treated with convalescent plasma needed invasive mechanical ventilation or died. Evidence suggests that treatment with convalescent plasma has little to no impact on the need for invasive mechanical ventilation or death when compared to no convalescent plasma (RR 1.03, 95% CI 0.97 to 1.11; 296 per 1000; I² = 13%; high‐certainty evidence; <a href="./references#CD013600-fig-0007" title="">Analysis 1.5</a>). </p> </li> <li> <p><b>Improvement of clinical status:</b> six studies reported the number of participants discharged from hospital for 12,721 participants. Considering the reported event rates within the study, we estimated that 665 of 1000 participants not treated with convalescent plasma were discharged from hospital. Evidence suggests that treatment with convalescent plasma has no impact on whether participants are discharged from hospital when compared to no convalescent plasma (RR 1.00, 95% CI 0.97 to 1.02; 665 per 1000; I² = 0%; high‐certainty evidence; <a href="./references#CD013600-fig-0008" title="">Analysis 1.6</a>). </p> </li> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0107"> <li> <p><b>Severity of disease:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the need for invasive mechanical ventilation or death for people with moderate disease (WHO score 4 and 5) or severe disease (WHO score ≥ 6), according to WHO Clinical Progression Scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-fig-0007" title="">Analysis 1.5</a>). We did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the number of participants discharged from hospital for people with moderate disease (WHO score 4 and 5), or severe disease (WHO score ≥ 6), according to WHO Clinical Progression Scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-fig-0008" title="">Analysis 1.6</a>). </p> </li> <li> <p><b>Antibodies in recipients detected at baseline:</b> for both clinical status outcomes, the test for subgroup differences suggests significant subgroup differences in the effectiveness of convalescent plasma with regard to antibodies in recipients detected at baseline (P = 0.02; I² = 82.8%; 2 studies; <a href="./references#CD013600-fig-0049" title="">Analysis 6.3</a>); (P = 0.04; I² = 76.9%; 2 studies; <a href="./references#CD013600-fig-0050" title="">Analysis 6.4</a>), however, due to the small number of studies included in both subgroup analyses and the high heterogeneity, we are uncertain whether the analyses produced useful findings. </p> </li> <li> <p><b>Length of time since symptom onset:</b> for the outcome 'need for invasive mechanical ventilation or death', we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the length of time since symptom onset onset; <a href="./references#CD013600-fig-0053" title="">Analysis 7.3</a>). For the outcome 'participants discharged from hospital, we identified significant subgroup differences in the effect of convalescent plasma with regard to the length of time since symptom onset (P = 0.09; I² = 65.2%; 2 studies; <a href="./references#CD013600-fig-0054" title="">Analysis 7.4</a>), however, due to the small number of studies included in the subgroup analysis and the high heterogeneity, we are uncertain whether the analysis produced useful findings. </p> </li> <li> <p><b>Other subgroups</b> </p> <ul id="CD013600-list-0108"> <li> <p>For the outcome 'need for invasive mechanical ventilation or death', we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the pre‐existing condition of diabetes at baseline (<a href="./references#CD013600-fig-0065" title="">Analysis 12.2</a>); or respiratory disease at baseline (<a href="./references#CD013600-fig-0071" title="">Analysis 14.2</a>). We identified significant subgroup differences for the effect of convalescent plasma with regard to participants' age (P = 0.02; I² = 68%; 2 studies; <a href="./references#CD013600-fig-0076" title="">Analysis 16.2</a>) and sex (P = 0.04; 3 studies; I² = 75.6%, <a href="./references#CD013600-fig-0082" title="">Analysis 18.2</a>), however due to the small number of studies included in the subgroup analyses and the high heterogeneity, we are uncertain whether the analyses produced useful findings. We did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0088" title="">Analysis 20.2</a>). </p> </li> <li> <p>For the outcome 'participants discharged from hospital', we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the pre‐existing condition of immunosuppression at baseline (<a href="./references#CD013600-fig-0060" title="">Analysis 10.2</a>); diabetes at baseline (<a href="./references#CD013600-fig-0066" title="">Analysis 12.3</a>); respiratory disease at baseline (<a href="./references#CD013600-fig-0072" title="">Analysis 14.3</a>); or hypertension at baseline (<a href="./references#CD013600-fig-0074" title="">Analysis 15.2</a>); or with regard to participants' age (<a href="./references#CD013600-fig-0077" title="">Analysis 16.3</a>), sex (<a href="./references#CD013600-fig-0083" title="">Analysis 18.3</a>); or country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0089" title="">Analysis 20.3</a>). </p> </li> </ul> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone for both outcomes summarised under 'clinical status'. </p> </li> </ul> </li> <li> <p><b>Sensitivity analyses:</b> we summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0009">Table 4</a>. Reported effects of our main analyses were robust when we removed studies at high risk of bias, or studies that were terminated early. We did not include any preprint articles in the main analysis of this outcome. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0079"> <p><b>Quality of life</b></p> <p>We assessed quality of life, including fatigue and neurological functioning of participants, if assessed with standardised scales (e.g. WHOQOL‐100) for the following time points: at up to 7 days, up to 28 days, and longest follow‐up available. </p> <p>One study reported quality of life, assessed with the standardised scale EQ‐5D‐5L questionnaire at day 28, for 483 participants (<a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a>). Considering the reported event rates within the study, we estimated a mean quality of life of 72 when treated without convalescent plasma. Evidence suggests that treatment with convalescent plasma may have little to no impact on quality of life up to day 28 when compared to no convalescent plasma (MD 1.00, 95% CI −2.14 to 4.14; low‐certainty evidence; <a href="./references#CD013600-fig-0009" title="">Analysis 1.7</a>). Our main reasons for downgrading were very serious imprecision, because of few participants and wide confidence interval. </p> <p> <ul id="CD013600-list-0109"> <li> <p><b>Subgroup analyses:</b> we could not perform any of our planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone. </p> </li> <li> <p><b>Sensitivity analyses:</b> we summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0009">Table 4</a>. We did not include any studies at high risk of bias, preprint articles, or studies terminated early in the main analysis of this outcome. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0080"> <p><b>Adverse events (grade 3 to 4)</b></p> <p>We defined the outcome as the number of participants with any grades 3 to 4 adverse event. We summarised data in <a href="#CD013600-tbl-0010">Table 5</a>, including the potential relationship between the intervention and the adverse event, as reported in the primary studies. </p> <div class="table" id="CD013600-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events of any grade</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Any grade AEs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Convalescent plasma group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 in CP group and 224 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0110"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> <li> <p>15 individuals with transfusion‐related events, within 6 h of CP transfusion</p> <ul id="CD013600-list-0111"> <li> <p>1 with pain at the infusion site</p> </li> <li> <p>1 with chills</p> </li> <li> <p>1 with nausea</p> </li> <li> <p>1 with bradycardia</p> </li> <li> <p>1 with dizziness</p> </li> <li> <p>3 with fever and tachycardia</p> </li> <li> <p>2 with dyspnoea</p> </li> <li> <p>2 with blockage of an intravenous catheter</p> </li> <li> <p>3 with mortality possibly related to CP transfusion</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0112"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 in CP group and 20 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0113"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> <li> <p>3 transient adverse reactions, but not considered to be related to therapy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0114"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 in CP group and 172 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0115"> <li> <p>4 individuals with grade 3‐4 AEs, included in Analysis 1.14</p> </li> <li> <p>10 individuals with transfusion‐related events:</p> <ul id="CD013600-list-0116"> <li> <p>2 fever</p> </li> <li> <p>1 nausea/vomiting</p> </li> <li> <p>5 dyspnoea</p> </li> <li> <p>2 allergic reaction (immediate)</p> </li> <li> <p>0 TRALI</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0117"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP and 39 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0118"> <li> <p>3 treatment‐related AEs</p> <ul id="CD013600-list-0119"> <li> <p>nausea, pruritis, and an acute allergic reaction; all grade 2</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 in CP group, 307 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0120"> <li> <p>35 individuals with infusion‐related complications:</p> <ul id="CD013600-list-0121"> <li> <p>13 TAD</p> </li> <li> <p>9 minor allergic reaction</p> </li> <li> <p>5 TACO</p> </li> <li> <p>4 febrile non‐haemolytic reaction</p> </li> <li> <p>2 other (hypertensive reaction</p> </li> <li> <p>1 hypotensive reaction</p> </li> <li> <p>1 possible TRALI</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 in CP and 71 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0122"> <li> <p>0 serious adverse reactions (≥ grade 3) attributable to CP transfusion were observed during study follow‐up </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 in CP group, 163 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0123"> <li> <p>19 individuals with infusion‐related side effects:</p> <ul id="CD013600-list-0124"> <li> <p>0 TRALI</p> </li> <li> <p>2 serious allergic transfusion reactions</p> </li> <li> <p>3 TACO</p> </li> <li> <p>5 non‐haemolytic febrile reaction</p> </li> <li> <p>9 other related side effects</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1078 in CP group, 909 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0125"> <li> <p>1 transfusion reaction</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0126"> <li> <p>0 transfusion reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 in CP group and 43 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0127"> <li> <p>0 individuals with serious transfusion‐related AEs</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 in CP group and 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0128"> <li> <p>0 individuals with transfusion‐related complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 in CP and 14 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0129"> <li> <p>1 patient developed high fever within two hours after the first plasma administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0130"> <li> <p>0 AEs reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5795 in CP group and 5763 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0131"> <li> <p>13 individuals with transfusion‐related serious adverse reactions reported to SHOT:</p> <ul id="CD013600-list-0132"> <li> <p>9 with pulmonary reactions (including 3 deaths possibly related to transfusion)</p> </li> <li> <p>4 with serious febrile, allergic or hypotensive reactions</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 in CP, 67 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0133"> <li> <p>15 AEs, of these, 3 AEs were judged definitely related and 3 judged to be possibly related to plasma transfusion, while the rest were thought to be unrelated to plasma transfusion. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0134"> <li> <p>14 AEs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 in CP, 52 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0135"> <li> <p>Only number of SAEs reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 in CP group and 254 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0136"> <li> <p>3 participants had serious infusion reactions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 in CP group and 51 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0137"> <li> <p>2 individuals with transfusion‐related AEs</p> <ul id="CD013600-list-0138"> <li> <p>1 with possible severe TAD (shortness of breath, cyanosis, and severe dyspnoea) within 6 h of transfusion </p> </li> <li> <p>1 with non‐severe allergic transfusion reaction and probable non‐severe febrile non‐haemolytic transfusion reaction (chills and rashes) within 2 h of transfusion </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 in CP and 241 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0139"> <li> <p>2 events with worsening of respiratory failure without fever</p> </li> <li> <p>2 events with worsening of respiratory failure with fever and a skin rash</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 in CP and 463 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0140"> <li> <p>8 transfusion reactions</p> <ul id="CD013600-list-0141"> <li> <p>1 of these TRALI or TACO</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0142"> <li> <p>2 transfusion reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 in CP and 30 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013600-list-0143"> <li> <p>0 participants with any serious side effects</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP group 40 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0144"> <li> <p>0 individuals with transfusion‐related AEs</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 in CP and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0145"> <li> <p>2 individuals with transfusion‐related AEs:</p> <ul id="CD013600-list-0146"> <li> <p>2 allergic reactions</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0147"> <li> <p>4 allergic reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 in CP group and</p> <p>105 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0148"> <li> <p>11 individuals with transfusion‐related events:</p> <ul id="CD013600-list-0149"> <li> <p>0 TRALI</p> </li> <li> <p>0 TACO</p> </li> <li> <p>5 non‐haemolytic febrile reaction</p> </li> <li> <p>4 allergic reaction</p> </li> <li> <p>1 unexplained event</p> </li> <li> <p>1 technical resolution event</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0150"> <li> <p>2 individuals with transfusion‐related events:</p> <ul id="CD013600-list-0151"> <li> <p>allergic reactions</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 in CP group and 51 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0152"> <li> <p>1 grade 1 allergic reaction</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0153"> <li> <p>1 grade 1 allergic reaction</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus standard plasma for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 in CP group and 15</p> <p>in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0154"> <li> <p>1 individual with transfusion‐related events: signs of mild urticaria during plasma transfusion </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0155"> <li> <p>1 individual with transfusion‐related events: signs of mild urticaria during plasma transfusion </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 in CP group and 95 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0156"> <li> <p>0 SAEs associated with plasma treatments</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 in CP, 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0157"> <li> <p>1 participant experienced a serious transfusion reaction after a small volume was administered and thus did not complete the 2‐unit administration </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 in CP group, 18 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0158"> <li> <p>0 infusion‐related reactions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0159"> <li> <p>1 infusion‐related reaction (hypotension)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 in CP group and 72 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0160"> <li> <p>4 individual with probably or definitely transfusion‐related events, included worsening anaemia, urticaria, skin rash, and transfusion‐associated circulatory overload </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0161"> <li> <p>3 individuals with probably or definitely transfusion‐related events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 in CP, 60 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0162"> <li> <p>The CP group did not develop adverse effects attributable to its administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0163"> <li> <p>2 participants in the IVIg group developed AEs associated with its administration</p> <ul id="CD013600-list-0164"> <li> <p>1 anaphylactic reaction</p> </li> <li> <p>1 hypertensive crisis</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with asymptomatic or mild disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 in CP group and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0165"> <li> <p>0 individuals with solicited AEs (the definition was unclear and we were unsure whether only drug‐related adverse events were assessed, and we did not receive additional information from the study authors) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0166"> <li> <p>0 individuals with solicited AEs (the definition was unclear and we were unsure whether only drug‐related adverse events were assessed, and we did not receive additional information from the study authors) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 in CP, 188 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0167"> <li> <p>24 treatment‐related AEs:</p> <ul id="CD013600-list-0168"> <li> <p>mild allergic reactions, fever, and local reactions</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0169"> <li> <p>8 treatment‐related AEs</p> <ul id="CD013600-list-0170"> <li> <p>2 local reactions</p> </li> <li> <p>3 vasovagal syndrome</p> </li> <li> <p>2 fever or chills</p> </li> <li> <p>1 gastrointestinal symptoms</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Convalescent plasma versus standard plasma for individuals with asymptomatic or mild disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>592 in CP and 589 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0171"> <li> <p>2 severe transfusion reactions</p> <ul id="CD013600-list-0172"> <li> <p>1 pneumonia</p> </li> <li> <p>1 unspecified</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0173"> <li> <p>2 participants with Infusion‐related reaction and 0 severe reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>CP:</b> convalescent plasma; <b>IVIg:</b> intravenous immunoglobulin; <b>NR:</b> not reported; <b>SAE:</b> serious adverse event; <b>SHOT:</b> serious hazards of transfusion; <b>TACO:</b> transfusion‐associated circulatory overload; <b>TAD:</b> transfusion‐associated dyspnoea; <b>TRALI:</b> transfusion‐related acute lung injury </p> </td> </tr> </tbody> </table> </div> <p>Six studies reported grade 3 to 4 adverse events for both groups in a total of 2392 participants. Considering the reported event rates across studies, we estimated that 181 of 1000 participants not treated with convalescent plasma experience a grade 3 or 4 adverse event. Evidence suggests that treatment with convalescent plasma may have little to no effect on the risk of grades 3 and 4 adverse events (RR 1.17, 95% CI 0.96 to 1.42; 212 per 1000; I² = 31%; low‐certainty evidence; <a href="./references#CD013600-fig-0012" title="">Analysis 1.10</a>). Our main reasons for downgrading were serious indirectness, because some studies did not provide clear definitions of how the adverse events were measured and the number of events are inconsistent, and suspected publication bias, because most studies assessed and reported safety outcomes for the convalescent plasma group only. </p> <p> <ul id="CD013600-list-0174"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0175"> <li> <p><b>Severity of disease:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to grade 3 or 4 adverse events for people with moderate disease (WHO score 4 and 5), or moderate to severe disease (WHO score ≥ 4), according to WHO Clinical Progression Scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-fig-0012" title="">Analysis 1.10</a>). </p> </li> <li> <p><b>Other subgroups:</b> we identified significant subgroup differences for the effect of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; P = 0.07; I² = 68.5%; 5 studies; <a href="./references#CD013600-fig-0090" title="">Analysis 20.4</a>), however due to the small number of studies included in the subgroup analyses and the high heterogeneity, we are uncertain whether the analyses produced useful findings. </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for any adverse events. </p> </li> </ul> </li> <li> <p><b>Sensitivity analyses:</b> we summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0009">Table 4</a>. The effects of our main analysis for the outcome grade 3 or 4 adverse events were robust when we removed a study that was terminated early. We did not include any studies at high risk of bias or preprint articles in the main analysis of this outcome. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0081"> <p><b>Serious adverse events</b></p> <p>We summarised data on serious adverse events reported only in participants who received convalescent plasma without reporting in the control group, and adverse events with a potential relationship to transfusion in <a href="#CD013600-tbl-0011">Table 6</a>. </p> <div class="table" id="CD013600-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CP group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 in CP group and 224 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 in CP group and 20 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 in CP group and 43 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP group and 39 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0176"> <li> <p>12 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0177"> <li> <p>15 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 in CP group, 307 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0178"> <li> <p>205 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0179"> <li> <p>81 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 in CP group, 204 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 in CP group, 71 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 in CP group, 163 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0180"> <li> <p>66 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0181"> <li> <p>34 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1078 in CP group, 909 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0182"> <li> <p>32 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0183"> <li> <p>12 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 in group and 43 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 in group and 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 in CP group and 14 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5795 in group and 5763 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 in CP group, 67 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 in CP, 52 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0184"> <li> <p>22 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0185"> <li> <p>25 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 in CP group and 254 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 in CP group and 241 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 in CP group and 463 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 in CP group and 30 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP group and 40 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 in CP group and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 in CP group and 105 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0186"> <li> <p>54 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0187"> <li> <p>19 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 in CP group and 51 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus standard plasma for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 in CP group and 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 in CP group and 95 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 in CP group, 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0188"> <li> <p>16 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0189"> <li> <p>4 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 in CP group, 18 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0190"> <li> <p>2 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0191"> <li> <p>1 individual with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 in CP group an 72 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0192"> <li> <p>39 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0193"> <li> <p>26 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 in CP group and 60 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with mild disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 in CP group and 188 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0194"> <li> <p>25 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0195"> <li> <p>22 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 in CP group and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Convalescent plasma versus standard plasma for individuals with mild disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>592 in CP group and 589 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CP:</b> convalescent plasma; <b>NR:</b> not reported; <b>TACO:</b> transfusion‐associated circulatory overload; <b>TRALI:</b> transfusion‐related acute lung injury; <b>SAEs:</b> serious adverse events </p> </td> </tr> </tbody> </table> </div> <p>Six studies reported serious adverse events for both groups and a total of 4901 participants. Considering the event rates reported across studies, we estimated that 118 of 1000 participants not treated with convalescent plasma experienced a serious adverse event. Evidence suggests that treatment with convalescent plasma probably has little to no effect on the risk of serious adverse events (RR 1.14, 95% CI 0.91 to 1.44; 135 per 1000; 6 studies, 3901 participants; I² = 45%%; moderate‐certainty evidence; <a href="./references#CD013600-fig-0013" title="">Analysis 1.11</a>). Our main reason for downgrading was suspected publication bias because most studies assessed and reported transfusion‐related events only; that is, they reported safety data only for the intervention group. </p> <p> <ul id="CD013600-list-0196"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0197"> <li> <p><b>Severity of disease:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to serious adverse events for people with moderate disease (WHO score 4 and 5), or moderate to severe disease (WHO score ≥ 4), according to WHO Clinical Progression Scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-fig-0013" title="">Analysis 1.11</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0091" title="">Analysis 20.5</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for any outcome that summarised adverse events. </p> </li> </ul> </li> <li> <p><b>Sensitivity analyses</b> </p> <ul id="CD013600-list-0198"> <li> <p>We summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0009">Table 4</a>. Reported effects of our main analysis for the outcome serious adverse events were robust when we removed a study that was terminated early. We did not include any studies at high risk of bias, or preprint articles in the main analysis of this outcome. </p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD013600-sec-0082"> <h6 class="title">Secondary outcomes (not included in the summary of findings table)</h6> <section id="CD013600-sec-0083"> <p><b>Improvement of clinical status</b></p> <p>We assessed improvement of clinical status up to day 28, and up to longest follow‐up.</p> <p>Two studies reported weaning or liberation from invasive mechanical ventilation in surviving patients for 630 participants; the subgroup of participants who were ventilated at baseline (i.e. WHO ≥ 7). Evidence suggests that treatment with convalescent plasma may have little to no impact on being weaned or liberated from invasive mechanical ventilation (RR 1.04, 95% CI 0.57 to 1.93; I² = 75%; <a href="./references#CD013600-fig-0014" title="">Analysis 1.12</a>). Two studies reported ventilator‐free days by day 28 for 1028 participants. Evidence suggests that treatment with convalescent plasma could have little to no impact on ventilator‐free days (MD −0.53, 95% CI −1.90 to 0.84; I² = 0%; <a href="./references#CD013600-fig-0015" title="">Analysis 1.13</a>). Two studies reported liberation from supplemental oxygen in surviving patients for 560 participants; the subgroup of participants requiring any supplemental oxygen or ventilator support at baseline. Evidence suggests little to no difference in the chance of being liberated from supplemental oxygen when treated with convalescent plasma (RR 0.99, 95% CI 0.91 to 1.08; I² = 0%; <a href="./references#CD013600-fig-0016" title="">Analysis 1.14</a>). </p> </section> <section id="CD013600-sec-0084"> <p><b>Need for dialysis</b></p> <p>Two studies reported the need for dialysis at up to 28 days for 12,325 participants. Evidence suggests little to no difference between participants receiving convalescent plasma or not (OR 1.03, 95% CI 0.86 to 1.23; I² = 0%; <a href="./references#CD013600-fig-0017" title="">Analysis 1.15</a>). </p> </section> <section id="CD013600-sec-0085"> <p><b>Admission to the ICU</b></p> <p>Two studies reported admission to the ICU for 816 participants. Evidence suggests that treatment with convalescent plasma may have little to no impact on being admitted to the ICU (RR 0.93, 95% CI 0.77 to 1.11; I² = 0%; <a href="./references#CD013600-fig-0018" title="">Analysis 1.16</a>). </p> </section> <section id="CD013600-sec-0086"> <p><b>Duration of hospitalisation</b></p> <p>Two studies reported duration of hospitalisation for 97 participants. Evidence suggests that treatment with convalescent plasma may have little to no impact on the duration of hospitalisation when compared to placebo or standard care alone (MD −1.04, 95% CI −6.87 to 4.79; I² = 96%; <a href="./references#CD013600-fig-0019" title="">Analysis 1.17</a>). </p> </section> <section id="CD013600-sec-0087"> <p><b>Viral clearance</b></p> <p>We included data of viral clearance if assessed with RT‐PCR test for SARS‐CoV‐2 for the following time points: at baseline, up to 3, 7, and 14 days. </p> <p>Four studies reported viral clearance for 674 participants. Evidence suggests that more people treated with convalescent plasma may achieve viral clearance at up to day 3 (RR 1.29, 95% CI 0.76 to 2.18; 4 studies, 619 participants; I² = 86%; <a href="./references#CD013600-fig-0020" title="">Analysis 1.18</a>) day 7 (RR 1.24, 95% CI 0.85 to 1.79; 4 studies, 674 participants; I² = 80%; <a href="./references#CD013600-fig-0021" title="">Analysis 1.19</a>), and day 14 (RR 1.46, 95% CI 0.58 to 3.68; 2 studies, 212 participants; I² = 93%; <a href="./references#CD013600-fig-0022" title="">Analysis 1.20</a>). </p> </section> <section id="CD013600-sec-0088"> <p><b>Adverse events (any grade and grades 1 to 2)</b></p> <p>We summarised data in <a href="#CD013600-tbl-0010">Table 5</a>, including the potential relationship between the intervention and the adverse event, as reported in the primary studies. </p> <p>Seven studies reported adverse events of any grade for both groups and a total of 1809 participants. Evidence suggests little to no difference in the occurrence of any adverse events when treated with convalescent plasma (RR 1.05, 95% CI 0.95 to 1.17; I² = 0%; <a href="./references#CD013600-fig-0010" title="">Analysis 1.8</a>). </p> <p>One study reported adverse events of grades 1 to 2 for both groups and a total of 160 participants (<a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a>). Evidence suggests little to no difference in the occurrence of grades 1 to 2 events when treated with convalescent plasma (RR 1.11, 95% CI 0.87 to 1.41; <a href="./references#CD013600-fig-0011" title="">Analysis 1.9</a>). </p> </section> </section> </section> <section id="CD013600-sec-0089"> <h5 class="title">Convalescent plasma versus standard plasma</h5> <section id="CD013600-sec-0090"> <h6 class="title">Primary outcomes (included in the summary of findings table)</h6> <section id="CD013600-sec-0091"> <p><b>All‐cause mortality</b></p> <p>We assessed all‐cause mortality at day 28, day 60, by time until death and during hospital stay. </p> <p>Four studies reported all‐cause mortality for 484 participants. Considering the reported event rates within the study, we estimated that 177 of 1000 participants not treated with convalescent plasma die up to 28 days after treatment. We are uncertain whether convalescent plasma reduces or increases all‐cause mortality up to day 28 when compared to standard plasma (RR 0.73, 95% CI 0.45 to 1.19; 129 per 1000; 4 studies, 484 participants; I² = 16%, very low‐certainty evidence; <a href="./references#CD013600-fig-0023" title="">Analysis 2.1</a>); or when measured over time (HR 0.94, 95% CI 0.41 to 2.14; 4 studies, 484 participants; I² = 48%; <a href="./references#CD013600-fig-0024" title="">Analysis 2.2</a>). Our main reasons for downgrading were serious inconsistency because direction of effect was not consistent in both studies, and serious imprecision due to few participants and wide confidence intervals. All‐cause mortality at day 60 and during hospital stay was not reported in the studies. </p> <p> <ul id="CD013600-list-0199"> <li> <p>Subgroup analyses</p> <ul id="CD013600-list-0200"> <li> <p><b>Length of time since symptom onset:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the length of time since symptom onset (<a href="./references#CD013600-fig-0055" title="">Analysis 8.1</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0092" title="">Analysis 21.1</a>). We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma and the outcome all‐cause mortality. </p> </li> </ul> </li> <li> <p><b>Sensitivity analyses:</b> we summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0012">Table 7</a>. The effects of our main analysis were robust when we removed preprint articles and studies that were terminated early. We did not include any studies with high risk of bias in the main analysis of this outcome. </p> </li> </ul> </p> <div class="table" id="CD013600-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analyses for the comparison of convalescent plasma versus standard plasma for the population of individuals with moderate to severe disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Main analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias (excluding studies<sup>a</sup> at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Publication status (excluding preprints<sup>b</sup>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study termination (excluding studies terminated early<sup>c</sup>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73 (95% CI 0.45 to 1.19); including 484 participants from 4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73 (95% CI 0.45 to 1.19); including 484 participants from 4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (95% CI 0.43 to 1.01); including 455 participants from 3 studies<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.17 to 5.29); including 252 participants from 2 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation (for the subgroup of participants not requiring invasive mechanical ventilation at baseline, i.e. WHO ≤ 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.59 (95% CI 0.29 to 108.38) including 34 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.59 (95% CI 0.29 to 108.38) including 34 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study included<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.59 (95% CI 0.29 to 108.38) including 34 participants from 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 or 4 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80 (95% CI 0.55 to 1.15); including <br/>327 participants from 3 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80 (95% CI 0.55 to 1.15); including <br/>327 participants from 3 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.53 to 1.13); including <br/>293 participants from 2 studies<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (95% CI 0.51 to 1.14); including <br/>253 participants from 2 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval;<b>NR:</b> not reported; <b>RR:</b> risk ratio; <b>WHO:</b> World Health Organization </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Excluded studies with high risk of bias: no study.<br/><sup>b</sup>Excluded preprints (no peer reviewed results published; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>)<br/><sup>c</sup>Excluded studies with premature termination (<a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>) </p> </div> </div> </section> <section id="CD013600-sec-0092"> <p><b>Clinical status</b></p> <p>We assessed the clinical status of participants by the need for invasive mechanical ventilation or death (worsening of clinical status) and by participants discharged from hospital (improvement of clinical status) up to day 28, day 60, and up to longest follow‐up. </p> <p> <ul id="CD013600-list-0201"> <li> <p><b>Worsening of clinical status:</b> one study reported the need for invasive mechanical ventilation or death for 34 participants (<a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>). Considering the reported event rates within the study, we estimated that 56 of 1000 participants treated with standard plasma needed invasive mechanical ventilation or died. Evidence is uncertain whether treatment with convalescent plasma reduces or increases the need for invasive mechanical ventilation or death when compared to standard plasma (RR 5.59, 95% CI 0.29 to 108.38; 311 per 1000; 1 study, 34 participants; very low‐certainty evidence; <a href="./references#CD013600-fig-0025" title="">Analysis 2.3</a>). Our main reasons for downgrading were extreme imprecision due to very few participants, very few events, and very wide confidence intervals. </p> </li> <li> <p><b>Improvement of clinical status:</b> we did not identify any study reporting this outcome. </p> </li> <li> <p><b>Subgroup analyses:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0093" title="">Analysis 21.2</a>). We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for the outcome, clinical worsening. </p> </li> <li> <p><b>Sensitivity analyses:</b> we summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0012">Table 7</a>. We did not see the reported effects of our main analysis when we removed the study with no published peer‐reviewed results. We did not include a study with high risk of bias, or a study that was terminated early in the main analysis of this outcome. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0093"> <p><b>Quality of life</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0094"> <p><b>Adverse events (grades 3 to 4)</b></p> <p>We defined the outcome as the number of participants with any grades 3 or 4 events. We summarised data in <a href="#CD013600-tbl-0010">Table 5</a>, including the potential relationship between intervention and adverse event, as reported in the primary studies. </p> <p>None of the studies reported the number of participants who experienced grades 3 or 4 adverse events. However, <a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a> reported separately the number of participants who experienced any grade 3 adverse event (27 events in 147 participants treated with convalescent plasma versus 17 events in 72 participants without convalescent plasma) and any grade 4 adverse event (26 events in 147 participants treated with convalescent plasma versus 15 events in 72 participants without convalescent plasma). We are uncertain whether convalescent plasma reduces or increases the risk of grade 3 or 4 adverse events compared to standard plasma. Our main concerns were serious indirectness, because outcome definitions differed from the definitions used in our review, and very serious imprecision because of few participants and few events. </p> </section> <section id="CD013600-sec-0095"> <p><b>Serious adverse events</b></p> <p>We summarised data on serious adverse events reported only in participants who received convalescent plasma, with no reporting in the control group and including potential relationships between events and transfusion in <a href="#CD013600-tbl-0011">Table 6</a>. </p> <p>Three studies reported serious adverse events for both groups and a total of 327 participants. Considering the reported event rates across studies, we estimated that 295 of 1000 participants not treated with convalescent plasma experience a serious adverse event. We are uncertain whether treatment with convalescent plasma reduces or increases the risk of serious adverse events when compared to standard plasma (RR 0.80, 95% CI 0.55 to 1.15; 236 per 1000; 3 studies, 327 participants; I² = 0%; very low‐certainty evidence; <a href="./references#CD013600-fig-0028" title="">Analysis 2.6</a>). Our main reasons for downgrading were serious imprecision because of few participants and few events, and suspected publication bias because most studies assessed and reported transfusion‐related events only; that is, they reported safety data only for the intervention group. </p> <p> <ul id="CD013600-list-0202"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0203"> <li> <p><b>Severity of disease:</b> we could not investigate subgroup differences between participants with moderate and severe disease, because the three studies included in the main analysis for this outcome included participants with moderate disease only (WHO score 4 and 5), according to WHO Clinical Progression Scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-fig-0028" title="">Analysis 2.6</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0094" title="">Analysis 21.3</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for any outcome that summarised adverse events. </p> </li> </ul> </li> <li> <p><b>Sensitivity analyses:</b> we summarised the effects of sensitivity analyses in <a href="#CD013600-tbl-0012">Table 7</a>. Reported effects of our main analysis were robust when we removed preprint articles and studies that were terminated early. We did not include any studies with high risk of bias in the main analysis of this outcome. </p> </li> </ul> </p> </section> </section> <section id="CD013600-sec-0096"> <h6 class="title">Secondary outcomes (not included in the summary of findings table)</h6> <section id="CD013600-sec-0097"> <p><b>Improvement of clinical status</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0098"> <p><b>Need for dialysis</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0099"> <p><b>Admission to the ICU</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0100"> <p><b>Duration of hospitalisation</b></p> <p>Two studies reported duration of hospitalisation for 189 participants. Evidence suggests that treatment with convalescent plasma may have little to no impact on the duration of hospitalisation when compared to standard plasma (MD −2.14, 95% CI −5.24 to 0.95; I² = 52%; <a href="./references#CD013600-fig-0026" title="">Analysis 2.4</a>). </p> </section> <section id="CD013600-sec-0101"> <p><b>Viral clearance</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0102"> <p><b>Adverse events (any grade and grade 1 to 2)</b></p> <p>We defined the outcome as the number of participants with events of any grade and grades 1 to 2. We summarised data in <a href="#CD013600-tbl-0010">Table 5</a>, including the potential relationship between the intervention and the adverse event, as reported in the primary studies. </p> <p>Two studies reported adverse events of any grade for both groups and a total of 253 participants. Evidence suggests an increase of any adverse events when treated with convalescent plasma (RR 1.18, 95% CI 0.93 to 1.50; I² = 0%; <a href="./references#CD013600-fig-0027" title="">Analysis 2.5</a>). None of the studies reported the number of participants who experienced grade 1 or 2 adverse events. </p> </section> </section> </section> <section id="CD013600-sec-0103"> <h5 class="title">Convalescent plasma versus human immunoglobulin</h5> <section id="CD013600-sec-0104"> <h6 class="title">Primary outcomes (included in the summary of findings table)</h6> <section id="CD013600-sec-0105"> <p><b>All‐cause mortality</b></p> <p>We assessed all‐cause mortality at day 28, day 60, by time until death and during hospital stay. </p> <p>One study reported all‐cause mortality for 190 participants (<a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a>). Considering the reported event rates across studies, we estimated that 433 of 1000 participants die at up to 28 days when treated with human immunoglobulin. Convalescent plasma may have little to no effect on all‐cause mortality at up to day 28 (RR 1.07, 95% CI 0.76 to 1.50; 464 per 1000; 1 study, 190 participants; low‐certainty evidence; <a href="./references#CD013600-fig-0029" title="">Analysis 3.1</a>); when measured over time (HR 1.14, 95% CI 0.84 to 1.54; 1 study, 190 participants; or low‐certainty evidence; <a href="./references#CD013600-fig-0030" title="">Analysis 3.2</a>); or during hospital stay (RR 1.01, 95% CI 0.76 to 1.34; 1 study, 190 participants; low‐certainty evidence; <a href="./references#CD013600-fig-0031" title="">Analysis 3.3</a>). Our main reason for downgrading was very serious imprecision due to few events and few participants. This study did not report all‐cause mortality at day 60. </p> <p> <ul id="CD013600-list-0204"> <li> <p><b>Subgroup analyses:</b> we could not perform any of our planned subgroup analyses for the comparison of convalescent plasma versus human immunoglobulin. </p> </li> <li> <p><b>Sensitivity analyses:</b> we did not summarise the effects of sensitivity analyses in a separate table, as we included only one study in the analysis for this outcome. We did not see the reported effects of our main analysis after we removed the study as a preprint article. We did not judge the study at high risk of bias, nor was it terminated early. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0106"> <p><b>Clinical status</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0107"> <p><b>Quality of life</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0108"> <p><b>Adverse events (grades 3 to 4)</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0109"> <p><b>Serious adverse events</b></p> <p>We did not identify any study reporting this outcome.</p> </section> </section> <section id="CD013600-sec-0110"> <h6 class="title">Secondary outcomes (not included in the summary of findings table)</h6> <section id="CD013600-sec-0111"> <p><b>Improvement of clinical status</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0112"> <p><b>Need for dialysis</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0113"> <p><b>Admission to the ICU</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0114"> <p><b>Duration of hospitalisation</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0115"> <p><b>Viral clearance</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0116"> <p><b>Adverse events (any grade and grades 1 to 2)</b></p> <p>We did not identify any study reporting this outcome.</p> </section> </section> </section> </section> <section id="CD013600-sec-0117"> <h4 class="title">Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </h4> <p>We present certainty of the evidence for our prioritised outcomes for individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease in <a href="./full#CD013600-tbl-0004">summary of findings Table 4</a> and <a href="./full#CD013600-tbl-0005">summary of findings Table 5</a> (please see 'Summary of findings and assessment of the certainty of the evidence' in Methods). <a href="./full#CD013600-tbl-0004">summary of findings Table 4</a> includes the comparison of convalescent plasma versus placebo or standard care alone and <a href="./full#CD013600-tbl-0005">summary of findings Table 5</a> includes the comparison of convalescent plasma versus standard plasma. </p> <section id="CD013600-sec-0118"> <h5 class="title">Convalescent plasma versus placebo or standard care alone</h5> <section id="CD013600-sec-0119"> <h6 class="title">Primary outcomes (included in the summary of findings table)</h6> <section id="CD013600-sec-0120"> <p><b>All‐cause mortality</b></p> <p>We assessed all‐cause mortality at day 28, day 60, by time until death, and at longest follow‐up available. </p> <p>Two studies reported all‐cause mortality for 536 participants. Considering the reported event rates across studies, we estimated that 22 of 1000 participants die at up to 28 days when treated with placebo or standard care alone. Evidence is uncertain whether or not treatment with convalescent plasma reduces all‐cause mortality at up to day 28 (OR 0.36, 95% CI 0.09 to 1.46; 8 per 1000; 2 studies, 536 participants; I² = 0%; very low‐certainty evidence; <a href="./references#CD013600-fig-0032" title="">Analysis 4.1</a>); or at up to day 60 (OR 0.13, 95% CI 0.01 to 2.16, 1 study, 376 participants; <a href="./references#CD013600-fig-0033" title="">Analysis 4.2</a>). Our main reasons for downgrading were serious indirectness, because in one study (<a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>), the authors defined the outcome as deaths associated with COVID‐19, and may not have reported other causes of mortality, and serious imprecision due to few events and wide confidence intervals. None of the studies reported all‐cause mortality measured over time. </p> <p> <ul id="CD013600-list-0205"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0206"> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>; <a href="./references#CD013600-fig-0095" title="">Analysis 22.1</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone for this outcome. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD013600-sec-0121"> <p><b>Admission to hospital or death within 28 days</b></p> <p>One study reported admission to hospital or death within 28 days for 376 participants (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). Considering the reported event rates across studies, we estimated that 112 of 1000 participants are admitted to hospital or died within 28 days when treated with placebo or standard care alone. Evidence suggests that the treatment with convalescent plasma may have little to no impact on admission to hospital or death within 28 days (RR 1.05, 95% CI 0.60 to 1.84; 117 per 1000; low‐certainty evidence; <a href="./references#CD013600-fig-0034" title="">Analysis 4.3</a>). Our main reason for downgrading was very serious imprecision, due to very few events, few participants and wide confidence intervals. </p> <p> <ul id="CD013600-list-0207"> <li> <p><b>Subgroup analyses:</b> we could not perform any of our planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone for this outcome. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0122"> <p><b>Symptom resolution</b></p> <p>We assessed the outcome symptom resolution by all initial symptoms resolved (asymptomatic) at day 14, day 28, and at longest follow‐up available and by time to symptom resolution. </p> <p> <ul id="CD013600-list-0208"> <li> <p><b>All initial symptoms resolved:</b> we did not identify any study reporting this outcome. </p> </li> <li> <p><b>Time to symptom resolution:</b> one study reported time to symptom resolution for 376 participants (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). Considering the reported event rates across studies, we estimated that 500 of 1000 participants' symptoms resolved after 12 days when treated with placebo or standard care alone. Evidence suggests that treatment with convalescent plasma may have little to no impact on the time to symptom resolution (HR 1.05, 95% CI 0.85 to 1.30; 483 per 1000; low‐certainty evidence; <a href="./references#CD013600-fig-0035" title="">Analysis 4.4</a>). Our main reason for downgrading was very serious imprecision due to very few events, few participants, and wide confidence intervals. </p> </li> <li> <p><b>Subgroup analyses:</b> we could not perform any of our planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone for both outcomes of symptom resolution. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0123"> <p><b>Quality of life</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0124"> <p><b>Adverse events (grades 3 to 4)</b></p> <p>We defined the outcome as the number of participants with any adverse events of grades 3 to 4. We summarised data in <a href="#CD013600-tbl-0010">Table 5</a>, including the potential relationship between the intervention and the adverse event, as reported in the primary study. </p> <p>One study reported grades 3 or 4 adverse events for both groups and a total of 376 participants (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). Considering the reported event rates across studies, we estimated that 112 of 1000 participants not treated with convalescent plasma experience a grade 3 or 4 adverse event. Evidence suggests that treatment with convalescent plasma may have little to no impact on the risk of grade 3 and 4 adverse events (RR 1.29, 95% CI 0.75 to 2.19; 144 per 1000; low‐certainty evidence; <a href="./references#CD013600-fig-0039" title="">Analysis 4.8</a>). Our main reason for downgrading was very serious imprecision, due to few participants, few events and wide confidence intervals. One study reported that convalescent plasma was not associated with any "solicited adverse events" (<a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>). Because the definition was unclear and we were unsure whether only drug‐related adverse events were assessed, and we did not receive additional information from the study authors, we did not include this outcome in the analysis. We do not know whether convalescent plasma is associated with a higher risk for grades 3 or 4 adverse events (very low‐certainty evidence). </p> <p> <ul id="CD013600-list-0209"> <li> <p><b>Subgroup analyses:</b> we could not investigate the difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>), as the study included in this analysis was from a high‐income country (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-fig-0096" title="">Analysis 22.2</a>). </p> </li> <li> <p>We could not perform any of our planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone for the adverse events analyses. </p> </li> </ul> </p> </section> <section id="CD013600-sec-0125"> <p><b>Serious adverse events</b></p> <p>One study reported serious adverse events for both groups and a total of 376 participants (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). Considering the reported event rates across studies, we estimated that 117 of 1000 participants not treated with convalescent plasma experience a serious adverse event. Evidence suggests that treatment with convalescent plasma may have little to no impact on the risk of serious adverse events (RR 1.14, 95% CI 0.66 to 1.94; 133 per 1000; low‐certainty evidence; <a href="./references#CD013600-fig-0040" title="">Analysis 4.9</a>). Our main reason for downgrading was very serious imprecision, due to few participants, few events and wide confidence intervals. One study reported that convalescent plasma was not associated with any "solicited serious adverse events" (<a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>). Because the definition was unclear and we were unsure whether only drug‐related serious adverse events were assessed, and we did not receive additional information from the study authors, we did not include this outcome in the analysis. We do not know whether convalescent plasma is associated with a higher risk for serious adverse events (very low‐certainty evidence). </p> <p> <ul id="CD013600-list-0210"> <li> <p><b>Subgroup analyses</b>: we could not investigate the difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>), as the study included in this analysis was from a high‐income country (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>; <a href="./references#CD013600-fig-0097" title="">Analysis 22.3</a>). </p> </li> <li> <p>We could not perform any of our planned subgroup analyses for the comparison of convalescent plasma versus placebo or standard care alone for the serious adverse events analysis. </p> </li> </ul> </p> </section> </section> <section id="CD013600-sec-0126"> <h6 class="title">Secondary outcomes (not included in the summary of findings table)</h6> <section id="CD013600-sec-0127"> <p><b>Worsening of clinical status</b></p> <p>We assessed worsening of clinical status at day 28, and up to the longest follow‐up available, by need for hospitalisation with oxygen by mask or nasal prongs, or death, and by need for invasive mechanical ventilation, or death. </p> <p>Two studies reported the need for hospitalisation with oxygen by mask or nasal prongs, or death, at up to 28 days for 536 participants. Evidence suggests little to no difference between participants receiving convalescent plasma or not (RR 0.76, 95% CI 0.36 to 1.59; I² = 68%; <a href="./references#CD013600-fig-0036" title="">Analysis 4.5</a>). One study reported need for invasive mechanical ventilation or death up to day 28 and up to day 60 for 376 participants (<a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a>). Evidence suggests that fewer people treated with convalescent plasma may need invasive mechanical ventilation or die at up to day 28 (OR 0.51, 95% CI 0.10 to 2.55; <a href="./references#CD013600-fig-0037" title="">Analysis 4.6</a>), or at up to day 60 (OR 0.51, 95% CI 0.10 to 2.55; <a href="./references#CD013600-fig-0038" title="">Analysis 4.7</a>) </p> </section> <section id="CD013600-sec-0128"> <p><b>Viral clearance (assessed with RT‐PCR)</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0129"> <p><b>Adverse events (any grade and grades 1 to 2)</b></p> <p>We identified no study reporting adverse events of any grade or grades 1 to 2.</p> </section> </section> </section> <section id="CD013600-sec-0130"> <h5 class="title">Convalescent plasma versus standard plasma</h5> <section id="CD013600-sec-0131"> <h6 class="title">Primary outcomes (included in the summary of findings table)</h6> <section id="CD013600-sec-0132"> <p><b>All‐cause mortality</b></p> <p>We assessed all‐cause mortality at day 28, day 60, by time until death, and at longest follow‐up available. </p> <p>Two studies reported all‐cause mortality for 1597 participants. Considering the reported event rates across studies, we estimated that 5 of 1000 participants die at up to 28 days when treated with standard plasma. We are uncertain whether convalescent plasma reduces all‐cause mortality at up to day 28 (OR 0.30, 95% CI 0.05 to 1.75; 2 per 1000; 2 studies, 1597 participants; I² = 19%; very low‐certainty evidence; <a href="./references#CD013600-fig-0041" title="">Analysis 5.1</a>). Our main reason for downgrading was very serious imprecision due to few events and very wide confidence intervals. The studies did not report all‐cause mortality at up to day 60, or measured over time. </p> <p> <ul id="CD013600-list-0211"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0212"> <li> <p><b>Length of time since symptom onset:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the length of time since symptom onset (<a href="./references#CD013600-fig-0056" title="">Analysis 9.1</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the pre‐existing condition of diabetes at baseline (<a href="./references#CD013600-fig-0067" title="">Analysis 13.1</a>), or participant's age (<a href="./references#CD013600-fig-0078" title="">Analysis 17.1</a>). We could not calculate the difference in the effectiveness of convalescent plasma with regard to the sex of participants, as none of the female participants died in either group (out of 43 with convalescent plasma and 52 with standard plasma), and one of the male participants died in each group (out of 163 with convalescent plasma and 158 with standard plasma; <a href="./references#CD013600-fig-0084" title="">Analysis 19.1</a>). We could not investigate the difference in the effectiveness of convalescent plasma with regard to country income groups, according to the World Bank definitions (<a href="./references#CD013600-bbs2-0393" title="The World Bank. Countries and Economies. Available from https://data.worldbank.org/country (accessed 28 March, 2022).">The World Bank 2022</a>), as both studies included in this analysis were set in high‐income countries (<a href="./references#CD013600-fig-0098" title="">Analysis 23.1</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for this outcome. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD013600-sec-0133"> <p><b>Admission to hospital or death within 28 days</b></p> <p>Two studies reported admission to hospital or death within 28 days for 1595 participants. Considering the reported event rates across studies, we estimated that 73 of 1000 participants treated with standard plasma are admitted to hospital or died within 28 days. Evidence suggests that treatment with convalescent plasma probably reduces admission to hospital or death within 28 days (RR 0.49, 95% CI 0.31 to 0.75; 36 per 1000; I² = 0%; moderate‐certainty evidence; <a href="./references#CD013600-fig-0042" title="">Analysis 5.2</a>). Our main reason for downgrading was serious imprecision because the optimal information size is not met for a power of 0.90. </p> <p> <ul id="CD013600-list-0213"> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0214"> <li> <p><b>Length of time since symptom onset:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the length of time since symptom onset (<a href="./references#CD013600-fig-0057" title="">Analysis 9.2</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the pre‐existing condition of diabetes at baseline (<a href="./references#CD013600-fig-0068" title="">Analysis 13.2</a>), sex of participants (<a href="./references#CD013600-fig-0085" title="">Analysis 19.2</a>), or age of participants (<a href="./references#CD013600-fig-0079" title="">Analysis 17.2</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for this outcome. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD013600-sec-0134"> <p><b>Symptom resolution</b></p> <p>We assessed the outcome symptom resolution by all initial symptoms resolved (asymptomatic) at day 14, day 28, and at longest follow‐up available and by time to symptom resolution. </p> <p> <ul id="CD013600-list-0215"> <li> <p><b>All initial symptoms resolved:</b> one study reported all initial symptoms resolved for 417 participants (<a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>). Considering the reported event rates across studies, we estimated that all symptoms of 657 of 1000 participants treated with standard plasma would be resolved at up to 28 days. Evidence suggests that treatment with convalescent plasma may have little to no effect on resolution of all initial symptoms up to day 28 (RR 1.12, 95% CI 0.98 to 1.27; 736 per 1000; 1 study, 416 participants; low‐certainty evidence; <a href="./references#CD013600-fig-0043" title="">Analysis 5.3</a>) or at up to day 14 (RR 1.00, 95% CI 0.83 to 1.21; 1 study, 417 participants; <a href="./references#CD013600-fig-0044" title="">Analysis 5.4</a>). Our main reason for downgrading was very serious imprecision due to few events, few participants, and wide confidence intervals. </p> </li> <li> <p><b>Time to symptom resolution:</b> we did not identify any study reporting this outcome. </p> </li> <li> <p><b>Subgroup analyses</b> </p> <ul id="CD013600-list-0216"> <li> <p><b>Length of time since symptom onset:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to length of time since symptom onset (<a href="./references#CD013600-fig-0058" title="">Analysis 9.3</a>). </p> </li> <li> <p><b>Other subgroups:</b> we did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the pre‐existing condition of diabetes at baseline (<a href="./references#CD013600-fig-0069" title="">Analysis 13.3</a>), participants' age (<a href="./references#CD013600-fig-0080" title="">Analysis 17.3</a>), or sex (<a href="./references#CD013600-fig-0086" title="">Analysis 19.3</a>). </p> </li> <li> <p>We could not perform any further planned subgroup analyses for the comparison of convalescent plasma versus standard plasma for the outcome of all initial symptoms resolved. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD013600-sec-0135"> <p><b>Quality of life</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0136"> <p><b>Adverse events (grades 3 to 4)</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0137"> <p><b>Serious adverse events</b></p> <p>We did not identify any study reporting this outcome.</p> </section> </section> <section id="CD013600-sec-0138"> <h6 class="title">Secondary outcomes (not included in the summary of findings table)</h6> <section id="CD013600-sec-0139"> <p><b>Worsening of clinical status</b></p> <p>We assessed worsening of clinical status at day 28, and up to the longest follow‐up available, by need for hospitalisation with oxygen by mask or nasal prongs, or death, and by need for invasive mechanical ventilation, or death. </p> <p>One study reported the need for hospitalisation with oxygen by mask or nasal prongs, or death, at up to 28 days for 1181 participants (<a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a>). Evidence suggests that fewer people treated with convalescent plasma may need hospitalisation and receive oxygen by mask or nasal prongs, or die up to day 28 (RR 46, 95% CI 0.23 to 0.90; <a href="./references#CD013600-fig-0045" title="">Analysis 5.5</a>). One study reported need for invasive mechanical ventilation or death up to day 28 for 414 participants (<a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a>). Evidence suggests that fewer people treated with convalescent plasma may need invasive mechanical ventilation or die up to day 28 (OR 0.30, 95% CI 0.05 to 1.77; <a href="./references#CD013600-fig-0046" title="">Analysis 5.6</a>). </p> </section> <section id="CD013600-sec-0140"> <p><b>Viral clearance (assessed with RT‐PCR)</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013600-sec-0141"> <p><b>Adverse events (any grade and grades 1 to 2)</b></p> <p>We did not identify any study reporting adverse events of any grade or grades 1 to 2. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013600-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013600-sec-0142"></div> <section id="CD013600-sec-0143"> <h3 class="title" id="CD013600-sec-0143">Summary of main results</h3> <p>The aim of this review was to assess the effectiveness and safety of convalescent plasma in the treatment of COVID‐19. This is the fifth version of our living systematic review. </p> <p>We identified 33 RCTs that evaluated 24,861 participants, of whom 11,432 received convalescent plasma. We identified a further 49 ongoing studies evaluating convalescent plasma. We also identified 28 completed but not yet published studies and two studies terminated early for futility, that we categorised as 'Awaiting classification', as well as three platform trials that we have also placed in that category. </p> <section id="CD013600-sec-0144"> <h4 class="title">Effects of interventions</h4> <section id="CD013600-sec-0145"> <h5 class="title">Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</h5> <p>29 RCTs investigated the use of convalescent plasma for 22,728 participants with moderate to severe disease, of which 23 RCTs compared convalescent plasma to placebo treatment or standard care alone, five compared convalescent plasma to standard plasma, and one RCT compared convalescent plasma to human immunoglobulin. </p> <section id="CD013600-sec-0146"> <h6 class="title">Convalescent plasma versus placebo or standard care alone</h6> <p>Convalescent plasma does not reduce all‐cause mortality at up to day 28 (RR 0.98, 95% CI 0.92 to 1.03; 220 per 1000; 21 RCTs, 19,021 participants; high‐certainty evidence). It has little to no impact on need for invasive mechanical ventilation or death (RR 1.03, 95% CI 0.97 to 1.11; 296 per 1000; 6 RCTs, 14,477 participants; high‐certainty evidence) and has no impact on whether participants are discharged from hospital (RR 1.00, 95% CI 0.97 to 1.02; 665 per 1000; 6 studies, 12,721 participants; high‐certainty evidence). Convalescent plasma may have little to no impact on quality of life, assessed with standardised scale EQ‐5D‐5L questionnaire (MD 1.00, 95% CI −2.14 to 4.14; 1 RCT, 483 participants; low‐certainty evidence). Convalescent plasma may have little to no impact on the risk of grade 3 and 4 adverse events (RR 1.17, 95% CI 0.96 to 1.42; 212 per 1000; 6 RCTs, 2392 participants; low‐certainty evidence). Convalescent plasma probably has little to no effect on the risk of serious adverse events (RR 1.12, 95% CI 0.96 to 1.31; 133 per 1000; 6 RCTs, 4901 participants; moderate‐certainty evidence). </p> <p>We did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to the detection of antibodies in the recipients at baseline, to length of time since symptom onset, disease severity, country income groups, or certain pre‐existing conditions. For improvement and worsening of clinical status, we identified significant subgroup differences for the effect of convalescent plasma with regard to antibodies in recipients detected at baseline and age of people, but we are uncertain whether the analyses produced useful findings. </p> </section> <section id="CD013600-sec-0147"> <h6 class="title">Convalescent plasma versus standard plasma</h6> <p>We are uncertain whether convalescent plasma reduces or increases all‐cause mortality at up to day 28 (RR 0.73, 95% CI 0.45 to 1.19; 129 per 1000; 4 studies, 484 participants; very‐low‐certainty evidence). We are uncertain whether convalescent plasma reduces or increases need for invasive mechanical ventilation or death (RR 5.59, 95% CI 0.29 to 108.38; 311 per 1000; 1 study, 34 participants; very low‐certainty evidence). None of the studies reported the number of participants who experienced grade 3 or 4 adverse events, only one study reported the number of participants with any adverse event of grade 3 and grade 4 separately. However, we are uncertain whether convalescent plasma reduces or increases the risk of grade 3 or 4 adverse events and the risk of serious adverse events (RR 0.80, 95% CI 0.55 to 1.15; 236 per 1000; 3 studies, 327 participants; very low‐certainty evidence). We identified no study reporting quality of life. </p> <p>We did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to length of time since symptom onset, country income groups, or disease severity. </p> </section> <section id="CD013600-sec-0148"> <h6 class="title">Convalescent plasma versus human immunoglobulin</h6> <p>Convalescent plasma may have little to no effect on all‐cause mortality at up to day 28 (RR 1.07, 95% CI 0.76 to 1.50; 464 per 1000; 1 study, 190 participants; low‐certainty evidence). </p> <p>We identified no study reporting on clinical status, quality of life or safety.</p> </section> </section> <section id="CD013600-sec-0149"> <h5 class="title">Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and mild disease</h5> <p>We identified four RCTs that investigated the use of convalescent plasma for 2133 participants with mild disease, of which two RCTs with 536 participants compared convalescent plasma to placebo or standard care alone, and two RCTs with 1597 participants compared convalescent plasma to standard plasma. </p> <section id="CD013600-sec-0150"> <h6 class="title">Convalescent plasma versus placebo or standard care alone</h6> <p>We are uncertain whether convalescent plasma reduces all‐cause mortality at up to day 28 (OR 0.36, 95% CI 0.09 to 1.46; 8 per 1000; 2 RCTs, 536 participants; very low‐certainty evidence). Evidence suggests that it may have little to no impact on admission to hospital or death within 28 days (RR 1.05, 95% CI 0.60 to 1.84; 117 per 1000; 1 study, 376 participants; low‐certainty evidence) and on time to COVID‐19 symptom resolution (HR 1.05, 95% CI 0.85 to 1.30; 483 per 1000; 1 study, 376 participants; low‐certainty evidence). Convalescent plasma may have little to no impact on the risk of grade 3 and 4 adverse events (RR 1.29, 95% CI 0.75 to 2.19; 144 per 1000; 1 study, 376 participants; low‐certainty evidence) and the risk of serious adverse events (RR 1.14, 95% CI 0.66 to 1.94; 133 per 1000; 1 study, 376 participants; low‐certainty evidence). We identified no study reporting symptom resolution or quality of life. </p> <p>We did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to length of time since symptom onset. We were unable to perform any further subgroup analysis. </p> </section> <section id="CD013600-sec-0151"> <h6 class="title">Convalescent plasma versus standard plasma</h6> <p>We are uncertain whether convalescent plasma reduces all‐cause mortality at up to day 28 (OR 0.30, 95% CI 0.05 to 1.75; 2 per 1000; 2 studies, 1597 participants; very low‐certainty evidence). It probably reduces admission to hospital or death within 28 days (RR 0.49, 95% CI 0.31 to 0.75; 36 per 1000; 2 studies, 1595 participants; moderate‐certainty evidence). Convalescent plasma may have little to no effect on resolution of all initial symptoms at up to day 28 (RR 1.12, 95% CI 0.98 to 1.27; 736 per 1000; 1 study, 416 participants; low‐certainty evidence). We did not identify any study reporting time to symptom resolution, quality of life or safety. </p> <p>We did not identify any significant subgroup difference in the effectiveness of convalescent plasma with regard to country income groups, pre‐existing condition, sex, or age of participants. </p> </section> </section> </section> </section> <section id="CD013600-sec-0152"> <h3 class="title" id="CD013600-sec-0152">Overall completeness and applicability of evidence</h3> <p>Most of the included participants had received additional treatment options to convalescent plasma or control, including, for instance, antivirals, antimicrobials, corticosteroids, hydroxychloroquine, respiratory support (extracorporeal membrane oxygenation, mechanical ventilation or oxygen), or a combination of those. </p> <p>Thanks to high‐certainty evidence, we are confident that treatment with convalescent plasma does not reduce all‐cause mortality at up to 28 days, has little to no impact on need for invasive mechanical ventilation or death at day 28, and has no impact on whether participants are discharged from hospital when compared to placebo treatment or standard care alone. For the same comparison, we found low‐certainty evidence. Convalescent plasma may have little to no impact on quality of life and may result in a clinically relevant increased risk of grade 3 or 4 adverse events, but the treatment probably has little to no effect on the risk of serious adverse events (moderate‐certainty evidence). Not all the included RCTs reported adverse events for the control arm. When compared to standard plasma, we are uncertain about the effect of convalescent plasma on all‐cause mortality at up to 28 days, and very uncertain whethe convalescent plasma therapy increases the risk of need for invasive mechanical ventilation or death at day 28. For the same comparison, the evidence for grade 3 and 4 adverse events is uncertain (very‐low evidence), but convalescent plasma therapy may result in little to no impact on serious adverse events (low‐certainty evidence). When comparing the treatment to human immunoglobulin, we have low‐certainty evidence; convalescent plasma may have little to no impact on all‐cause mortality at up to 28 days. </p> <p>Four RCTs investigated the use of convalescent plasma treatment for individuals with mild disease, of which two RCTs compared the therapy to placebo or standard care alone, and two RCTs compared it to standard plasma. We have low confidence in the evidence; treatment with convalescent plasma may have little to no impact on all‐cause mortality at up to day 28, on admission to hospital or death within 28 days and on time to symptom resolution. For the same comparison, convalescent plasma may result in a clinically relevant increased risk of grade 3 or 4 adverse events and serious adverse events (low‐certainty evidence). When compared to standard plasma, we have low certainty evidence; convalescent plasma may have little to no impact on all‐cause mortality at up to day 28, and on time to symptom resolution. For the same comparison, convalescent plasma probably reduces admission to hospital or death within 28 days (moderate‐certainty evidence). </p> <p>28 RCTs have been completed, or completed their recruitment, and two RCTs have been terminated early, but no results have been published yet. We are also keeping track of three ongoing platform trials that might potentially add an intervention arm on convalescent plasma. Therefore, we categorised all these as 'Awaiting classification' and we will consider including them in an update of this review, once results are available. </p> <p>We identified 49 ongoing studies, all RCTs assessing the benefits and safety of convalescent plasma therapy for the treatment of COVID‐19. </p> </section> <section id="CD013600-sec-0153"> <h3 class="title" id="CD013600-sec-0153">Quality of the evidence</h3> <section id="CD013600-sec-0154"> <h4 class="title">Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</h4> <p>We included data from 23 RCTs to assess effectiveness and safety of convalescent plasma when compared to treatment with placebo or standard care alone. We were very confident in the identified evidence for effectiveness outcomes, but less confident in the identified evidence for safety outcomes. Our main concerns were that some studies still assessed and reported safety outcomes for the convalescent plasma group only, indicating publication bias and serious imprecision because the optimal information size was not met for a power of 0.90 (the optimal information size indicates the threshold for the number of included participants for an adequately powered trial or meta‐analysis; <a href="./references#CD013600-bbs2-0339" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [DOI: 10.1016/j.jclinepi.2011.01.012]">Guyatt 2011</a>). </p> <p>We included data from five RCTs to assess effectiveness and safety of convalescent plasma when compared to treatment with standard plasma. Our confidence in the evidence was very low to low for effectiveness and safety outcomes. Our main concerns were serious inconsistency for the outcome mortality at up to day 28, very serious imprecision for mortality and safety outcomes, and extreme serious imprecision for clinical worsening due to wide confidence intervals, few to extremely few participants and events, and because the optimal information size was not met for a power of 0.80. Also, some studies still reported safety outcomes for the convalescent plasma group only, indicating publication bias. </p> <p>We included data from one RCT to assess effectiveness of convalescent plasma when compared to treatment with human immunoglobulin. We had low confidence in the identified evidence for mortality. Our main concern was very serious imprecision due to few events and few participants. </p> </section> <section id="CD013600-sec-0155"> <h4 class="title">Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and mild disease</h4> <p>We included data from two RCTs to assess effectiveness and safety of convalescent plasma when compared to treatment with placebo or standard care alone. We had low confidence in the identified evidence for effectiveness and safety outcomes. Our main concerns were serious to very serious imprecision due to the small information size and serious indirectness for all the reported outcomes, and serious indirectness for mortality, because the outcome definition did not precisely match our outcome definition. </p> <p>We included data from two RCTs to assess effectiveness of convalescent plasma when compared to treatment with standard plasma. We had moderate to low confidence in the identified evidence for effectiveness. Our main concerns were serious imprecision for admission to hospital or death, because the optimal information size was not met for a power of 0.90. and very serious imprecision for mortality and symptom resolution, due to few events and very wide confidence intervals. </p> </section> </section> <section id="CD013600-sec-0156"> <h3 class="title" id="CD013600-sec-0156">Potential biases in the review process</h3> <p>To avoid potential biases in the review process, we planned to include the best available evidence and adhered to the guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> in all steps of the review(<a href="./references#CD013600-bbs2-0342" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook2022.">Higgins 2022</a>). Even though COVID‐19 is still a novel disease, we identified more high‐quality evidence and included only RCTs in this version, as we have identified a large number of RCTs since the last update (<a href="./references#CD013600-bbs2-0420" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a>). For this update, we were able to include 33 RCTs. To increase the informative value of our review, we are tracking all registered trials and will continually update this review as more evidence becomes available. There are currently still many new trials being registered in trials registries, as can be seen from the additional 49 RCTs added to the list of ongoing studies in this update of the review. </p> <p>Two experienced information specialists developed a sensitive search strategy, to identify all ongoing and completed studies. We searched all relevant databases and trials registries, and two review authors conducted all review steps independently and in duplicate. </p> <p>Another consideration for this rapidly evolving field is the availability of preprint articles that have not yet undergone peer review. We included preprints in this review, however, we are aware of the potentially lower quality of these publications, and investigated the robustness of our results in sensitivity analyses. </p> <p>The necessary adaptation of review methods to the development of research output, as described in <a href="#CD013600-tbl-0006">Table 1</a>, is in general a potential source of bias in the review process. Since the available evidence has changed rapidly in a comparably short period of time during the COVID‐19 pandemic, we needed to take this approach to give a comprehensive answer to the review question. Before we start an update, our interdisciplinary team of review authors meets to review the methods and to discuss necessary amendments. We follow the methods we agreed upon before starting the update, and adhere to these decisions throughout each update process. </p> <p>For this review update, we removed 'hyperimmune immunoglobulin' from the eligibility criteria because we identified several studies that evaluated this intervention treatment and therefore, we decided to assess this as a separate research question in a new review. We do not think that the bias arising from this adaptation was substantial, since the change was driven by objective reasons. </p> <p>For changes in outcomes and outcome measurement, we specified the outcome 'worsening of clinical status' from standardised scales (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>; <a href="./references#CD013600-bbs2-0408" title="World Health Organization. COVID-19 therapeutic trial synopsis. Available from www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf (accessed 22 March 2021).">WHO 2020f</a>), in the third (<a href="./references#CD013600-bbs2-0417" title="ChaiKL , ValkSJ , PiechottaV , KimberC , MonsefI , DoreeC , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub3]">Chai 2020</a>), and fourth version (<a href="./references#CD013600-bbs2-0420" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a>), to 'worsening of clinical status, assessed by need for invasive mechanical ventilation or death' and added the competing event of death to the outcome. We do not think that this change has led to any bias in the review process. Instead, we think that changing the inclusion criteria for outcome measurement to a standardised scale can facilitate identifying studies with objective and higher‐quality results and, additionally, can contribute to a lower heterogeneity among included studies. We also added a new secondary outcome 'quality of life' from version 2 of this review (<a href="./references#CD013600-bbs2-0419" title="PiechottaV , ChaiKL , ValkSJ , DoreeC , MonsefI , WoodEM , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub2]">Piechotta 2020b</a>) onward, but do not suspect that this had an impact on bias since the outcome was suggested by an external patient representative. </p> <p>For inclusion criteria regarding different study designs, we tried to anticipate possible changes of the evidence landscape already at protocol stage and therefore excluded study designs of lower‐level evidence, as more RCTs were published. So, for this update, we decided to only include RCTs, as enough RCT data were available to investigate the research question. </p> <p>In previous versions of this review (<a href="./references#CD013600-bbs2-0419" title="PiechottaV , ChaiKL , ValkSJ , DoreeC , MonsefI , WoodEM , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub2]">Piechotta 2020b</a>), we used RoB 1 for RCTs (<a href="./references#CD013600-bbs2-0341" title="HigginsJP , Altman DG, SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). We started using ROB 2 (<a href="./references#CD013600-bbs2-0390" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>) from the second update (<a href="./references#CD013600-bbs2-0417" title="ChaiKL , ValkSJ , PiechottaV , KimberC , MonsefI , DoreeC , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 10. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub3]">Chai 2020</a>). This led to changes in the risk of bias rating and the GRADE assessment for the mortality, clinical status and safety outcomes of one included study (<a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>). We think using RoB 2 corrected our judgement from potential personal biases, since it is less sensitive to subjective interpretations and allows for more nuanced assessment of potential bias in open‐label trials. </p> </section> <section id="CD013600-sec-0157"> <h3 class="title" id="CD013600-sec-0157">Agreements and disagreements with other studies or reviews</h3> <p>In the previous version of this systematic review, we compared our findings to two systematic reviews, <a href="./references#CD013600-bbs2-0352" title="JaniaudP , AxforsC , SchmittAM , GloyV , EbrahimiF , HepprichM , et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA2021:e212747. [DOI: 10.1001/jama.2021.2747]">Janiaud 2021</a>, which included only RCTs, and <a href="./references#CD013600-bbs2-0357" title="KlassenSA , SenefeldJW , JohnsonPW , CarterRE , WigginsCC , ShohamS , et al. Evidence favoring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv [Preprint]2021. [DOI: 10.1101/2020.07.29.20162917]">Klassen 2021</a>, which included RCTs together with other study designs. For the current update, we have been looking for more recent high‐quality, RCT‐only systematic reviews on the effect and safety of convalescent plasma for people with COVID‐19, to compare them to our RCT‐based findings. </p> <p><a href="./references#CD013600-bbs2-0354" title="JordaA , KussmannM , KolencheryN , Siller-Matula JM , ZeitlingerM , JilmaB , et al. Convalescent plasma treatment in patients with COVID-19: a systematic review and meta-analysis. Frontiers in Immunology2022;13:817829. [DOI: 10.3389/fimmu.2022.817829]">Jorda 2022</a> aggregated data from 16 RCTs with 16,317 participants with moderate to severe disease, except one included trial (<a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a>), and they found similar results to our review. Their meta‐analysis of 16 RCTs indicated that there is high‐certainty evidence for convalescent plasma not being associated with lower all‐cause morality (RR 0.97, 95% CI 0.90 to 1.04), lower initiation of mechanical ventilation (RR 0.97, 95% CI 0.88 to 1.07), and increased time to hospital discharge (HR 0.95, 95% CI 0.89‐1.02). They did not identify any subgroup differences for disease severity and baseline antibody level in recipients. Their results may be comparable to our findings, as all their included RCTs are also evaluated in our review. </p> <p><a href="./references#CD013600-bbs2-0415" title="YangP , WangJ , ZhengR , TanR , LiX , LiuX , et al. Convalescent plasma may not be an effective treatment for severe and critically ill COVID-19 patients: a systematic review &amp; meta-analysis of randomized controlled trials. Heart &amp; lung : the journal of critical care2022;53:51-60. [DOI: 10.1016/j.hrtlng.2022.01.019]">Yang 2022</a>, another systematic review, indicated similar results in their meta‐analysis. They included 14 RCTs with 4543 participants and found that convalescent plasma treatment for patients with severe COVID‐19 infection, who were critically ill, did not reduce mortality risk (RR 0.94, 95% CI 0.85 to 1.03, low‐certainty evidence) nor increase clinical improvement (RR 1.07, 95% CI 0.97 to 1.17, moderate‐certainty evidence). Also, there were no subgroup differences for disease severity. </p> <p><a href="./references#CD013600-bbs2-0335" title="Fernández-LázaroD , OrtegaCD , Sánchez-SerranoN , Beddar ChaibF , Jerves DonosoD , Jiménez-CallejoE , et al. Convalescent plasma therapy, therapeutic formulations of repurposed drugs in 20th century epidemics against COVID-19: a systematic review. Pharmaceutics2022;14(5):1020. [DOI: 10.3390/pharmaceutics14051020]">Fernández‐Lázaro 2022</a>, a systematic review that included six studies (classified as RCTs) in a qualitative synthesis, indicated contradictory results to our review. They found that treatment with convalescent plasma in hospitalised COVID‐19 patients could decrease mortality, viral load and period of infection, without the occurrence of serious adverse events. One potential reason for the difference between their results and ours could be the inclusion of <a href="./references#CD013600-bbs2-0096" title="LiuST , LinHM , BaineI , WajnbergA , GumprechtJP , RahmanF , et al. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Medicine2020;26:1708–13. [DOI: https://doi.org/10.1038/s41591-020-1088-9]">Liu 2020a</a>, <a href="./references#CD013600-bbs2-0206" title="RasheedAM , FatakDF , HashimHA , MauloodMF , KabahKK , AlmusawiYA , et al. The therapeutic effectiveness of convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv [Preprint]2020. [DOI: 10.1101/2020.06.24.20121905]">Rasheed 2020</a> and <a href="./references#CD013600-bbs2-0226" title="ZengQL , YuZJ , GouJJ , LiGM , MaSH , ZhangGF , et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. Journal of Infectious Diseases2020;222(1):38-43. [DOI: 10.1093/infdis/jiaa228]">Zeng 2020</a>, which they had classified as RCTs. We did not identify these studies as RCTs, however, and therefore excluded them from our review analyses. <a href="./references#CD013600-bbs2-0206" title="RasheedAM , FatakDF , HashimHA , MauloodMF , KabahKK , AlmusawiYA , et al. The therapeutic effectiveness of convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv [Preprint]2020. [DOI: 10.1101/2020.06.24.20121905]">Rasheed 2020</a>, for instance, reported that controls were matched to participants according to the disease stage, age, and sex, and assigned participants to convalescent plasma based on ABO compatibility and limited availability of plasma. In our opinion, this does not fit the criteria for a randomised allocation method and we classified it as a controlled non‐randomised study of interventions (NRSI), since we did not receive any further information on their methods. </p> <p>Also, the FDA and the USA Government considered that there was sufficient evidence of efficacy to widen access to convalescent plasma under the 'Emergency Use Authorization' (EUA) issued on 23 August 2020 (<a href="./references#CD013600-bbs2-0333" title="US Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma. Available from www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (accessed 22 March 2021).">FDA 2020</a>). However, on 11 February 2021, the FDA revised the EUA for convalescent plasma. The authorisation is now limited to the use of high‐titre convalescent plasma for hospitalised individuals at an early stage of disease (<a href="./references#CD013600-bbs2-0334" title="US Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma. Available from www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma (accessed 22 March 2021).">FDA 2021</a>). </p> <p>Furthermore, <a href="./references#CD013600-bbs2-0314" title="BarteltLA , Markmann A, NelsonB , KeysJ , RootH , HendersonHI , et al. Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study. medRxiv [Preprint]2022. [DOI: 10.1101/2022.04.29.22274387]">Bartelt 2022</a>, an RCT available in preprint, evaluated the safety and effectiveness of convalescent plasma with high‐ (&gt; 1:640) compared to lower‐ (≥ 1:160) neutralising antibody titres. The study authors reported that participants treated with high titre convalescent plasma had earlier hospital discharge and lower occurrences of life‐threatening serious adverse events. Even though this study is limited by its small sample size, and further RCTs are needed to confirm their findings, the results might indicate how varying titre levels can have an impact on between‐study differences in our analyses. This could be one potential reason why some of our included RCTs have different safety and effectiveness results. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013600-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013600-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013600-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: All‐cause mortality at up to day 60" data-id="CD013600-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: All‐cause mortality at up to day 60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: All‐cause mortality (time to event)" data-id="CD013600-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: All‐cause mortality (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: All‐cause mortality during hospital stay" data-id="CD013600-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: All‐cause mortality during hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 5: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28" data-id="CD013600-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 5: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 6: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 6: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 7: Quality of life, assessed with standardised scales at day 28" data-id="CD013600-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 7: Quality of life, assessed with standardised scales at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 8: Any grade adverse events" data-id="CD013600-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 8: Any grade adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 9: Grades 1‐2 adverse events" data-id="CD013600-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 9: Grades 1‐2 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 10: Grades 3 and 4 adverse events" data-id="CD013600-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 10: Grades 3 and 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 11: Serious adverse events" data-id="CD013600-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 11: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 12: Clinical improvement: weaning or liberation from invasive mechanical ventilation in surviving participants, for subgroups of participants requiring invasive mechanical ventilation at baseline" data-id="CD013600-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 12: Clinical improvement: weaning or liberation from invasive mechanical ventilation in surviving participants, for subgroups of participants requiring invasive mechanical ventilation at baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 13: Clinical improvement: ventilator‐free days by day 28" data-id="CD013600-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 13: Clinical improvement: ventilator‐free days by day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 14: Clinical improvement: liberation from supplemental oxygen in surviving participants, for subgroup of participants requiring any supplemental oxygen or ventilator support at baseline" data-id="CD013600-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 14: Clinical improvement: liberation from supplemental oxygen in surviving participants, for subgroup of participants requiring any supplemental oxygen or ventilator support at baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 15: Need for dialysis at up to 28 days" data-id="CD013600-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 15: Need for dialysis at up to 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 16: Admission to the intensive care unit (ICU)" data-id="CD013600-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 16: Admission to the intensive care unit (ICU) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 17: Duration of hospitalisation" data-id="CD013600-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 17: Duration of hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 18: Viral clearance at up to day 3" data-id="CD013600-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 18: Viral clearance at up to day 3 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 19: Viral clearance at up to day 7" data-id="CD013600-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 19: Viral clearance at up to day 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 20: Viral clearance at up to day 14" data-id="CD013600-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 20: Viral clearance at up to day 14 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event)" data-id="CD013600-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 3: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28" data-id="CD013600-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 3: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 4: Duration of hospitalisation" data-id="CD013600-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 4: Duration of hospitalisation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 5: Any grade adverse events" data-id="CD013600-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 5: Any grade adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 6: Serious adverse events" data-id="CD013600-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 6: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event)" data-id="CD013600-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease, Outcome 3: All‐cause mortality during hospital stay" data-id="CD013600-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease, Outcome 3: All‐cause mortality during hospital stay </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 2: All‐cause mortality at up to day 60" data-id="CD013600-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 2: All‐cause mortality at up to day 60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 3: Admission to hospital or death within 28 days" data-id="CD013600-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 3: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 4: Time to symptom resolution" data-id="CD013600-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 4: Time to symptom resolution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 5: Clinical worsening: need for hospitalisation with at least need of oxygen by mask or nasal prongs, or death" data-id="CD013600-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 5: Clinical worsening: need for hospitalisation with at least need of oxygen by mask or nasal prongs, or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 6: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28" data-id="CD013600-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 6: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 7: Clinical worsening: need for invasive mechanical ventilation or death at up to day 60" data-id="CD013600-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 7: Clinical worsening: need for invasive mechanical ventilation or death at up to day 60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 8: Grades 3 and 4 adverse events" data-id="CD013600-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 8: Grades 3 and 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 9: Serious adverse events" data-id="CD013600-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 9: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days" data-id="CD013600-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28" data-id="CD013600-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 4: All initial symptoms resolved (asymptomatic) at up to day 14" data-id="CD013600-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 4: All initial symptoms resolved (asymptomatic) at up to day 14 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 5: Clinical worsening: need for hospitalisation with need of at least oxygen by mask or nasal prongs, or death" data-id="CD013600-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 5: Clinical worsening: need for hospitalisation with need of at least oxygen by mask or nasal prongs, or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 6: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28" data-id="CD013600-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 6: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects analysis)" data-id="CD013600-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event)" data-id="CD013600-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model)" data-id="CD013600-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects model)" data-id="CD013600-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event) (random‐effects model)" data-id="CD013600-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: All‐cause mortality (time to event) (random‐effects model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model)" data-id="CD013600-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects analysis)" data-id="CD013600-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days" data-id="CD013600-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28" data-id="CD013600-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects model)" data-id="CD013600-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 (random‐effects model) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0060" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0061" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days" data-id="CD013600-fig-0062" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28" data-id="CD013600-fig-0063" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0064" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death" data-id="CD013600-fig-0065" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0066" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0067" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days" data-id="CD013600-fig-0068" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28" data-id="CD013600-fig-0069" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0070" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death" data-id="CD013600-fig-0071" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0072" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Subgroup analysis: pre‐existing condition hypertension for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0073" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Subgroup analysis: pre‐existing condition hypertension for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Subgroup analysis: pre‐existing condition hypertension for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0074" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Subgroup analysis: pre‐existing condition hypertension for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0075" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation, or death" data-id="CD013600-fig-0076" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation, or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0077" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0078" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days" data-id="CD013600-fig-0079" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28" data-id="CD013600-fig-0080" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0081" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death" data-id="CD013600-fig-0082" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0083" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0084" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days" data-id="CD013600-fig-0085" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28" data-id="CD013600-fig-0086" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 3: All initial symptoms resolved (asymptomatic) at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0087" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28" data-id="CD013600-fig-0088" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-020.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital" data-id="CD013600-fig-0089" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-020.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 3: Clinical improvement: participants discharged from hospital </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-020.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: Grades 3 and 4 adverse events" data-id="CD013600-fig-0090" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-020.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.4</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 4: Grades 3 and 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-020.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 5: Serious adverse events" data-id="CD013600-fig-0091" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-020.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.5</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease, Outcome 5: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-020.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0092" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28" data-id="CD013600-fig-0093" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 2: Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 3: Serious adverse events" data-id="CD013600-fig-0094" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 1: All‐cause mortality at up tp day 28" data-id="CD013600-fig-0095" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 1: All‐cause mortality at up tp day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 2: Grades 3 and 4 adverse events" data-id="CD013600-fig-0096" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 2: Grades 3 and 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 3: Serious adverse events" data-id="CD013600-fig-0097" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013600-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/urn:x-wiley:14651858:media:CD013600:CD013600-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28" data-id="CD013600-fig-0098" src="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_t/tCD013600-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease, Outcome 1: All‐cause mortality at up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/media/CDSR/CD013600/image_n/nCD013600-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013600-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with moderate to severe disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to placebo or standard care alone for individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> individualswith moderate to severe disease<br/><b>Setting:</b> inpatient <br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> placebo or standard care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or standard care alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28 ‐ total</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b><br/>(207 to 232) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b><br/>(0.92 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19021<br/>(21 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma does not reduce all‐cause mortality at up to day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>287 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b><br/>(278 to 319) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b><br/>(0.97 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14477<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma has little to no impact on the need for invasive mechanical ventilation, or death at day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>665 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>665 per 1000</b><br/>(645 to 678) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/>(0.97 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12721<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma has no impact on whether participants are discharged from hospital.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with EQ‐5D‐5L‐questionnaire, at day 28 (0 indicates worst heath and 100 best health) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life, assessed with EQ‐5D‐5L‐questionnaire, at day 28 was <b>72</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD <b>1 higher</b><br/>(2.14 lower to 4.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on quality of life at up to day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b><br/>(174 to 257) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.17</b><br/>(0.96 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2392<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on the risk of grades 3 and 4 adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ total<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>135 per 1000</b><br/>(108 to 170) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.91 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3901<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma probably has little to no effect on the risk of serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423533352409190077" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423533352409190077</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because of few participants and wide confidence interval.<br/><sup>b</sup> Downgraded one level for serious indirectness, because some studies did not provide clear definitions of how the adverse events were measured and the number of events are inconsistent.<br/><sup>c</sup> Downgraded one level for publication bias, because safety outcomes were assessed and reported in most studies for convalescent plasma group only. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013600-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to standard plasma for individuals with moderate to severe disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to standard plasma for individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> individuals with moderate to severe disease<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> standard plasma </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard plasma</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b><br/>(80 to 210) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73</b><br/>(0.45 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>484<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduces or increases all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>311 per 1000</b><br/>(16 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.59</b><br/>(0.29 to 108.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduces or increases the risk of need for invasive mechanical ventilation, or death at day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with standardised scales at longest follow‐up ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The identified study reported the number of participants experiencing any event of grade 3 (27/147 in CP group versus 17/72 in SP group), or grade 4 (26/147 in CP group versus 15/72 in SP group). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduced or increases the risk for grades 3 and 4 adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>236 per 1000</b><br/>(162 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b><br/>(0.55 to 1.15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>327<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f,</sup><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether convalescent plasma reduces or increases the risk of serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575562054934976" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575562054934976</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for serious inconsistency, because direction of effect is not consistent in all the studies.<br/><sup>b</sup> Downgraded two levels for very serious imprecision, because of few participants and because optimal information size is not met at a power of 0.80.<br/><sup>c</sup> Downgraded three levels due to extreme imprecision, because of extremely few participants, extremely few events, very wide confidence interval and optimal information size is not met at a power of 0.80.<br/><sup>d</sup> Downgraded one level for serious indirectness, because definition of outcomes was different to the definition used in our review.<br/><sup>e</sup> Downgraded two levels for very serious imprecision, because of few participants, and few events.<br/><sup>f</sup> Downgraded two levels for very serious imprecision, because of few participants, and few events and optimal information size is not met at a power of 0.80.<br/><sup>g</sup> Downgraded one level for publication bias, because safety outcomes were assessed and reported in most studies for convalescent plasma group only. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to standard plasma for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013600-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to human immunoglobulin for individuals with moderate to severe disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to human immunoglobulin for individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> individuals with moderate to severe disease<br/><b>Setting:</b> inpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> human immunoglobulin </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with human immunoglobulin</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b><br/>(329 to 650) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b><br/>(0.76 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no effect on all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432005298021526745" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432005298021526745</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by two levels for very serious imprecision, because of few events, few participants and because optimal information size is not met at a power of 0.90. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to human immunoglobulin for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013600-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with mild disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to placebo or standard care alone for individuals with mild disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> outpatients withmild disease<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> placebo or standard care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or standard care alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(2 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.36</b><br/>(0.09 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not convalescent plasma reduces all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to hospital or death within 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(67 to 206) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.05</b><br/>(0.60 to 1.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on admission to hospital or death within 28 days. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom resolution‐ all initial symptoms resolved ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Time to symptom resolution (absolute effect calculated for day 12)<br/>follow‐up: 60 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 1.05</b><br/>(0.85 to 1.30)<br/>[symptoms resolution ] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Convalescent plasma may have little to no impact on time to symptom resolution.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b><br/>(406 to 555) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with standardised scales at longest follow‐up ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b><br/>(84 to 245) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b><br/>(0.75 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on the risk of grades 3 and 4 adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/>(77 to 227) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b><br/>(0.66 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no impact on the risk of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>HR:</b> hazard Ratio; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575913930302502" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423575913930302502</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for serious indirectness, because outcome definition did not exactly match our definition (defined as death associated with COVID‐19).<br/><sup>b</sup> Downgraded two levels for very serious imprecision, because of few participants, few events, wide confidence intervals and because optimal information size is not met for a power of 0.90. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to placebo or standard care alone for individuals with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013600-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to standard plasma for outpatients with mild disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Convalescent plasma compared to standard plasma for outpatients withmild disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> outpatients withmild disease<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> convalescent plasma<br/><b>Comparison:</b> standard plasma </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard plasma</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with convalescent plasma</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b><br/>(0 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.30</b><br/>(0.05 to 1.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1597<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not convalescent plasma reduces all‐cause mortality at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Admission to hospital or death within 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/>(23 to 55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b><br/>(0.31 to 0.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1595<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma probably reduces admission to hospital or death at up to day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom resolution‐ all initial symptoms resolved<br/>follow‐up: 28 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>657 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>736 per 1000</b><br/>(644 to 835) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.98 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>416<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma may have little to no effect on symptom resolution at up to day 28. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to symptom resolution ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life, assessed with standardised scales ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432020765287988004" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_432020765287988004</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded by three levels for extremely serious imprecision, because few events, extremely wide confidence intervals and because optimal information size is not met for a power of 0.90. <br/><sup>b</sup> Downgraded one level for serious imprecision, because optimal information size is not met for a power of 0.90.<br/><sup>c</sup> Downgraded by two levels for very serious imprecision, because few events, very wide confidence intervals and because optimal information size is not met for a power of 0.90. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings table ‐ Convalescent plasma compared to standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of PICO development from protocol stage to current review version</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Publication date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparators</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study designs</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Protocol</b> </p> <p><b>Piechotta 2020a</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 April 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0001"> <li> <p>Individuals with a confirmed diagnosis of COVID‐19</p> </li> <li> <p>No age, gender or ethnicity restrictions</p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0002"> <li> <p>Populations with other coronavirus diseases</p> </li> <li> <p>Populations with mixed virus diseases, unless the trial authors provide subgroup data for people with COVID‐19 </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0003"> <li> <p>Convalescent plasma</p> </li> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0004"> <li> <p>Standard care</p> </li> <li> <p>Placebo</p> </li> <li> <p>Control treatment (e.g. drug treatments)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients (<a href="./references#CD013600-bbs2-0326" title="Core outcome set developers’ response to COVID-19 (2nd April 2020). Available from www.comet-initiative.org/Studies/Details/1538 (accessed 9 April 2020).">COMET 2020</a>) </p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0005"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0006"> <li> <p>Improvement of clinical symptoms, assessed through need for respiratory support:</p> <ul id="CD013600-list-0007"> <li> <p>oxygen by mask or nasal prongs</p> </li> <li> <p>oxygen by NIV or high‐flow</p> </li> <li> <p>Intubation and MV</p> </li> <li> <p>MV</p> </li> <li> <p>ECMO</p> </li> </ul> </li> <li> <p>30‐day and 90‐day mortality</p> </li> <li> <p>Admission to the ICU</p> </li> <li> <p>Length of stay on the ICU</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Number of participants with grades 3 and grade 4 AEs</p> </li> <li> <p>Number of participants with SAEs</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planned inclusion priority, determined by availability of sufficient evidence</b> </p> <p> <ol id="CD013600-list-0008"> <li> <p>RCTs</p> </li> <li> <p>Prospective controlled NRSIs, including quasi‐RCTs, CBA studies, and ITS studies</p> </li> <li> <p>Prospective observational studies with a control group</p> </li> <li> <p>Prospective non‐comparative study designs (e.g. case series)</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 1</b> </p> <p><b>Valk 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0009"> <li> <p>Convalescent plasma</p> </li> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0010"> <li> <p>Studies on standard immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based onCOMET Initiative for COVID‐19 patients</p> <p>(COMET 2020)</p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0011"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0012"> <li> <p>Improvement of clinical symptoms, assessed through need for respiratory support:</p> <ul id="CD013600-list-0013"> <li> <p>oxygen by mask or nasal prongs</p> </li> <li> <p>oxygen by NIV or high‐flow</p> </li> <li> <p>intubation and MV</p> </li> <li> <p>MV plus high‐flow oxygen</p> </li> <li> <p>ECMO</p> </li> <li> <p>30‐day and 90‐day mortality</p> </li> </ul> </li> <li> <p>Admission to the intensive care unit</p> </li> <li> <p>Length of stay on the intensive care unit</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0014"> <li> <p>Prospective non‐comparative study designs (e.g. case series)</p> </li> </ul> </p> <p><b>No evidence available for</b> </p> <p> <ul id="CD013600-list-0015"> <li> <p>RCTs</p> </li> <li> <p>NRSIs</p> </li> <li> <p>Prospective observational studies with a control group</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added exclusion criteria</p> <p> <ul id="CD013600-list-0016"> <li> <p>For studies on standard immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Revised secondary outcome "Improvement of clinical symptoms, assessed through need for respiratory support": </p> <p> <ul id="CD013600-list-0017"> <li> <p>added to the fourth bullet point (MV) "plus high‐flow oxygen"</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 2</b> </p> <p><b>Piechotta 2020b</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 July 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0018"> <li> <p>Standard care</p> </li> <li> <p>Placebo</p> </li> <li> <p>Control treatment (e.g. drug treatments, standard immunoglobulin)</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients</p> <p>(COMET 2020)</p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0019"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0020"> <li> <p>Improvement of clinical symptoms, assessed through need for respiratory support:</p> <ul id="CD013600-list-0021"> <li> <p>Oxygen by mask or nasal prongs</p> </li> <li> <p>Oxygen by NIV or high flow</p> </li> <li> <p>Intubation and MV</p> </li> <li> <p>MV plus high‐flow oxygen</p> </li> <li> <p>ECMO</p> </li> </ul> </li> <li> <p>30‐day and 90‐day mortality</p> </li> <li> <p>Admission to the intensive care unit</p> </li> <li> <p>Length of stay on the intensive care unit</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0022"> <li> <p>RCTs</p> </li> <li> <p>Prospective controlled NRSIs</p> </li> </ul> </p> <p><b>Further inclusion</b> </p> <p> <ul id="CD013600-list-0023"> <li> <p>Prospective and retrospective controlled NRSIs</p> </li> <li> <p>Safety data of prospective and retrospective non‐comparative study designs</p> </li> </ul> </p> <p>According to originally planned inclusion priorities</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added eligible control treatment</p> <p> <ul id="CD013600-list-0024"> <li> <p>Standard immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added a secondary outcome:</p> <p> <ul id="CD013600-list-0025"> <li> <p>Quality of life</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added inclusion criteria for safety data</p> <p> <ul id="CD013600-list-0026"> <li> <p>Retrospective controlled NRSIs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 3</b> </p> <p><b>Chai 2020</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 October 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients (COMET 2020)</p> <p><b>Primary outcomes</b> </p> <p> <ul id="CD013600-list-0027"> <li> <p>All‐cause mortality at hospital discharge</p> </li> <li> <p>Time to death</p> </li> </ul> </p> <p><b>Secondary outcomes</b> </p> <p> <ul id="CD013600-list-0028"> <li> <p>Improvement of clinical symptoms, assessed by need for respiratory support with standardised scales (e.g. WHO Clinical Progression Scale (WHO 2020e), WHO Ordinal Scale for Clinical Improvement (WHO 2020f)) </p> </li> <li> <p>30‐day and 90‐day mortality</p> </li> <li> <p>Admission to the intensive care unit</p> </li> <li> <p>Length of stay on the intensive care unit</p> </li> <li> <p>Time to discharge from hospital</p> </li> <li> <p>Virological response</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events</p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0029"> <li> <p>RCTs</p> </li> <li> <p>Prospective controlled NRSIs</p> </li> </ul> </p> <p><b>Further inclusion</b> </p> <p> <ul id="CD013600-list-0030"> <li> <p>Prospective and retrospective controlled NRSIs</p> </li> <li> <p>Safety data of prospective and retrospective non‐comparative study designs</p> </li> </ul> </p> <p>According to originally planned inclusion priorities</p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0031"> <li> <p>Unregistered non‐comparative studies (e.g. case series)</p> </li> <li> <p>Efficacy data of non‐comparative studies</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Revised and renamed secondary outcome “Improvement of clinical symptoms”</p> <p> <ul id="CD013600-list-0032"> <li> <p>Cut‐offs are no longer self‐set, but now based on standardised scales</p> </li> </ul> </p> <p>Added secondary outcome:</p> <p> <ul id="CD013600-list-0033"> <li> <p>Virological response</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added exclusion criteria:</p> <p> <ul id="CD013600-list-0034"> <li> <p>Unregistered non‐comparative studies (e.g. case series)</p> </li> <li> <p>Efficacy data of non‐comparative studies</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0420" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0035"> <li> <p>Individuals with a confirmed diagnosis of COVID‐19</p> </li> <li> <p>No age, gender or ethnicity restrictions</p> </li> <li> <p>Participants with any disease severity</p> </li> <li> <p>Separate analyses for populations with ambulatory mild disease and for hospitalised participants with moderate to severe disease<sup>c</sup> </p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0036"> <li> <p>Populations with other coronavirus diseases</p> </li> <li> <p>Populations with mixed virus diseases, unless the trial authors provide subgroup data for people with COVID‐19 </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0037"> <li> <p>Standard care</p> </li> <li> <p>Placebo (saline solution)</p> </li> <li> <p>Control treatment (e.g. drug treatments, standard immunoglobulin)</p> </li> <li> <p>Standard plasma</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All criteria based on COMET Initiative for COVID‐19 patients (COMET 2020), and outcomes prioritised by consumer representatives, referees of previous versions of this review, and the German guideline panel for inpatient therapy of people with COVID‐19. </p> <p><b>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</b>Effectiveness of convalescent plasma </p> <p><i>Prioritised outcomes</i> </p> <p> <ul id="CD013600-list-0038"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and at hospital discharge</p> </li> <li> <p>Clinical status at up to day 28, day 60, and up to longest follow‐up); including</p> <ul id="CD013600-list-0039"> <li> <p>Improvement of clinical status</p> <ul id="CD013600-list-0040"> <li> <p>Liberation from supplemental oxygen in surviving patients i.e. WHO ≤ 4 on the Clinical Progression Scale (WHO 2020e) (for the subgroup of participants requiring any supplemental oxygen or ventilator support at baseline, i.e. WHO ≥ 5); </p> </li> <li> <p>Weaning or liberation from invasive MV in surviving patients i.e. WHO ≤ 6 (for the subgroup of participants requiring invasive mechanical ventilation at baseline, i.e WHO ≥ 7); </p> </li> </ul> </li> <li> <p>Worsening of clinical status</p> <ul id="CD013600-list-0041"> <li> <p>Need for invasive MV i.e. WHO 7‐9 (for the subgroup of participants not requiring invasive MV at baseline, i.e. WHO ≤ 6) </p> </li> <li> <p>Need for non‐invasive MV or high flow i.e. WHO = 6 (for the subgroup of participants not requiring non‐invasive or non‐invasive MV, or high flow oxygen at baseline, i.e WHO ≤ 5); </p> </li> <li> <p>Need for oxygen by mask or nasal prongs i.e. WHO = 5 (for the subgroup of participants not requiring any supplemental oxygen or ventilator support at baseline, i.e WHO ≤ 4) </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 30 days, and longest follow‐up available </p> </li> </ul> </p> <p><i>Additional outcomes</i> </p> <p> <ul id="CD013600-list-0042"> <li> <p>Duration of hospitalisation, or time to discharge from hospital</p> </li> <li> <p>Admission to the intensive care unit (ICU)</p> </li> <li> <p>Length of stay on the ICU, or time to discharge from ICU</p> </li> <li> <p>Viral clearance at baseline, up to 3, 7, and 15 days</p> </li> <li> <p>Need for dialysis</p> </li> </ul> </p> <p>Safety of convalescent plasma </p> <p> <ul id="CD013600-list-0043"> <li> <p>Adverse events (any grade, grade 1‐2, grade 3‐4)</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> <p><b>Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease</b> </p> <p>Effectiveness of convalescent plasma </p> <p><i>Prioritised outcomes</i> </p> <p> <ul id="CD013600-list-0044"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and at longest follow‐up.</p> </li> <li> <p>Development of moderate to severe clinical COVID‐19 symptoms, defined as WHO Clinical Progression Scale ≥ 4 (WHO 2020e), up to longest follow‐up </p> <ul id="CD013600-list-0045"> <li> <p>Need for invasive MV, non‐invasive MV or high flow i.e. WHO ≥ 6, severe disease;</p> <ul id="CD013600-list-0046"> <li> <p>Need for invasive MV i.e. WHO 7‐9;</p> </li> <li> <p>Need for non‐invasive mechanical ventilation or high flow i.e. WHO = 6.</p> </li> </ul> </li> <li> <p>Need for hospitalisation with or without supplemental oxygen i.e. WHO = 4‐5, moderate disease; </p> <ul id="CD013600-list-0047"> <li> <p>Need for oxygen by mask or nasal prongs i.e. WHO = 5;</p> </li> <li> <p>Need for hospitalisation without oxygen therapy i.e. WHO = 4.</p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life at up to 7 days, up to 30 days, and longest follow‐up available</p> </li> </ul> </p> <p><i>Additional outcomes</i> </p> <p> <ul id="CD013600-list-0048"> <li> <p>Admission to hospital</p> </li> <li> <p>Time to symptom onset</p> </li> <li> <p>Length of hospital stay, for subgroup of participants hospitalised during course of disease </p> </li> <li> <p>Admission to the ICU</p> </li> <li> <p>Viral clearance at baseline, up to 3, 7, and 15 days</p> </li> </ul> </p> <p>Safety of convalescent plasma </p> <p> <ul id="CD013600-list-0049"> <li> <p>Adverse events (any grade, grade 1‐2, grade 3‐4)</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0050"> <li> <p>RCTs</p> </li> <li> <p>Prospectively registered single‐arm studies with inclusion of ≥ 500 participants, even if upcoming RCTs report safety data for both groups </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Introduced separate populations<sup>c</sup> </p> <p> <ul id="CD013600-list-0051"> <li> <p>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</p> </li> <li> <p>Individuals with with confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added eligible control treatment</p> <p> <ul id="CD013600-list-0052"> <li> <p>Standard plasma</p> </li> </ul> </p> <p>Added specifications on placebo treatment</p> <p> <ul id="CD013600-list-0053"> <li> <p>Saline solution</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Changed primary and secondary outcomes to prioritised (included in 'Summary of findings' table) and additional outcomes (not included in 'Summary of findings' table). </p> <p>Revised and specified outcomes per population.</p> <p>Individuals with moderate to severe disease</p> <p> <ul id="CD013600-list-0054"> <li> <p>Outcome measures for all‐cause mortality were summarised below one outcome</p> </li> <li> <p>Sub‐outcomes for clinical improvement, and clinical worsening were introduced</p> </li> <li> <p>'Need for dialysis' was added as additional outcome</p> </li> <li> <p>'Time to discharge from hospital' was renamed to 'duration of hospitalisation, or time to discharge from hospital' to clarify that we are interested in both, continuous and time‐to‐event data. </p> </li> <li> <p>'Virological response' was renamed to 'viral clearance' to clarify that we are interested in test‐negativity and not in changes of viral load. </p> </li> </ul> </p> <p>Added outcomes for individuals with asymptomatic or mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added inclusion criteria</p> <p> <ul id="CD013600-list-0055"> <li> <p>For prospectively registered single‐arm studies with inclusion of ≥ 500 participants, even if upcoming RCTs report safety data for both groups </p> </li> </ul> </p> <p>Added exclusion criteria</p> <p> <ul id="CD013600-list-0056"> <li> <p>Controlled studies not being truly randomised</p> </li> <li> <p>Studies comparing early versus deferred plasma</p> </li> <li> <p>Studies on plasma donors</p> </li> <li> <p>Pharmacokinetics studies</p> </li> <li> <p>Studies terminated early because the sponsor was changed</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Version 5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Current version)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0057"> <li> <p>Convalescent plasma</p> </li> </ul> </p> <p><b>Exclusion</b> </p> <p> <ul id="CD013600-list-0058"> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease</b>Effectiveness of convalescent plasma </p> <p><i>Primary outcomes</i> </p> <p> <ul id="CD013600-list-0059"> <li> <p>All‐cause mortality at day 28, day 60, time to event, and during hospital stay;</p> </li> <li> <p>Clinical status, at day 28, day 60, and up to the longest follow‐up, including the following: </p> <ul id="CD013600-list-0060"> <li> <p>worsening of clinical status: participants with clinical deterioration (new need for IMV) or death; </p> </li> <li> <p>Improvement of clinical status: participants discharged from hospital. Participants should be discharged without clinical deterioration </p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100, a standardised scale for assessing quality of life) at up to 7 days, up to 28 days, and longest follow‐up available; </p> </li> <li> <p>AEs (any grade, grades 1‐2, grades 3‐4), defined as the number of participants with any event and including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions, headache, thromboembolic events); </p> </li> <li> <p>SAEs, defined as the number of participants with any event.</p> </li> </ul> </p> <p><i>Secondary outcomes</i> </p> <p> <ul id="CD013600-list-0061"> <li> <p>Improvement of clinical status, at day 28 and up to the longest follow‐up, including:</p> <ul id="CD013600-list-0062"> <li> <p>weaning or liberation from IMV in surviving participants;</p> </li> <li> <p>ventilator‐free days (defined as days alive and free from MV);</p> </li> <li> <p>liberation from supplemental oxygen in surviving participants;</p> </li> </ul> </li> <li> <p>Need for dialysis at up to 28 days;</p> </li> <li> <p>Admission to the ICU on day 28;</p> </li> <li> <p>Duration of hospitalisation;</p> </li> <li> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days. </p> </li> </ul> </p> <p><b>Individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease</b> </p> <p>Effectiveness of convalescent plasma </p> <p><i>Primary outcomes</i> </p> <p> <ul id="CD013600-list-0063"> <li> <p>All‐cause mortality at day 28, day 60, time to event, and at the longest follow‐up;</p> </li> <li> <p>Admission to hospital or death within 28 days;</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD013600-list-0064"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14, day 28, and up to the longest follow‐up; </p> </li> <li> <p>time to symptom resolution.</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 28 days, and longest follow‐up available; </p> </li> <li> <p>AEs (any grade, grades 1‐2, grades 3‐4)</p> </li> <li> <p>SAEs, defined as the number of participants with any event.</p> </li> </ul> </p> <p><i>Secondary outcomes</i> </p> <p> <ul id="CD013600-list-0065"> <li> <p>Worsening of clinical status, at day 28 and up to the longest follow‐up, including (moderate to severe COVID‐19 symptoms): </p> <ul id="CD013600-list-0066"> <li> <p>need for hospitalisation with the need for oxygen by mask or nasal prongs, or death;</p> </li> <li> <p>Need for IMVor death</p> </li> </ul> </li> <li> <p>Viral clearance, assessed with RT‐PCR for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Inclusion</b> </p> <p> <ul id="CD013600-list-0067"> <li> <p>RCTs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Removed inclusion criteria:</p> <p> <ul id="CD013600-list-0068"> <li> <p>Hyperimmune immunoglobulin</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We renamed 'Prioritised outcomes' to 'Primary outcomes' and 'Additional outcomes' to 'Secondary outcomes'. </p> <p>We revised and redefined outcomes for individuals with a confirmed diagnosis of COVID‐19 and moderate to severe disease: </p> <p> <ul id="CD013600-list-0069"> <li> <p>For the primary outcomes, we renamed the outcome 'all‐cause mortality at hospital discharge' to 'all‐cause mortality during hospital stay' </p> </li> <li> <p>We redefined the outcome of worsening of clinical status to 'new need for IMV or death' (including the competing event of death) and the outcome of improvement of clinical status to 'participants discharged alive'. </p> </li> <li> <p>We added the outcome: 'improvement of clinical status' with 3 sub‐outcomes (weaning or liberation from IMV in surviving participants; ventilator‐free days; and liberation from supplemental oxygen in surviving participants). </p> </li> <li> <p>We removed the secondary outcome 'Length of stay on the ICU or time to discharge from ICU'. </p> </li> </ul> </p> <p>We revised and redefined outcomes for individuals with a confirmed diagnosis of SARS‐CoV‐2 infection and asymptomatic or mild disease. </p> <p> <ul id="CD013600-list-0070"> <li> <p>We added the outcome</p> <ul id="CD013600-list-0071"> <li> <p>'admission to hospital or death' (including the competing event of death)</p> </li> <li> <p>'symptom resolution' with 2 sub‐outcomes (all initial symptoms resolved and time to symptom resolution) </p> </li> <li> <p>'need for hospitalisation with the need for oxygen by mask or nasal prongs, or death'</p> </li> <li> <p>'need for IMV or death' (including the competing event of death)</p> </li> </ul> </li> <li> <p>We removed the outcome</p> <ul id="CD013600-list-0072"> <li> <p>'development of moderate to severe clinical COVID‐19 symptoms' including all the sub‐outcomes</p> </li> <li> <p>'admission to hospital'</p> </li> <li> <p>'time to symptom onset'</p> </li> <li> <p>'length of hospital stay'</p> </li> <li> <p>'admission to the ICU'</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Added exclusion criteria</p> <p> <ul id="CD013600-list-0073"> <li> <p>Prospectively registered single‐arm studies with inclusion of ≥ 500 participants</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>CBA:</b> controlled before‐and‐after; <b>COMET:</b> Core Outcome Measures in Effectiveness Trials; <b>ECMO:</b> extracorporeal membrane oxygenation; <b>ICU:</b> intensive care unit;<b>IMV:</b> invasive mechanical ventilation; <b>ITS:</b> interrupted time series; <b>MV:</b> mechanical ventilation; <b>NIV:</b> non‐invasive ventilation; <b>NRSI:</b> non‐randomised studies of interventions; <b>RCT:</b> randomised controlled trial; <b>RT‐PCR:</b> reverse‐transcription polymerase chain reaction; <b>SAE:</b> serious adverse event; <b>TACO:</b> transfusion‐associated circulatory overload;<b>TAD:</b> transfusion‐associated dyspnoea; <b>TRALI:</b> transfusion‐related acute lung injury; <b>WHO:</b> World Health Organization; <b>WHOQOL‐100:</b> World Health Organization quality‐of‐life scale </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Including changes in study designs and methodology.<br/><sup>b</sup>Changes in PICO compared to the previously published version.<br/><sup>c</sup>According to the latest WHO clinical progression score (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of PICO development from protocol stage to current review version</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">World Health Organization clinical progression scale a </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Patient state</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Descriptor</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Score</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uninfected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uninfected; no viral RNA detected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Ambulatory mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic; viral RNA detected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic; independent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic; assistance needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hospitalised: moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised; no oxygen therapy<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised; oxygen by mask or nasal prongs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hospitalised: severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalised; oxygen by non‐invasive mechanical ventilation or high flow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intubation and mechanical ventilation; pO<sub>2</sub>/FiO<sub>2</sub> ≥ 150 or SpO<sub>2</sub>/FiO<sub>2</sub> ≥ 200 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive mechanical ventilation; pO<sub>2</sub>/FiO<sub>2</sub> &lt; 150 (SpO<sub>2</sub>/FiO<sub>2</sub> &lt; 200) or vasopressors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive mechanical ventilation; pO<sub>2</sub>/FiO<sub>2</sub> &lt; 150 and vasopressors, dialysis or ECMO </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ECMO:</b> extracorporeal membrane oxygenation; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>pO<sub>2</sub> </b> : partial pressure of oxygen; <b>SpO<sub>2</sub>:</b> oxygen saturation </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>World Health Organization (WHO) clinical progression scale (<a href="./references#CD013600-bbs2-0407" title="WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7.">WHO 2020e</a>).<br/><sup>b</sup>If hospitalised for isolation only, record status as for ambulatory patient. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">World Health Organization clinical progression scale a </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of ongoing convalescent plasma studies: design and planned completion date</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Title</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Link</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Design</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Planned number of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Planned completion date</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Results available</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Other study ID</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized, double‐blind, parallel‐controlled, trial to evaluate the efficacy and safety of anti‐SARS‐CoV‐2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID‐19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=49777 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID‐19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50059 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 April 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study on the application of convalescent plasma therapy in severe COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50727 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 May 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for the treatment of common COVID‐19: a prospective randomized controlled trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50537 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 August 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ChiCTR2000030929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized, double‐blind, parallel‐controlled trial to evaluate the efficacy and safety of anti‐SARS‐CoV‐2 virus inactivated plasma in the treatment of severe novel </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.chictr.org.cn/showproj.aspx?proj=50696 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTRI/2020/04/024915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID‐19 associated complications </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43332 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTRI/2020/05/025346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma in severe COVID‐19 patients </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43005 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 June 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTRI/2020/06/026123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma therapy in corona patients (severe COVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44667 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 December 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐001632‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized open label phase‐II clinical trial with or without infusion of plasma from subjects after convalescence of SARS‐CoV‐2 infection in high‐risk patients with confirmed severe SARS‐CoV‐2 disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐001632‐10/DE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04433910</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐001936‐86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A prospective, randomized, open label phase 2 clinical trial to evaluate superiority of anti‐SARS‐CoV‐2 convalescent plasma versus standard‐of‐care in hospitalized patients with mild COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐001936‐86/DE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐002122‐82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective open‐label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID‐19 convalescent plasma plus standard treatment vs. standard treatment alone of subjects with severe COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐002122‐82/DE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐005410‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre, randomized, double‐blind, placebo‐controlled, non‐commercial clinical trial to evaluate the efficacy and safety of specific anti‐SARS‐CoV‐2 immunoglobulin in the treatment of COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.clinicaltrialsregister.eu/ctr‐search/trial/2020‐005410‐18/PL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ISRCTN49832318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SURCOVID trial: A randomized controlled trial using convalescent plasma early during moderate COVID‐19 disease course in Suriname </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN49832318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>01/04/2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>jRCTs031200374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An open‐label, randomized, controlled trial to evaluate the efficacy of convalescent plasma therapy for COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-JPRN-jRCTs031200374" target="_blank">https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-JPRN-jRCTs031200374</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04333251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluating convalescent plasma to decrease coronavirus associated complications. A phase I study comparing the efficacy and safety of high‐titer anti‐SARS‐CoV‐2 plasma vs best supportive care in hospitalized patients with interstitial pneumonia due to COVID‐19. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04333251 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04345289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy and safety of novel treatment options for adults with COVID‐19 pneumonia (CCAP) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04345289 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUCTR2020‐001367‐88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04372979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy of convalescent plasma therapy in the early care of COVID‐19 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04372979 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04374487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A phase II, open label, randomized controlled trial to assess the safety and efficacy of convalescent plasma to limit COVID‐19 associated complications </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04374487 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04376788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exchange transfusion versus plasma from convalescent patients with methylene blue in patients with COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04376788 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 June 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04380935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effectiveness and safety of convalescent plasma therapy on COVID‐19 patients with acute respiratory distress syndrome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04380935 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 August 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04385043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperimmune plasma in patients with COVID‐19 severe infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04385043 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04385186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inactivated convalescent plasma as a therapeutic alternative in patients CoViD‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04385186 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 November 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04388410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety and efficacy of convalescent plasma transfusion for patients with SARS‐CoV‐2 infection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04388410 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04390503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for COVID‐19 close contacts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04390503 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 April 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04391101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for the treatment of severe SARS‐CoV‐2 (COVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04391101 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04403477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma therapy in severe COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04403477 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 October 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04415086</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment of patients with COVID‐19 with convalescent plasma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04415086 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 May 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04418518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A trial of convalescent plasma for hospitalized adults with acute COVID‐19 respiratory illness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04418518 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04425837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effectiveness and safety of convalescent plasma in patients with high‐risk COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04425837 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 February 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04438057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evaluating the efficacy of convalescent plasma in symptomatic outpatients infected with COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04438057 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 July 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04442191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as a possible treatment for COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04442191 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04452812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistical and epidemiological study based on the use of convalescent plasma for the management of patients with COVID‐19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04452812 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 April 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04456413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as treatment for subjects with early COVID‐19 infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04456413 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 July 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04483960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australasian COVID‐19 trial (ASCOT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04483960 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 July 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACTRN12620000445976</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04521036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for COVID‐19 patients (CPCP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04521036 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 October 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04528368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma for treating patients with COVID‐19 pneumonia without iIndication of ventilatory support </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04528368 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04558476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy of convalescent plasma in patients with COVID‐19 treated with mechanical ventilation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04558476 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 September 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04567173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as adjunctive therapy for hospitalized patients with COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/show/NCT04567173 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04634422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma exchange (PLEX) and convalescent plasma (CCP) in COVID‐19 patients with multiorgan failure (COVID‐PLEX) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04634422 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04712344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessment of efficacy and safety of therapy with COVID‐19 convalescent plasma in subjects with severe COVID‐19 (IPCO) (IPCO) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04712344 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 September 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT04730401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma in the treatment of COVID‐19 (CP_COVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinicaltrials.gov/ct2/show/NCT04730401 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT04803370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy of Reinforcing Standard Therapy in COVID‐19 Patients With Repeated Transfusion of Convalescent Plasma </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>https://clinicaltrials.gov/ct2/show/NCT04803370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 September 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT05077930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Convalescent Plasma Therapy for Hospitalized Patients With COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>https://clinicaltrials.gov/ct2/show/NCT05077930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL8633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non‐ICU patients with COVID‐19 infections </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.trialregister.nl/trial/8633 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 May 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PACTR202006760881890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lagos COVID‐19 convalescent plasma trial (LACCPT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12168 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 November 2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PACTR202007653923168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A clinical trial comparing use of convalescent plasma therapy plus standard treatment to standard treatment alone in patients with severe COVID‐19 infection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11047 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 December 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PER‐013‐20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Convalescent plasma as treatment for COVID‐19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=013‐20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 June 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PER‐060‐20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomized phase 2 clinical trial to evaluate safety and efficacy of the use of plasma from convalescent plasma with the Coronavirus disease (COVID‐19) for the experimental treatment of patients hospitalized in the Centro Médico Naval "Cirujano Mayor Santiago Távara" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=060‐20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 March 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RBR‐7jqpnw</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effect of COVID‐19 convalescent plasma produced by HEMOPE: a randomized study, with a comparative group in several centers </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>www.ensaiosclinicos.gov.br/rg/RBR‐7jqpnw/ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 July 2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>RCT:</b> randomised controlled trial </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Summary of ongoing convalescent plasma studies: design and planned completion date</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses for the comparison of convalescent plasma versus placebo or standard care alone for the population of individuals with moderate to severe disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Main analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias (excluding studies<sup>a</sup> at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Publication status (excluding preprints<sup>b</sup>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study termination (excluding studies terminated early<sup>c</sup>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.92 to 1.03); including 19,021 participants from 21 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.93 to 1.03); including 18,510 participants from 20 studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.92 to 1.03); including 19,021 participants from 21 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.98 (95% CI 0.93 to 1.03); including 17,460 participants from 16 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation (for the subgroup of participants not requiring invasive mechanical ventilation at baseline, i.e. WHO ≤ 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (95% CI 0.97 to 1.11); including 14,477 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (95% CI 0.97 to 1.07); including 13,966 participants from 5 studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.03 (95% CI 0.97 to 1.11); including 14,477 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02 (95% CI 0.96 to 1.09); including 13,556 participants from 5 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12,721 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12,721 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12.,21 participants from 6 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (95% CI 0.97 to 1.02); including 12,534 participants from 4 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.00 (−2.14 to 4.14); including 483 participants from 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 and 4 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (95% CI 0.96 to 1.42); including <br/>2392 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (95% CI 0.96 to 1.42); including <br/>2392 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17 (95% CI 0.96 to 1.42); including <br/>2392 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18 (95% CI 0.77 to 1.80); including 1471 participants from 5 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (95% CI 0.91 to 1.44) including <br/>3901 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (95% CI 0.91 to 1.44) including <br/>3901 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14 (95% CI 0.91 to 1.44) including <br/>3901 participants from 6 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95% CI 0.81 to 1.50); including 2980 participants from 5 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>NR:</b> not reported; <b>RR:</b> risk ratio; <b>WHO:</b> World Health Organization </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Excluded studies with high risk of bias (<a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a>).<br/><sup>b</sup>Excluded preprints: no study.<br/><sup>c</sup>Excluded studies with premature termination (<a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a>; <a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a>; <a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a>; <a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a>; <a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Sensitivity analyses for the comparison of convalescent plasma versus placebo or standard care alone for the population of individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0010"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events of any grade</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Any grade AEs</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Convalescent plasma group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 in CP group and 224 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0110"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> <li> <p>15 individuals with transfusion‐related events, within 6 h of CP transfusion</p> <ul id="CD013600-list-0111"> <li> <p>1 with pain at the infusion site</p> </li> <li> <p>1 with chills</p> </li> <li> <p>1 with nausea</p> </li> <li> <p>1 with bradycardia</p> </li> <li> <p>1 with dizziness</p> </li> <li> <p>3 with fever and tachycardia</p> </li> <li> <p>2 with dyspnoea</p> </li> <li> <p>2 with blockage of an intravenous catheter</p> </li> <li> <p>3 with mortality possibly related to CP transfusion</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0112"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 in CP group and 20 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0113"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> <li> <p>3 transient adverse reactions, but not considered to be related to therapy</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0114"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 in CP group and 172 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0115"> <li> <p>4 individuals with grade 3‐4 AEs, included in Analysis 1.14</p> </li> <li> <p>10 individuals with transfusion‐related events:</p> <ul id="CD013600-list-0116"> <li> <p>2 fever</p> </li> <li> <p>1 nausea/vomiting</p> </li> <li> <p>5 dyspnoea</p> </li> <li> <p>2 allergic reaction (immediate)</p> </li> <li> <p>0 TRALI</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0117"> <li> <p>0 individuals with grades 3‐4 AEs, included in Analysis 1.14</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP and 39 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0118"> <li> <p>3 treatment‐related AEs</p> <ul id="CD013600-list-0119"> <li> <p>nausea, pruritis, and an acute allergic reaction; all grade 2</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 in CP group, 307 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0120"> <li> <p>35 individuals with infusion‐related complications:</p> <ul id="CD013600-list-0121"> <li> <p>13 TAD</p> </li> <li> <p>9 minor allergic reaction</p> </li> <li> <p>5 TACO</p> </li> <li> <p>4 febrile non‐haemolytic reaction</p> </li> <li> <p>2 other (hypertensive reaction</p> </li> <li> <p>1 hypotensive reaction</p> </li> <li> <p>1 possible TRALI</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 in CP and 71 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0122"> <li> <p>0 serious adverse reactions (≥ grade 3) attributable to CP transfusion were observed during study follow‐up </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 in CP group, 163 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0123"> <li> <p>19 individuals with infusion‐related side effects:</p> <ul id="CD013600-list-0124"> <li> <p>0 TRALI</p> </li> <li> <p>2 serious allergic transfusion reactions</p> </li> <li> <p>3 TACO</p> </li> <li> <p>5 non‐haemolytic febrile reaction</p> </li> <li> <p>9 other related side effects</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1078 in CP group, 909 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0125"> <li> <p>1 transfusion reaction</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0126"> <li> <p>0 transfusion reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 in CP group and 43 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0127"> <li> <p>0 individuals with serious transfusion‐related AEs</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 in CP group and 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0128"> <li> <p>0 individuals with transfusion‐related complications</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 in CP and 14 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0129"> <li> <p>1 patient developed high fever within two hours after the first plasma administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0130"> <li> <p>0 AEs reported</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5795 in CP group and 5763 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0131"> <li> <p>13 individuals with transfusion‐related serious adverse reactions reported to SHOT:</p> <ul id="CD013600-list-0132"> <li> <p>9 with pulmonary reactions (including 3 deaths possibly related to transfusion)</p> </li> <li> <p>4 with serious febrile, allergic or hypotensive reactions</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 in CP, 67 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0133"> <li> <p>15 AEs, of these, 3 AEs were judged definitely related and 3 judged to be possibly related to plasma transfusion, while the rest were thought to be unrelated to plasma transfusion. </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0134"> <li> <p>14 AEs</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 in CP, 52 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0135"> <li> <p>Only number of SAEs reported</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 in CP group and 254 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0136"> <li> <p>3 participants had serious infusion reactions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0022" title="LiL , ZhangW , HuY , TongX , ZhengS , YangJ , et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 3 June 2020;324(5):460-70. [DOI: 10.1001/jama.2020.10044]LiL , ZhangW , HuY . Correction to data in trial of convalescent plasma treatment for COVID-19. JAMA2020;324(5):519. LiuZ . Errors in trial of effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA2020;324(5):518-9. ">Li 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 in CP group and 51 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0137"> <li> <p>2 individuals with transfusion‐related AEs</p> <ul id="CD013600-list-0138"> <li> <p>1 with possible severe TAD (shortness of breath, cyanosis, and severe dyspnoea) within 6 h of transfusion </p> </li> <li> <p>1 with non‐severe allergic transfusion reaction and probable non‐severe febrile non‐haemolytic transfusion reaction (chills and rashes) within 2 h of transfusion </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 in CP and 241 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0139"> <li> <p>2 events with worsening of respiratory failure without fever</p> </li> <li> <p>2 events with worsening of respiratory failure with fever and a skin rash</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 in CP and 463 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0140"> <li> <p>8 transfusion reactions</p> <ul id="CD013600-list-0141"> <li> <p>1 of these TRALI or TACO</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0142"> <li> <p>2 transfusion reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 in CP and 30 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013600-list-0143"> <li> <p>0 participants with any serious side effects</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP group 40 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0144"> <li> <p>0 individuals with transfusion‐related AEs</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 in CP and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0145"> <li> <p>2 individuals with transfusion‐related AEs:</p> <ul id="CD013600-list-0146"> <li> <p>2 allergic reactions</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0147"> <li> <p>4 allergic reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 in CP group and</p> <p>105 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0148"> <li> <p>11 individuals with transfusion‐related events:</p> <ul id="CD013600-list-0149"> <li> <p>0 TRALI</p> </li> <li> <p>0 TACO</p> </li> <li> <p>5 non‐haemolytic febrile reaction</p> </li> <li> <p>4 allergic reaction</p> </li> <li> <p>1 unexplained event</p> </li> <li> <p>1 technical resolution event</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0150"> <li> <p>2 individuals with transfusion‐related events:</p> <ul id="CD013600-list-0151"> <li> <p>allergic reactions</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 in CP group and 51 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0152"> <li> <p>1 grade 1 allergic reaction</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0153"> <li> <p>1 grade 1 allergic reaction</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus standard plasma for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 in CP group and 15</p> <p>in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0154"> <li> <p>1 individual with transfusion‐related events: signs of mild urticaria during plasma transfusion </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0155"> <li> <p>1 individual with transfusion‐related events: signs of mild urticaria during plasma transfusion </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 in CP group and 95 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0156"> <li> <p>0 SAEs associated with plasma treatments</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 in CP, 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0157"> <li> <p>1 participant experienced a serious transfusion reaction after a small volume was administered and thus did not complete the 2‐unit administration </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 in CP group, 18 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0158"> <li> <p>0 infusion‐related reactions</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0159"> <li> <p>1 infusion‐related reaction (hypotension)</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 in CP group and 72 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0160"> <li> <p>4 individual with probably or definitely transfusion‐related events, included worsening anaemia, urticaria, skin rash, and transfusion‐associated circulatory overload </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0161"> <li> <p>3 individuals with probably or definitely transfusion‐related events</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 in CP, 60 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0162"> <li> <p>The CP group did not develop adverse effects attributable to its administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0163"> <li> <p>2 participants in the IVIg group developed AEs associated with its administration</p> <ul id="CD013600-list-0164"> <li> <p>1 anaphylactic reaction</p> </li> <li> <p>1 hypertensive crisis</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with asymptomatic or mild disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 in CP group and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0165"> <li> <p>0 individuals with solicited AEs (the definition was unclear and we were unsure whether only drug‐related adverse events were assessed, and we did not receive additional information from the study authors) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0166"> <li> <p>0 individuals with solicited AEs (the definition was unclear and we were unsure whether only drug‐related adverse events were assessed, and we did not receive additional information from the study authors) </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 in CP, 188 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0167"> <li> <p>24 treatment‐related AEs:</p> <ul id="CD013600-list-0168"> <li> <p>mild allergic reactions, fever, and local reactions</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0169"> <li> <p>8 treatment‐related AEs</p> <ul id="CD013600-list-0170"> <li> <p>2 local reactions</p> </li> <li> <p>3 vasovagal syndrome</p> </li> <li> <p>2 fever or chills</p> </li> <li> <p>1 gastrointestinal symptoms</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Convalescent plasma versus standard plasma for individuals with asymptomatic or mild disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>592 in CP and 589 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0171"> <li> <p>2 severe transfusion reactions</p> <ul id="CD013600-list-0172"> <li> <p>1 pneumonia</p> </li> <li> <p>1 unspecified</p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0173"> <li> <p>2 participants with Infusion‐related reaction and 0 severe reactions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>CP:</b> convalescent plasma; <b>IVIg:</b> intravenous immunoglobulin; <b>NR:</b> not reported; <b>SAE:</b> serious adverse event; <b>SHOT:</b> serious hazards of transfusion; <b>TACO:</b> transfusion‐associated circulatory overload; <b>TAD:</b> transfusion‐associated dyspnoea; <b>TRALI:</b> transfusion‐related acute lung injury </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events of any grade</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0011"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serious adverse events</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Serious adverse events</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CP group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0001" title="Agarwal A, MukherjeeA , Kumar G, ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in India: an open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.03.20187252]AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ2020;371:m3939. AgarwalA , MukherjeeA , KumarG , ChatterjeeP , BhatnagarT , MalhotraP , et al. Erratum: Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) (The BMJ (2020) 371 (m3939) DOI: 10.1136/bmj.m3939). The BMJ2020;371 (no pagination)(m4232):1-10. ">Agarwal 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 in CP group and 224 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0003" title="AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. MedRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.02.20224303]AlQahtaniM , AbdulrahmanA , AlmadaniA , AlaliSY , Al ZamrooniAM , HejabA , et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease. Scientific Reports2021;11(1):9927. [DOI: 10.1038/s41598-021-89444-5]">AlQahtani 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 in CP group and 20 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0004" title="Avendano-SolaC , Ramos-MartinezA , Munez-RubioE , Ruiz-AntoranB , Malo de MolinaR , TorresF , et al. Convalescent plasma for COVID-19: a multicenter, randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.08.26.20182444]Avendaño-SoláC , Ramos-MartínezA , Muñez-RubioE , Ruiz-AntoránB , Malo de MolinaR , TorresF , et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(20):e152740. [DOI: 10.1172/JCI152740]Diago-SempereE , BuenoJL , Sancho-LopezA , Munez-RubioE , TorresF , Malo de MolinaR , et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials2021;22(1):70. ">Avendano‐Sola 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 in CP group and 43 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0007" title="Bar KJ, ShawPA , ChoiGH , AquiN , FesnakA , YangJB , et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation2021;131(24):e155114. [DOI: 10.1172/JCI155114]">Bar 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP group and 39 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0176"> <li> <p>12 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0177"> <li> <p>15 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0008" title="BeginP , CallumJ , HeddleN , CookR , ZellerMP , TimmouthA , et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials2021;22(1):323. [DOI: 10.1186/s13063-021-05235-3]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Author correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2022;28:212. [DOI: 10.1038/s41591-021-01667-1]BéginP , CallumJ , JamulaE , CookR , HeddleNM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine2021;27:2012-24. [DOI: 10.1038/s41591-021-01488-2]The CONCOR-1 Study Group, BéginP , CallumJ , JamulaE , CookR , Heddle NM , TinmouthA , et al. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.29.21259427]">Begin 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>614 in CP group, 307 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0178"> <li> <p>205 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0179"> <li> <p>81 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0011" title="NCT04589949. Early convalescent plasma therapy for high-risk patients with COVID-19 in primary care (the CoV-Early Study). Available from clinicaltrials.gov/show/NCT04589949 (first received 19 October 2020). ">CoV‐Early</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 in CP group, 204 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0012" title="De SantisGC , Correa OliveiraL , GaribaldiPM , AlmadoCE , CrodaJ , ArcanjoGG , et al. High-dose convalescent plasma for treatment of severe COVID-19. Emerging Infectious Diseases2022;28(3):548-55. [DOI: 10.3201/eid2803.212299]">De Santis 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 in CP group, 71 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0013" title="DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 27 November 2020;21:981. [DOI: https://doi.org/10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauvliegheA , AriënK , BarbezangeC , CleerenM , et al. Correction to: a randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials 14 December 2020;21:981. [DOI: 10.1186/s13063-020-04876-0]DevosT , GeukensT , SchauwvliegheA , AriënK , BarbezangeC , CleerenM , et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-45324/v2]DevosT , Van ThilloQ , CompernolleV , NajdovskiT , RomanoM , DaubyN , et al. Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal2021;59(2):2101724. [DOI: 10.1183/13993003.01724-2021]">Devos 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320 in CP group, 163 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0180"> <li> <p>66 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0181"> <li> <p>34 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0014" title="The REMAP-CAP Investigators, EstcourtLJ . Convalescent plasma in critically ill patients with COVID-19. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.06.11.21258760]Writing committee for the REMAP-CAP Investigators, EstcourtLJ , TurgeonAF , McQuiltenZK , McVerryBJ , Al-BeidhF , AnnaneD , et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA2021;326:1690-702. [DOI: 10.1001/jama.2021.18178.]">Estcourt 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1078 in CP group, 909 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0182"> <li> <p>32 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0183"> <li> <p>12 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0015" title="GharbharanA , JordansC , GeurtsvanKesselC , HollanderJ , KarimF , MollemaF , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. ResearchSquare [Preprint]2020. [DOI: https://doi.org/10.21203/rs.3.rs-105265/v1]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.07.01.20139857]GharbharanA , JordansCC , GeurtsvanKesselC , den HollanderJG , KarimF , MollemaFP , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nature Communications2021;21:3189. [DOI: 10.1038/s41467-021-23469-2]">Gharbharan 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 in group and 43 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0016" title="Hamdy SalmanO , Ail MohamedHS . Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egyptian Journal of Anaesthesia2020;36(1):264-72. [DOI: 10.1080/11101849.2020.1842087]">Hamdy Salman 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 in group and 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0017" title="HolmK , LundgrenMN , Kjeldsen-KraghJ , LjungquistO , BöttigerB , WikénC , et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in southern Sweden. BMC Research Notes2021;14(1):440. [DOI: 10.1186/s13104-021-05847-7]">Holm 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 in CP group and 14 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0018" title="HorbyPW , EstcourtL , PetoL , EmbersonJR , StaplinN , SpataE , et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.09.21252736]RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet2021;397(10289):2049-59. [DOI: 10.1016/S0140-6736(21)00897-7]">Horby 2021b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5795 in group and 5763 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0019" title="KirengaB , Byakika-KibwikaP , MuttambaW , KayongoA , LoryndahNO , MugenyiL , et al. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ2021;8:e001017. [DOI: 10.1136/bmjresp-2021-001017]MuttambaW , LusibaJ , NamakulaLO , Byakika-KibwikaP , SsaliF , DdunguH , et al. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. PLoS One2021;16(6):e0252306. [DOI: 10.1371/journal.pone.0252306]">Kirenga 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 in CP group, 67 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0020" title="KoerperS , JahrsdoerferB , ApplT . Convalescent plasma for treatment of severe COVID-19: rationale and designing of a randomized, open-label clinical trial of convalescent plasma compared to best supportive care (CAPSID Trial). Transfusionsmedizin2020;10(3):143-9. KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , Corman VM et al. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID. medRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.05.10.21256192]KoerperS , WeissM , ZicklerD , WiesmannT , ZacharowskiK , CormanVM , et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. Journal of Clinical Investigation2021;131(20):e152264. [DOI: 10.1172/JCI152264]">Koerper 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 in CP, 52 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0184"> <li> <p>22 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0185"> <li> <p>25 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0021" title="KorleyFK , Durkalski-MauldinV , YeattsSD , SchulmanK , DavenportRD , DumontLJ , et al. Early convalescent plasma for high-risk outpatients with COVID-19. New England Journal of Medicine2021;385(21):1951-60. [DOI: 10.1056/NEJMoa2103784]">Korley 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257 in CP group and 254 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0024" title="MenichettiF , PopoliP , PuopoloM , Alegiani SpilaS , TiseonG , BartoliniA , et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Network Open2021;4(11):e2136246. [DOI: 10.1001/jamanetworkopen.2021.36246]">Menichetti 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 in CP group and 241 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0026" title="OrtigozaMB , YoonH , GoldfeldKS , TroxelAB , DailyJP , WuY , et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Internal Medicine2022;182(2):115-26. [DOI: 10.1001/jamainternmed.2021.6850]">Ortigoza 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463 in CP group and 463 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0028" title="PouladzadehM , SafdarianM , EshghiP , AbolghasemiH , BavaniAG , SheibaniB , et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Internal and Emergency Medicine2021;16:2181-91. [DOI: 10.1007/s11739-021-02734-8]">Pouladzadeh 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 in CP group and 30 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0029" title="BandopadhyayP , RozarioR , LahiriA , SarifJ , RayY , PaulSR , et al. Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.09.21.20199109]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , LahiriA , et al. Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.25.20237883]RayY , PaulSR , BandopadhyayP , D'RozarioR , SarifJ , RaychaudhuriD , et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications2022;13:383. [DOI: 10.1038/s41467-022-28064-7]">Ray 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 in CP group and 40 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0030" title="SekineL , ArnsB , FabroBR , CipolattMM , MachadoRR , DurigonEL , et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. European Respiratory Journal2021;59(2):2101471. [EMBASE: 10.1183/13993003.01471-2021]">Sekine 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 in CP group and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0031" title="SimonovichVA , BurgosPL , ScibonaP , BerutoMV , ValloneMG , VázquezC , et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. New England Journal of Medicine2020;384(7):619-29. [DOI: 10.1056/NEJMoa2031304]">Simonovich 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 in CP group and 105 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0186"> <li> <p>54 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0187"> <li> <p>19 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0033" title="Van den BergK , GlattTN , VermeulenM , LittleF , SwanevelderR , BarrettC , et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Scientific Reports2022;12:2552. [DOI: 10.1038/s41598-022-06221-8]">Van den Berg 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 in CP group and 51 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus standard plasma for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 in CP group and 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 in CP group and 95 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 in CP group, 15 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0188"> <li> <p>16 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0189"> <li> <p>4 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 in CP group, 18 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0190"> <li> <p>2 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0191"> <li> <p>1 individual with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0027" title="EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Correction to: evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):927. [DOI: 10.1186/s13063-020-04877-z]EckhardtCM , CummingsMJ , RajagopalanKN , BordenS , BitanZC , WolfA , et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):499. O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. Journal of Clinical Investigation 2021 [Epub ahead of print];11:150646. [DOI: 10.1172/JCI150646]O’DonnellM , GrinsztejnB , CummingsMJ , JustmanJ , LambMR , EckhardtCM , et al. A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19. MedRxiv [Preprint}2021. [DOI: https://doi.org/10.1101/2021.03.12.21253373]">O’Donnell 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147 in CP group an 72 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0192"> <li> <p>39 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0193"> <li> <p>26 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0009" title="Beltran GonzalezJL , Gonzalez GamezM , Mendoza EncisoEA , Esparza MaldonadoRJ , Hernandez PalaciosD , Duenas CamposS , et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. MedRxiv [Preprint]2021. [DOI: https://doi.org/10.1101/2021.03.28.21254507]">Beltran Gonzalez 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 in CP group and 60 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Convalescent plasma versus placebo or standard care alone for individuals with mild disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0002" title="AlemanyA , Millat-MartinezP , Corbacho-MonnéM , MalchairP , OuchiD , Ruiz-ComellasA , et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine2022;10(3):278-88. [DOI: 10.1016/S2213-2600(21)00545-2]">Alemany 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188 in CP group and 188 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0194"> <li> <p>25 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013600-list-0195"> <li> <p>22 individuals with SAEs, included in analysis</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0023" title="Libster R , Marc GP , Wappner D , Coviello S , Bianchi A , Braem V, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.11.20.20234013]LibsterR , MarcGP , WappnerD , CovielloS , BianchiA , BraemV , et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. New England Journal of Medicine2021;384(7):610-18. [DOI: 10.1056/NEJMoa2033700]">Libster 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 in CP group and 80 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Convalescent plasma versus standard plasma for individuals with mild disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013600-bbs2-0032" title="SullivanDJ , GeboKA , ShohamS , BlochEM , LauB , ShenoyAG , et al. Early outpatient treatment for COVID-19 with convalescent plasma. New England Journal of Medicine March 2022 [Epub ahead of print];Moa2119657:NP. [DOI: 10.1056/NEJMoa2119657]">Sullivan 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>592 in CP group and 589 in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CP:</b> convalescent plasma; <b>NR:</b> not reported; <b>TACO:</b> transfusion‐associated circulatory overload; <b>TRALI:</b> transfusion‐related acute lung injury; <b>SAEs:</b> serious adverse events </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013600-tbl-0012"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analyses for the comparison of convalescent plasma versus standard plasma for the population of individuals with moderate to severe disease</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Main analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk of bias (excluding studies<sup>a</sup> at high risk of bias)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Publication status (excluding preprints<sup>b</sup>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study termination (excluding studies terminated early<sup>c</sup>)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality at up to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73 (95% CI 0.45 to 1.19); including 484 participants from 4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73 (95% CI 0.45 to 1.19); including 484 participants from 4 studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (95% CI 0.43 to 1.01); including 455 participants from 3 studies<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.17 to 5.29); including 252 participants from 2 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical worsening: need for invasive mechanical ventilation (for the subgroup of participants not requiring invasive mechanical ventilation at baseline, i.e. WHO ≤ 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.59 (95% CI 0.29 to 108.38) including 34 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.59 (95% CI 0.29 to 108.38) including 34 participants from 1 study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study included<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 5.59 (95% CI 0.29 to 108.38) including 34 participants from 1 study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical improvement: participants discharged from hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grades 3 or 4 adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80 (95% CI 0.55 to 1.15); including <br/>327 participants from 3 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80 (95% CI 0.55 to 1.15); including <br/>327 participants from 3 studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.77 (95% CI 0.53 to 1.13); including <br/>293 participants from 2 studies<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (95% CI 0.51 to 1.14); including <br/>253 participants from 2 studies<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>CI:</b> confidence interval;<b>NR:</b> not reported; <b>RR:</b> risk ratio; <b>WHO:</b> World Health Organization </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Excluded studies with high risk of bias: no study.<br/><sup>b</sup>Excluded preprints (no peer reviewed results published; <a href="./references#CD013600-bbs2-0005" title="BajpaiM , KumarS , MaheshwariA , ChabraK , KaleP , GuptaA , et al. Efficacy of convalescent plasma therapy compared to fresh frozen plasma in severely ill COVID-19 patients: a pilot randomized controlled trial. Medrxiv [Preprint]2020. [DOI: https://doi.org/10.1101/2020.10.25.20219337]">Bajpai 2020</a>; <a href="./references#CD013600-bbs2-0025" title="NCT04421404. Effects of COVID-19 convalescent plasma (CCP) on coronavirus-associated complications in hospitalized patients. Available from clinicaltrials.gov/show/NCT04421404 (first received 9 June 2020). ">NCT04421404</a>)<br/><sup>c</sup>Excluded studies with premature termination (<a href="./references#CD013600-bbs2-0006" title="BaldeónME , MaldonadoA , Ochoa-AnradeM , LargoC , PesantezM , HerdoizaM . Effect of convalescent plasma as complementary treatment inpatients with moderate COVID-19 infection. Transfusion Medicine2022;32(2):153-61. [DOI: 10.1111/tme.12851]">Baldeon 2022</a>; <a href="./references#CD013600-bbs2-0010" title="Bennett-GuerreroE , RomeiserJL , TalbotLR , AhmedT , MamoneLJ , SinghSM , et al. Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York. Critical Care Medicine2021;49(7):1015-25. [DOI: 10.1097/CCM.0000000000005066]">Bennett‐Guerrero 2021</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Sensitivity analyses for the comparison of convalescent plasma versus standard plasma for the population of individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/full#CD013600-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Individuals with severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.50, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality at up to day 60 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.49, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.35, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Individuals with severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.48, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.55, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Individuals with severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.48, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.71, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Individuals with severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.56, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.77, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Individuals with severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.90, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Individuals with severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.90, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Quality of life, assessed with standardised scales at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐2.14, 4.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Any grade adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.95, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Grades 1‐2 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.87, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Grades 3 and 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.96, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.43, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.02, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.91, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.82, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.85, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Clinical improvement: weaning or liberation from invasive mechanical ventilation in surviving participants, for subgroups of participants requiring invasive mechanical ventilation at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.57, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Clinical improvement: ventilator‐free days by day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.90, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Clinical improvement: liberation from supplemental oxygen in surviving participants, for subgroup of participants requiring any supplemental oxygen or ventilator support at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>560</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Need for dialysis at up to 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Admission to the intensive care unit (ICU) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Duration of hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.04 [‐6.87, 4.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Viral clearance at up to day 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.76, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Viral clearance at up to day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.85, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Viral clearance at up to day 14 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.58, 3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Convalescent plasma versus standard plasma for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.45, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Individuals with moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.37, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.36, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.41, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [0.29, 108.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Duration of hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.14 [‐5.24, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Any grade adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.93, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.55, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Individuals with moderate to severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.55, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Convalescent plasma versus standard plasma for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.76, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 All‐cause mortality (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.84, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 All‐cause mortality during hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.76, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Convalescent plasma versus human immunoglobulin for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Convalescent plasma versus placebo or standard care alone for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.09, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 All‐cause mortality at up to day 60 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.60, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Time to symptom resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.85, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Clinical worsening: need for hospitalisation with at least need of oxygen by mask or nasal prongs, or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.36, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Clinical worsening: need for invasive mechanical ventilation or death at up to day 60 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.10, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Grades 3 and 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.75, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Convalescent plasma versus placebo or standard care alone for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Convalescent plasma versus standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1597</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.05, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.31, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 All initial symptoms resolved (asymptomatic) at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 All initial symptoms resolved (asymptomatic) at up to day 14 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Clinical worsening: need for hospitalisation with need of at least oxygen by mask or nasal prongs, or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.05, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Convalescent plasma versus standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 All‐cause mortality at up to day 28 (random‐effects analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 No antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 All‐cause mortality (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.94, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 No antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.50, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 No antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.84, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.95, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 No antibodies detected at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.99, 1.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Subgroup analysis: antibodies in recipients detected at baseline for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 All‐cause mortality at up to day 28 (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Duration of symptom onset up to and including 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.40, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.95, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 All‐cause mortality (time to event) (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.42, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.42, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Duration of symptom onset up to and including 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.50, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Duration of symptom onset up to 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.98, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.95, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 All‐cause mortality at up to day 28 (random‐effects analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Duration of symptom onset up to and including 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.26, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.24, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.13, 10.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 Duration of symptom onset up to and including 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [0.12, 73.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.02, 10.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.27, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Duration of symptom onset up to and including 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.24, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.14, 22.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 All initial symptoms resolved (asymptomatic) at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.65, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Duration of symptom onset up to and including 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.00, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.2 Duration of symptom onset more than 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.27, 1.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Subgroup analysis: length of time since symptom onset for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 All‐cause mortality at up to day 28 (random‐effects model) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.45, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.54, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 No immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.20, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.83, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.65, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 No immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.81, 1.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 No immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.26, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 No immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.26, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 All initial symptoms resolved (asymptomatic) at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 No immunosuppression (immune deficiency and cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Subgroup analysis: pre‐existing condition immunosuppression for the comparison of convalescent plasma vs. standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.17, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Clinical worsening: need for invasive mechanical ventilation or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.89, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.84, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.85, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.50, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.86, 1.59]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 34.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.33 [0.33, 163.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.32, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.09, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 All initial symptoms resolved (asymptomatic) at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.88, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.35, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.2 No diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Subgroup analysis: pre‐existing condition diabetes for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.04, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Pulmonary disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 No pulmonary disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.30, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Clinical worsening: need for invasive mechanical ventilation or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.94, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 Respiratory disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.81, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.2 No respiratory disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.88, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.83, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 Pulmonary disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.78, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.2 No pulmonary disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.73, 1.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Subgroup analysis: pre‐existing condition respiratory disease for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Subgroup analysis: pre‐existing condition hypertension for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.22, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.04, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 No hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.22, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.78, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.82, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.2 No hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Subgroup analysis: pre‐existing condition hypertension for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.22, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.03, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.2 ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.28, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.3 ≤ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.4 &gt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.06, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Clinical worsening: need for invasive mechanical ventilation, or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 &lt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.64, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.2 ≥ 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.92, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.3 &lt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.4 ≥ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.82, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.74, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.2 ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.74, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.3 &lt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.4 &gt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Subgroup analysis: age of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.11, 10.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.2 ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [0.14, 81.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.32, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.21, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.2 ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.40, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 All initial symptoms resolved (asymptomatic) at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.98, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.99, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.2 ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.83, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Subgroup analysis: age of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.17, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.10, 6.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.15, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Clinical worsening: need for invasive mechanical ventilation or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.88, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.01, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.96, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Subgroup analysis: sex of participants for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 15.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.32, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.21, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.31, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 All initial symptoms resolved (asymptomatic) at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.98, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.1 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.2 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Subgroup analysis: sex of participants for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.77, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.74, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.93, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.74, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.3 Clinical improvement: participants discharged from hospital <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.97, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.4 Grades 3 and 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.77, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.06 [1.00, 9.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.83, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.81, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.74, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.82, 2.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.53, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.34, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.41, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [0.29, 108.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [0.29, 108.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.48, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.48, 2.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for individuals with moderate to severe disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 All‐cause mortality at up tp day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.09, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.2 Low‐ to middle‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.09, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 Grades 3 and 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.75, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.75, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus placebo or standard care alone for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013600-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 All‐cause mortality at up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.03, 12.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.1 High‐income countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.03, 12.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Subgroup analysis: income levels of countries for the comparison of convalescent plasma versus standard plasma for outpatients with mild disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#CD013600-tbl-0035">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>AlQahtani 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized by computer‐generated random numbering in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 40 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not analysed in accordance with the predefined outcomes stated in the protocol, as the time point of the outcome measurement was not pre‐specified in the study protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality", there are some concerns for bias in selection of reported results. However, for all the other domains, there is a low risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality", all the domains have a low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Avendano‐Sola 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through a web‐based eCRF system (ORACLE clinical) in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 359 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28", there is a low risk of bias for all the domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Holm 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients eligible for inclusion were enrolled and randomized by a study physician (KH, OL, CW, JO, MR), 1:1 using the electronic software REDCap to either receive SOC or SOC with 200–250 mL of CCP administered intravenously during 30 min on three consecutive days. Blocks of ten patients were used for randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol is available online and the time point of all‐cause mortality reported in the article is not consistent with the planed time point indicated in the trial registry (three month in the ClinicalTrial registration). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized, in a modified intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention and this is probably a deviation from the intended intervention that arose because of the trial context. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were available for 453 out of 464 participants. Data of six participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality" in this study, there is a low risk of bias from the randomization process, missing outcome data, measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> <tr class="study-data"> <td> <p>Korley 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline differences (characteristics are not balanced) in hospitalisation between groups suggesting a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were blinded to the treatment, but those delivering the intervention were aware of intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received, so it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias arising from the randomization process.</p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.2 Individuals with severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, a total of 101 out of 103 participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28", all the domains have a low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.3 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ray 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably allocated randomly to either the standard of care group alone or standard of care with convalescent plasma group and there were no further information given on the randomization process. There is no information on the allocation concealment, the trial registry only indicates concealment through "Case Record Numbers". There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 80 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28" in this study, there is a low risk of bias due to deviations from intended interventions, due to missing outcome data, in measurement of the outcome and in selection of the reported result. There are some concerns for bias from the randomization process. </p> </td> </tr> <tr class="study-data"> <td> <p>Van den Berg 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eligible and consenting participants were randomized (1:1) to receive either a single infusion of 200–250 mL CCP or 200 mL of placebo, together with local standard of care. Random assignment was stratified by study site, age (≥ or &lt; 65 years), and body mass index (BMI) (≥ or &lt; 30 kg/m2). An electronic randomisation application (REDCap) hosted by SANB, was used to generate the treatment allocation. To mask treatment allocation, investigational product (IP) was covered in opaque paper wrapping prior to dispatch from the blood bank. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably not aware of intervention received, as treatment allocation was masked (plasma was covered in opaque paper wrapping) and there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized (two participants withdrew consent and two were transferred to alternative facilities prior to transfusion) . </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registry, the protocol was not available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "28‐day mortality", there was a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Ortigoza 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A centralized electronic system was used to randomly assign enrolled patients to receive CCP or placebo in a 1:1 ratio stratified by enrollment site and risk status using randomization block sizes of 4 and 6 to maintain balanced group sizes. Allocation was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, treating clinicians, trial personnel, and outcome assessors were blinded to group assignment and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause mortality at up to day 60</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.1 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Pouladzadeh 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This parallel‐group, single‐blind, and randomized controlled trial was designed by randomly assigning patients to the intervention and control groups using a 6‐item randomized block method by computer and an equal allocation ratio (1:1). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not mentioned as predefined outcomes in the trial registration and there was no protocol available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.2 Individuals with severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause mortality at up to day 60</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 All‐cause mortality (time to event)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Avendano‐Sola 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through a web‐based eCRF system (ORACLE clinical) in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 359 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized, in a modified intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality", all the domains have a low risk of bias.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.2 Individuals with severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 103 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality (time to event)", all the domains have a low risk of bias.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.3 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for all available</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "Mortality (time to event)", there is a low risk of bias from the randomization process, due to missing outcome data, in measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality (time to event)", there was a low risk of bias for all the domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Ray 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably allocated randomly to either the standard of care group alone or standard of care with convalescent plasma group and there were no further information given on the randomization process. There is no information on the allocation concealment, the trial registry only indicates concealment through "Case Record Numbers". There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 80 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not analysed in accordance with the predefined outcomes stated in the trial registration. The "time‐to‐event" measurement for mortality was not mentioned in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality (time to event)", there is a low risk of bias due to deviations from intended interventions, due to missing outcome data and in measurement of the outcome. There are some concerns for bias in selection of the reported result and from the randomization process. </p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Van den Berg 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eligible and consenting participants were randomized (1:1) to receive either a single infusion of 200–250 mL CCP or 200 mL of placebo, together with local standard of care. Random assignment was stratified by study site, age (≥ or &lt; 65 years), and body mass index (BMI) (≥ or &lt; 30 kg/m2). An electronic randomisation application (REDCap) hosted by SANB, was used to generate the treatment allocation. To mask treatment allocation, investigational product (IP) was covered in opaque paper wrapping prior to dispatch from the blood bank. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably not aware of intervention received, as treatment allocation was masked (plasma was covered in opaque paper wrapping) and there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized (two participants withdrew consent and two were transferred to alternative facilities prior to transfusion) . </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registry, the protocol was not available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 All‐cause mortality (time to event)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 All‐cause mortality during hospital stay</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention. This could be due to awareness of the intervention, because this trial was open‐label. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 451 out of 464 participants. Data of eight participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "mortality", there is a low risk of bias from the randomization process, missing outcome data, measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> <tr class="study-data"> <td> <p>AlQahtani 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized by computer‐generated random numbering in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 40 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there was no information on whether the data that produced this result was analysed in accordance with the predefined protocol, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "All‐cause mortality at hospital discharge" all the other domains were at low risk of bias. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.2 Individuals with severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "all‐cause mortality at hospital discharge" there is a low risk of bias from the randomization process, due to missing outcome data, in measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 All‐cause mortality during hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention and this is probably a deviation from the intended intervention that arose because of the trial context. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 453 out of 464 participants. Data of six participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Korley 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline differences (characteristics are not balanced) in hospitalisation between groups suggesting a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were blinded to the treatment, but those delivering the intervention were aware of intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received, so it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measure was appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.2 Individuals with severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.3 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.2 Individuals with severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, a total of 101 out of 103 participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.3 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was in accordance with the predefined outcomes stated in the trial protocol: "Duration of hospital and ICU stay: both parameters will be analysed as time‐to‐event parameters with competing risk, whereby the event of interest is discharge from hospital/ICU and the competing risk is hospital/ICU death". </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Quality of life, assessed with standardised scales at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, assessed with the EX‐5D‐5L‐questionnaire and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to bias of measurement outcome</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Quality of life, assessed with standardised scales at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Any grade adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Holm 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients eligible for inclusion were enrolled and randomized by a study physician (KH, OL, CW, JO, MR), 1:1 using the electronic software REDCap to either receive SOC or SOC with 200–250 mL of CCP administered intravenously during 30 min on three consecutive days. Blocks of ten patients were used for randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The safety outcome was not predefined in the trial registry, but the text says: "Patients were monitored once daily for adverse events, blood pressure, oxygen saturation, heart and respiratory rates and temperature. An adverse event was any adverse symptom or clinical sign that was not considered as an obvious symptom of COVID‐19" </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was not pre‐defined in the clinical trial registry and there is no protocol available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>It is not clearly indicated whethere all the participants were included in the analysis.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information whether the measurement of the outcome was appropriate. This is an open label trial and the outcome assessors were aware of the intervention allocation, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Ortigoza 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A centralized electronic system was used to randomly assign enrolled patients to receive CCP or placebo in a 1:1 ratio stratified by enrollment site and risk status using randomization block sizes of 4 and 6 to maintain balanced group sizes. Allocation was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, treating clinicians, trial personnel, and outcome assessors were blinded to group assignment and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on whether the outcome measure was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized, data was available for 228 participants in the convalescent plasma group and 104 participants in the placebo group. The data of two participants in control group was missing, of which one missing participants was due to withdrawal of consent after randomisation and therefore that participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measurement is an appropriate measure and it is unlikely that the measurement differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "Any grade adverse events", there is a low risk of bias for all the domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Van den Berg 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eligible and consenting participants were randomized (1:1) to receive either a single infusion of 200–250 mL CCP or 200 mL of placebo, together with local standard of care. Random assignment was stratified by study site, age (≥ or &lt; 65 years), and body mass index (BMI) (≥ or &lt; 30 kg/m2). An electronic randomisation application (REDCap) hosted by SANB, was used to generate the treatment allocation. To mask treatment allocation, investigational product (IP) was covered in opaque paper wrapping prior to dispatch from the blood bank. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably not aware of intervention received, as treatment allocation was masked (plasma was covered in opaque paper wrapping) and there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized (two participants withdrew consent and two were transferred to alternative facilities prior to transfusion) . </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information whether the measurement of the outcome was appropriate and it could be that it differed between intervention groups. The outcome assessors were aware of the intervention received, and knowledge of intervention received could have affected outcome measurement, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not analysed in accordance with the predefined outcomes stated in the trial registry and the protocol was not available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Any grade adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Grades 1‐2 adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on whether the outcome measure was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Grades 1‐2 adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Grades 3 and 4 adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention and this is probably a deviation from the intended intervention that arose because of the trial context. There is no information on whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 451 participants out of 464 participants randomized and the data of eight participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on the method of measuring for this outcome, as the data was provided on request by the study investigator. The outcome assessors were aware of the intervention received and the knowledge of intervention received could have affected outcome measurement, but it is probably not likely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with a pre‐specified trial registration, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "Grade 3 and 4 adverse events", there is a low risk of bias arising from the randomization process and due to missing outcome data and in the in selection of the reported result. But, there are some concerns for bias due to deviations from intended interventions and in measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>AlQahtani 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized by computer‐generated random numbering in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate.. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 40 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information available on whether the method of measuring the outcome was appropriate or whether the measurement could have differed between groups, as the data was provided on request by the study investigator and for safety different measurements are possible. The outcome assessors were aware of the intervention received, which is why the knowledge of intervention received could have affected safety outcome assessments, but this is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there was no information on whether the data that produced this result was analysed in accordance with the predefined protocol, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "Grade 3 and 4 adverse events", there is a low risk of bias arising from the randomization process, due to deviations from intended interventions, due to missing outcome data and in the in selection of the reported result. But, there are some concerns for bias in measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information whether the measurement of the outcome was appropriate. This is an open label trial and the outcome assessors were aware of the intervention allocation, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized, data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measurement is an appropriate measure and it is unlikely that the measurement differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "Grade 3 and 4 adverse events", there is a low risk of bias for all the domains. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.10.2 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the interventions received, but external monitoring was performed at all sites to assess protocol adherence, reporting of adverse events and accuracy of data entry, so it is unlikely that the outcome assessment was influenced by the intervention knowledge. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on whether the outcome measure was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Grades 3 and 4 adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomised, data were available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measurement is an appropriate measure and it is unlikely that the measurement differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "Serious adverse events", there is a low risk of bias for all the domains. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.2 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome were available for (nearly) all participants randomised</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the interventions received, but external monitoring was performed at all sites to assess protocol adherence, reporting of adverse events and accuracy of data entry, so it is unlikely that the outcome assessment was influenced by the intervention knowledge. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, the serious adverse events are listed in the supplement and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to bias of measurement outcome</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, the serious adverse events are listed in the supplement and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to bias of measurement outcome</p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.12 Clinical improvement: weaning or liberation from invasive mechanical ventilation in surviving participants, for subgroups of participants requiring invasive mechanical ventilation at baseline</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants requiring invasive mechanical ventilation at baseline, which was 13 out of 86 participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with a pre‐specified analysis plan, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "liberation from invasive mechanical ventilation", there is a low risk of bias from the randomization process, due to missing outcome data, in measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants requiring invasive mechanical ventilation at baseline, a total of 617 out of 11,558 participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "Weaning or liberation from invasive mechanical ventilation", there was a low risk of bias for all the domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.12 Clinical improvement: weaning or liberation from invasive mechanical ventilation in surviving participants, for subgroups of participants requiring invasive mechanical ventilation at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.13 Clinical improvement: ventilator‐free days by day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data for this outcome was provided by the study investigators on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.13 Clinical improvement: ventilator‐free days by day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.14 Clinical improvement: liberation from supplemental oxygen in surviving participants, for subgroup of participants requiring any supplemental oxygen or ventilator support at baseline</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of the intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined time‐to‐event parameters with competing risk of the outcome "time to clinical improvement" and the planned estimation of the event rates using cumulative incidence functions (CIF), stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants requiring any supplemental oxygen or ventilator support at baseline, being 77 out of 86 participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "liberation from supplemental oxygen", there is a low risk of bias from the randomization process, due to missing outcome data, in measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.14 Clinical improvement: liberation from supplemental oxygen in surviving participants, for subgroup of participants requiring any supplemental oxygen or ventilator support at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.16 Admission to the intensive care unit (ICU)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information available, but it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was not planned or pre‐specified in the protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.16 Admission to the intensive care unit (ICU)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.18 Viral clearance at up to day 3</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention, which could be due to awareness of the intervention, as this trial was open‐label. According to the study, a per protocol analysis was performed for this secondary outcome, but there was no potential for a substantial impact (on the result) of the failure to analyse randomized participants. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 367 out of 451 participants included in the per protocol analysis. Data of 51 participants in the convalescent plasma arm and of 46 participants in the control arm were missing and there is no evidence that the result was not biased by missing outcome data. However, there it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the method of measuring the outcome was inappropriate, as it was unclear how the outcome was exactly measured and the measurement could have differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "viral clearance", there is a low risk of bias from the randomization process and in selection of the reported result, there are some concerns for bias due to deviations from intended interventions and due to missing outcome data. However, there is a high risk in measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Hamdy Salman 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using website software in a 2:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 30 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome " viral clearance at day 3", there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcome data and in measurement of the outcome. However, there are some concerns for bias in selection of the reported result. </p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was not available for all, or nearly all, participants randomized (47/52 participants in plasma group and 40/51 participants in control group) and there is no evidence that the result was not biased by missing outcome data. However, it is unlikely that the missingness in the outcome could depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "viral clearance", there is a low risk of bias in all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.18 Viral clearance at up to day 3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.19 Viral clearance at up to day 7</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention, which could be due to awareness of the intervention, as this trial was open‐label. According to the study, a per protocol analysis was performed for this secondary outcome, but there was no potential for a substantial impact (on the result) of the failure to analyse randomized participants. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 342 out of 451 participants included in the per protocol analysis and there is no evidence that the result was not biased by missing outcome data. However, there it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the method of measuring the outcome was inappropriate, as it was unclear how the outcome was exactly measured and the measurement could have differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "viral clearance", there is a low risk of bias from the randomization process and in selection of the reported result, there are some concerns for bias due to deviations from intended interventions and due to missing outcome data. However, there is a high risk in measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was not available for all, or nearly all, participants randomized (47/52 participants in plasma group and 40/51 participants in control group) and there is no evidence that the result was not biased by missing outcome data. However, it is unlikely that the missingness in the outcome could depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "viral clearance", there is a low risk of bias in all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was only available for 117/160 participants randomized, and the missingness in the outcome could depend on its true value, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.19 Viral clearance at up to day 7</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-18"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.20 Viral clearance at up to day 14</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was not available for all, or nearly all, participants randomized (47/52 participants in plasma group and 40/51 participants in control group) and there is no evidence that the result was not biased by missing outcome data. However, it is unlikely that the missingness in the outcome could depend on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "viral clearance", there is a low risk of bias in all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.20 Viral clearance at up to day 14</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-18">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-19"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.1 Individuals with moderate disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Baldeon 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This was a random double blinded, non‐convalescent plasma (NCP)‐placebo controlled clinical trial. However, there are no information provided on the concealment of the allocation sequence:"A simple randomization scheme was used to allocate participants in the two treatment groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This study was triple blinded. Hospital personnel at the transfusion medicine services, physicians, and the participants were unaware which plasma was convalescent and which plasma was control. Intention to treat analysis was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for all the 158 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinical outcomes were assessed by investigators who were blinded to the treatment groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol was available, but the outcome was pre‐specified in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to bias arising from the randomization process.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.1.2 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bajpai 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized with concealed allocation using the Sequentially Numbered Opaque Sealed Envelopes (SNOSE) method, to receive either convalescent plasma with standard of care or standard plasma (fresh frozen plasma) with standard of care. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, in total 29 out of 31 participants (2 participants became PCR negative on the day of plasma transfusion). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "mortality at day 28", there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Bennett‐Guerrero 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized 4:1 to CP or SP using permuted block randomization lists generated using SAS software (version 9.4; SAS Institute, Cary NC) and implemented using an interactive web response randomization tool in Research Electronic Data Capture (REDCap). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The individuals who were unblinded were Blood Bank personnel since they needed to label and dispense the masked CP or SP. The bags of CP or SP had an identical label, stating “CP or SP” to preserve blinding. All study personnel who collected data were blinded to study assignment at all times. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the outcome is pre‐defined in Supplemental Detailed Methods.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>O’Donnell 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using a web‐based randomization platform in a 2:1 ratio to receive either convalescent plasma or standard plasma and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 223 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "28‐day mortality", there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-19">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-20"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 All‐cause mortality (time to event)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Bajpai 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized with concealed allocation using the Sequentially Numbered Opaque Sealed Envelopes (SNOSE) method, to receive either convalescent plasma with standard of care or standard plasma (fresh frozen plasma) with standard of care. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, in total 29 out of 31 participants (2 participants became PCR negative on the day of plasma transfusion). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Baldeon 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This was a random double blinded, non‐convalescent plasma (NCP)‐placebo controlled clinical trial. However, there are no information provided on the concealment of the allocation sequence:"A simple randomization scheme was used to allocate participants in the two treatment groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This study was triple blinded. Hospital personnel at the transfusion medicine services, physicians, and the participants were unaware which plasma was convalescent and which plasma was control. Intention to treat analysis was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for all the 158 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinical outcomes were assessed by investigators who were blinded to the treatment groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol was available, but the outcome was pre‐specified in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Bennett‐Guerrero 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized 4:1 to CP or SP using permuted block randomization lists generated using SAS software (version 9.4; SAS Institute, Cary NC) and implemented using an interactive web response randomization tool in Research Electronic Data Capture (REDCap). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The individuals who were unblinded were Blood Bank personnel since they needed to label and dispense the masked CP or SP. The bags of CP or SP had an identical label, stating “CP or SP” to preserve blinding. All study personnel who collected data were blinded to study assignment at all times. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but in Supplemental Detailed Methods mentioned</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>O’Donnell 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using a web‐based randomization platform in a 2:1 ratio to receive either convalescent plasma or standard plasma and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 223 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 All‐cause mortality (time to event)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-20">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-21"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>NCT04421404</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Subjects enrolled in the study will be randomized using a web based randomization procedure to receive convalescent plasma versus non‐immune plasma at a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received, there were no deviations from intended interventions and the analysis was appropriate. The nursing staff may be unblinded to the treatment assignment to ensure proper ABO checking of the plasma unit at bedside per standard transfusion procedures. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 34 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The are no information available (as the study still needs to be published in a journal) on whether the measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were blinded to the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-21">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-22"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Duration of hospitalisation</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Bajpai 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized with concealed allocation using the Sequentially Numbered Opaque Sealed Envelopes (SNOSE) method, to receive either convalescent plasma with standard of care or standard plasma (fresh frozen plasma) with standard of care. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Baldeon 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This was a random double blinded, non‐convalescent plasma (NCP)‐placebo controlled clinical trial. However, there are no information provided on the concealment of the allocation sequence:"A simple randomization scheme was used to allocate participants in the two treatment groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This study was triple blinded. Hospital personnel at the transfusion medicine services, physicians, and the participants were unaware which plasma was convalescent and which plasma was control. Intention to treat analysis was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for all the 158 participants randomised. They report that in the convalescent plasma group 66 participants were analysed, however only 63 were randomised to that group, so probably a tipo. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinical outcomes were assessed by investigators who were blinded to the treatment groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol was available, but the outcome was pre‐specified in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to bias arising from the randomization process.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Duration of hospitalisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-22">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-23"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Any grade adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>NCT04421404</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Subjects enrolled in the study will be randomized using a web based randomization procedure to receive convalescent plasma versus non‐immune plasma at a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received, there were no deviations from intended interventions and the analysis was appropriate. The nursing staff may be unblinded to the treatment assignment to ensure proper ABO checking of the plasma unit at bedside per standard transfusion procedures. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 34 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The are no information available (as the study still needs to be published in a journal) on whether the measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were blinded to the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>O’Donnell 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using a web‐based randomization platform in a 2:1 ratio to receive either convalescent plasma or standard plasma and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all (219 out of 223) participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "any adverse events", there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Any grade adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-23">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-24"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 2.6.1 Individuals with moderate to severe disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bennett‐Guerrero 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized 4:1 to CP or SP using permuted block randomization lists generated using SAS software (version 9.4; SAS Institute, Cary NC) and implemented using an interactive web response randomization tool in Research Electronic Data Capture (REDCap). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The individuals who were unblinded were Blood Bank personnel since they needed to label and dispense the masked CP or SP. The bags of CP or SP had an identical label, stating “CP or SP” to preserve blinding. All study personnel who collected data were blinded to study assignment at all times. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information available and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not pre‐defined in the registry of supplemental material .</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>NCT04421404</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Subjects enrolled in the study will be randomized using a web based randomization procedure to receive convalescent plasma versus non‐immune plasma at a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received, there were no deviations from intended interventions and the analysis was appropriate. The nursing staff may be unblinded to the treatment assignment to ensure proper ABO checking of the plasma unit at bedside per standard transfusion procedures. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 34 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The are no information available (as the study still needs to be published in a journal) on whether the measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were blinded to the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>O’Donnell 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using a web‐based randomization platform in a 2:1 ratio to receive either convalescent plasma or standard plasma and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all (219 out of 223) participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "serious adverse events", there is a low risk of bias for all the domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-24">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-25"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Beltran Gonzalez 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a controlled, randomized, open clinical trial including patients with secondary pneumonia to SARS‐CoV‐2 infection, and fulfilling severe or critical disease criteria, to compare the efficacy and safety of CP administration in comparison with the use of IVIg. No information on the concealment of the allication sequence. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-25">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-26"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 All‐cause mortality (time to event)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Beltran Gonzalez 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a controlled, randomized, open clinical trial including patients with secondary pneumonia to SARS‐CoV‐2 infection, and fulfilling severe or critical disease criteria, to compare the efficacy and safety of CP administration in comparison with the use of IVIg. No information on the concealment of the allication sequence. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 All‐cause mortality (time to event)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-26">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-27"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 All‐cause mortality during hospital stay</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Beltran Gonzalez 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a controlled, randomized, open clinical trial including patients with secondary pneumonia to SARS‐CoV‐2 infection, and fulfilling severe or critical disease criteria, to compare the efficacy and safety of CP administration in comparison with the use of IVIg. No information on the concealment of the allication sequence. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 All‐cause mortality during hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-27">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-28"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data that produced this result analysed in accordance with a pre‐specified outcome of the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Libster 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized using an electronic system numbering to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were unaware of their assigned intervention and those delivering the intervention were aware of intervention assigned during the trial, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 160 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "all‐cause mortality", there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-28">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-29"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 All‐cause mortality at up to day 60</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data that produced this result analysed in accordance with a pre‐specified outcome of the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 All‐cause mortality at up to day 60</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-29">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-30"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.3 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was provided on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.3 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-30">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-31"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.4 Time to symptom resolution</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data that produced this result analysed in accordance with a pre‐specified outcome of the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.4 Time to symptom resolution</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-31">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-32"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.5 Clinical worsening: need for hospitalisation with at least need of oxygen by mask or nasal prongs, or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was provided on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Libster 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized using an electronic system numbering to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were unaware of their assigned intervention and those delivering the intervention were aware of intervention assigned during the trial, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 160 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.5 Clinical worsening: need for hospitalisation with at least need of oxygen by mask or nasal prongs, or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-32">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-33"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.6 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was provided on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.6 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-33">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-34"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.7 Clinical worsening: need for invasive mechanical ventilation or death at up to day 60</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was provided on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.7 Clinical worsening: need for invasive mechanical ventilation or death at up to day 60</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-34">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-35"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.8 Grades 3 and 4 adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information to judge whether the outcome was measured appropriately.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data that produced this result analysed in accordance with a pre‐specified outcome of the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.8 Grades 3 and 4 adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-35">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-36"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.9 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was provided on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.9 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-36">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-37"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are some concerns, as the data was provided on request and the study results are not published yet. </p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of the intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with the predefined outcomes, as there is no protocol available and no information on mortality outcome provided in the trial registry. However, for this mortality outcome, the risk of bias remains still low. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-37">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-38"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are some concerns, as the data was provided on request and the study results are not published yet. </p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-38">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-39"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was provided on request by the study investigators.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are some concerns, as the data was provided on request and the study results are not published yet. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-39">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-40"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 All initial symptoms resolved (asymptomatic) at up to day 14</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was provided on request by the study investigator.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are some concerns, as the data was provided on request and the study results are not published yet. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 All initial symptoms resolved (asymptomatic) at up to day 14</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-40">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-41"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.5 Clinical worsening: need for hospitalisation with need of at least oxygen by mask or nasal prongs, or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with the predefined outcomes, as there is no protocol available and no information on this outcome provided in the trial registry. However, for this this outcome, the risk of bias remains still low. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Low risk of bias in all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.5 Clinical worsening: need for hospitalisation with need of at least oxygen by mask or nasal prongs, or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-41">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-42"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.6 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are some concerns, as the data was provided on request and the study results are not published yet. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.6 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-42">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-43"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 All‐cause mortality at up to day 28 (random‐effects analysis)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.1.1 Antibodies detected at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Avendano‐Sola 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through a web‐based eCRF system (ORACLE clinical) in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all the subgroup participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28", there is a low risk of bias for all the domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was awailable for all randomized participants for this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High because of first domain</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for the randomized participants wihtin this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome, there was a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Ortigoza 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A centralized electronic system was used to randomly assign enrolled patients to receive CCP or placebo in a 1:1 ratio stratified by enrollment site and risk status using randomization block sizes of 4 and 6 to maintain balanced group sizes. Allocation was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, treating clinicians, trial personnel, and outcome assessors were blinded to group assignment. ITT was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.1.2 No antibodies detected at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Avendano‐Sola 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through a web‐based eCRF system (ORACLE clinical) in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all the subgroup participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28", there is a low risk of bias for all the domains. </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was awailable for all randomized participants for this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High because of first domain</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for the randomized participants wihtin this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome, there was a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Ortigoza 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A centralized electronic system was used to randomly assign enrolled patients to receive CCP or placebo in a 1:1 ratio stratified by enrollment site and risk status using randomization block sizes of 4 and 6 to maintain balanced group sizes. Allocation was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, treating clinicians, trial personnel, and outcome assessors were blinded to group assignment. ITT was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 All‐cause mortality at up to day 28 (random‐effects analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-43">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-44"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.3 Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.3.1 Antibodies detected at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention. This could be due to awareness of the intervention, because this trial was open‐label. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for participants within this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was predefined in the trial reistry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.3.2 No antibodies detected at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention. This could be due to awareness of the intervention, because this trial was open‐label. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for participants within this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was predefined in the trial reistry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.3 Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-44">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-45"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.4 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.4.1 Antibodies detected at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized in this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 6.4.2 No antibodies detected at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized in this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.4 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-45">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-46"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 All‐cause mortality at up to day 28 (random‐effects model)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.1.1 Duration of symptom onset up to and including 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for the randomized participants within this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there was a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Korley 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline differences (characteristics are not balanced) in hospitalisation between groups suggesting a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were blinded to the treatment, but those delivering the intervention were aware of intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received, so it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias arising from the randomization process.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.1.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for the randomized participants within this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there was a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 All‐cause mortality at up to day 28 (random‐effects model)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-46">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-47"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 All‐cause mortality (time to event) (random‐effects model)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.2.1 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 All‐cause mortality (time to event) (random‐effects model)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-47">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-48"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.3.1 Duration of symptom onset up to and including 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for randomized participants within this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome, there was a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Korley 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline differences (characteristics are not balanced) in hospitalisation between groups suggesting a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were blinded to the treatment, but those delivering the intervention were aware of intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received, so it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.3.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>articipants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for all available</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for randomized participants within this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome, there was a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Clinical worsening: need for invasive mechanical ventilation or death (random‐effects model)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-48">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-49"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.4 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.4.1 Duration of symptom onset up to 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 7.4.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.4 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-49">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-50"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.1 All‐cause mortality at up to day 28 (random‐effects analysis)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 8.1.1 Duration of symptom onset up to and including 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>O’Donnell 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using a web‐based randomization platform in a 2:1 ratio to receive either convalescent plasma or standard plasma and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 217 participants randomized, within this subrgoup. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "28‐day mortality", there is a low risk of bias for all the domains.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 8.1.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>O’Donnell 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized using a web‐based randomization platform in a 2:1 ratio to receive either convalescent plasma or standard plasma and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 217 participants randomized, within this subrgoup. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "28‐day mortality", there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 8.1 All‐cause mortality at up to day 28 (random‐effects analysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-50">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-51"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 9.1.1 Duration of symptom onset up to and including 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 9.1.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-51">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-52"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 9.2.1 Duration of symptom onset up to and including 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 9.2.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-52">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-53"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 9.3.1 Duration of symptom onset up to and including 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 9.3.2 Duration of symptom onset more than 7 days</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 9.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-53">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-54"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.1 All‐cause mortality at up to day 28 (random‐effects model)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.1.1 Immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.1.2 No immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.1 All‐cause mortality at up to day 28 (random‐effects model)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-54">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-55"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.2.1 Immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 10.2.2 No immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 10.2 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-55">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-56"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.1.1 No immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-56">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-57"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.2.1 No immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-57">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-58"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 11.3.1 No immunosuppression (immune deficiency and cancer)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 11.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-58">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-59"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.1.1 Diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.1.2 No diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-59">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-60"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.2 Clinical worsening: need for invasive mechanical ventilation or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.2.1 Diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.2.2 No diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.2 Clinical worsening: need for invasive mechanical ventilation or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-60">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-61"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.3 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.3.1 Diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 12.3.2 No diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 12.3 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-61">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-62"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 13.1.1 Diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 13.1.2 No diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-62">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-63"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 13.2.1 Diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 13.2.2 No diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-63">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-64"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 13.3.1 Diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 13.3.2 No diabetes</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 13.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-64">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-65"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 14.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 14.1.1 Pulmonary disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 14.1.2 No pulmonary disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 14.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-65">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-66"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 14.2 Clinical worsening: need for invasive mechanical ventilation or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 14.2.1 Respiratory disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 14.2.2 No respiratory disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 14.2 Clinical worsening: need for invasive mechanical ventilation or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-66">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-67"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 14.3 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 14.3.1 Pulmonary disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 14.3.2 No pulmonary disease</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 14.3 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-67">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-68"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 15.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 15.1.1 Hypertension</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 15.1.2 No hypertension</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 15.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-68">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-69"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 15.2 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 15.2.1 Hypertension</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 15.2.2 No hypertension</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 15.2 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-69">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-70"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 16.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.1.1 &lt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.1.2 ≥ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.1.3 ≤ 60 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.1.4 &gt; 60 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 16.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-70">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-71"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 16.2 Clinical worsening: need for invasive mechanical ventilation, or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.2.1 &lt; 60 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.2.2 ≥ 60 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so the interim analysis was no deviation from the protocol and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all (921/938) participants. 17 Participants were lost to follow‐up at day 30 (after discharge). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.2.3 &lt; 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.2.4 ≥ 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 16.2 Clinical worsening: need for invasive mechanical ventilation, or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-71">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-72"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 16.3 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.3.1 &lt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.3.2 ≥ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.3.3 &lt; 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 16.3.4 &gt; 70 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 16.3 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-72">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-73"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 17.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 17.1.1 &lt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 17.1.2 ≥ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 17.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-73">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-74"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 17.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 17.2.1 &lt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 17.2.2 ≥ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 17.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-74">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-75"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 17.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 17.3.1 &lt; 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 17.3.2 ≥ 65 years</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 17.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-75">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-76"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 18.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 18.1.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 18.1.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 18.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-76">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-77"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 18.2 Clinical worsening: need for invasive mechanical ventilation or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 18.2.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data available for this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in teh SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for this subgroup, in a modified intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 18.2.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Begin 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised in a 2:1 ratio to receive convalescent plasma or standard of care using a secure, concealed, computer‐generated, web‐accessed randomization sequence (REDCap v11.0.1). Eligible patients were randomly assigned to receive either convalescent plasma or standard of care. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants and those delivering the intervention were aware of intervention received. The trial was terminated at 78% of planned enrollment after meeting stopping criteria for futility, according to protocol, so there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data available for this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in teh SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for this subgroup.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for this subgroup, in a modified intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 18.2 Clinical worsening: need for invasive mechanical ventilation or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-77">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-78"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 18.3 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 18.3.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 18.3.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 18.3 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-78">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-79"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 19.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 19.1.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 19.1.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 19.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-79">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-80"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 19.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 19.2.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 19.2.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on the measurement of the outcome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. COVID‐19 relatedness for hospitalizations was adjudicated by a three physician panel masked to treatment group. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but the data that produced this result was analysed in accordance with the predefined outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 19.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-80">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-81"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 19.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 19.3.1 Female</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 19.3.2 Male</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. The subgroup data was provided on request by the study investigator. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 19.3 All initial symptoms resolved (asymptomatic) at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-81">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-82"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.1.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized, in a modified intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that the assessment of the outcome was influenced by knowledge of intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "28‐day mortality", there was a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Ortigoza 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A centralized electronic system was used to randomly assign enrolled patients to receive CCP or placebo in a 1:1 ratio stratified by enrollment site and risk status using randomization block sizes of 4 and 6 to maintain balanced group sizes. Allocation was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients, treating clinicians, trial personnel, and outcome assessors were blinded to group assignment and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Avendano‐Sola 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through a web‐based eCRF system (ORACLE clinical) in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 359 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28", there is a low risk of bias for all the domains. </p> </td> </tr> <tr class="study-data"> <td> <p>AlQahtani 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized by computer‐generated random numbering in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 40 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not analysed in accordance with the predefined outcomes stated in the protocol, as the time point of the outcome measurement was not pre‐specified in the study protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality", there are some concerns for bias in selection of reported results. However, for all the other domains, there is a low risk of bias. </p> </td> </tr> <tr class="study-data"> <td> <p>Holm 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients eligible for inclusion were enrolled and randomized by a study physician (KH, OL, CW, JO, MR), 1:1 using the electronic software REDCap to either receive SOC or SOC with 200–250 mL of CCP administered intravenously during 30 min on three consecutive days. Blocks of ten patients were used for randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available online (could be requested), but clinical trial registry is available. All‐cause mortality within 28 days: this was changed from the three month in the ClinicalTrial registration due to a maximum follow‐up time of 28 days </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Korley 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline differences (characteristics are not balanced) in hospitalisation between groups suggesting a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were blinded to the treatment, but those delivering the intervention were aware of intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received, so it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>High risk of bias arising from the randomization process.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.1.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, a total of 101 out of 103 participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28", all the domains have a low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>De Santis 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study methods it is stated that this is a "investigator‐initiated multicenter open‐label randomized controlled trial", but no further information on the allocation sequence concealment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Ray 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were probably allocated randomly to either the standard of care group alone or standard of care with convalescent plasma group and there were no further information given on the randomization process. There is no information on the allocation concealment, the trial registry only indicates concealment through "Case Record Numbers". There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 80 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality at up to day 28" in this study, there is a low risk of bias due to deviations from intended interventions, due to missing outcome data, in measurement of the outcome and in selection of the reported result. There are some concerns for bias from the randomization process. </p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Van den Berg 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Eligible and consenting participants were randomized (1:1) to receive either a single infusion of 200–250 mL CCP or 200 mL of placebo, together with local standard of care. Random assignment was stratified by study site, age (≥ or &lt; 65 years), and body mass index (BMI) (≥ or &lt; 30 kg/m2). An electronic randomisation application (REDCap) hosted by SANB, was used to generate the treatment allocation. To mask treatment allocation, investigational product (IP) was covered in opaque paper wrapping prior to dispatch from the blood bank. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably not aware of intervention received, as treatment allocation was masked (plasma was covered in opaque paper wrapping) and there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized (two participants withdrew consent and two were transferred to alternative facilities prior to transfusion) . </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registry, the protocol was not available. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality", all the domains have a low risk of bias.</p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention and this is probably a deviation from the intended intervention that arose because of the trial context. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 453 out of 464 participants. Data of six participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "mortality" in this study, there is a low risk of bias from the randomization process, missing outcome data, measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> <tr class="study-data"> <td> <p>Kirenga 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted block randomisation with varying block sizes ranging from 4 to 8. Generation of randomisation numbers was done by the study biostatistician, who did not have contact with participants. The biostatistician printed individual randomisation numbers with their corresponding treatment assignment and placed each number in an opaque envelope. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-82">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-83"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.2 Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.2.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Korley 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-high col2" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Baseline differences (characteristics are not balanced) in hospitalisation between groups suggesting a problem with randomization. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were blinded to the treatment, but those delivering the intervention were aware of intervention received. There were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received, so it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.2.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention. This could be due to awareness of the intervention, because this trial was open‐label. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 451 out of 464 participants. Data of eight participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The data were collected in structured paper case record forms. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "mortality", there is a low risk of bias from the randomization process, missing outcome data, measurement of the outcome and in selection of the reported result. However, there are some concerns for bias due to deviations from intended interventions. </p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measure was appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.2 Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-83">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-84"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.3 Clinical improvement: participants discharged from hospital</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.3.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was in accordance with the predefined outcomes stated in the trial protocol: "Duration of hospital and ICU stay: both parameters will be analysed as time‐to‐event parameters with competing risk, whereby the event of interest is discharge from hospital/ICU and the competing risk is hospital/ICU death". </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2021b</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized through web‐based simple randomization with allocation concealment in a 1:1:1 ratio to a platform trial in a factorial design, receiving either convalescent plasma in addition to the standard therapy or standard of care alone. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 11,558 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.3.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Gharbharan 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a web‐based system in a 1:1 ratio to the current standard of care at each hospital with or without the addition of convalescent plasma. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there was no information on deviations from intended intervention, as insufficient information was provided on whether treatments were balanced across arms. The analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 86 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome assessors aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement or that the measurement differed between intervention groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was not a pre‐specified outcome from the registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Li 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized via computer‐generated random numbering in a 1:1 ratio to receive standard treatment coupled with convalescent plasma transfusion or standard treatment alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, a total of 101 out of 103 participants were included in the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.3 Clinical improvement: participants discharged from hospital</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-84">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-85"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.4 Grades 3 and 4 adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.4.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>AlQahtani 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized by computer‐generated random numbering in a 1:1 ratio to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate.. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 40 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information available on whether the method of measuring the outcome was appropriate or whether the measurement could have differed between groups, as the data was provided on request by the study investigator and for safety different measurements are possible. The outcome assessors were aware of the intervention received, which is why the knowledge of intervention received could have affected safety outcome assessments, but this is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there was no information on whether the data that produced this result was analysed in accordance with the predefined protocol, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "Grade 3 and 4 adverse events", there is a low risk of bias arising from the randomization process, due to deviations from intended interventions, due to missing outcome data and in the in selection of the reported result. But, there are some concerns for bias in measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Menichetti 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A stratified permuted block randomization procedure with a 1:1 ratio, with blocks of variable sizes and stratification for clinical sites, was generated by using Stata version 16.1 (StataCorp). Eligible patients underwent web‐based treatment allocation through REDcap platform to receive either administration of COVID‐19 CP in addition to standard therapy (ST) or ST alone. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information whether the measurement of the outcome was appropriate. This is an open label trial and the outcome assessors were aware of the intervention allocation, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.4.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Agarwal 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The allocation sequence was random and concealed and there were no differences between intervention groups suggesting a problem with the randomization process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Five participants in convalescent plasma arm and four in control arm did not receive the allocated intervention and this is probably a deviation from the intended intervention that arose because of the trial context. There is no information on whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 451 participants out of 464 participants randomized and the data of eight participants in the convalescent plasma arm and of five participants in the control arm were missing. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on the method of measuring for this outcome, as the data was provided on request by the study investigator. The outcome assessors were aware of the intervention received and the knowledge of intervention received could have affected outcome measurement, but it is probably not likely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with a pre‐specified trial registration, as the data was provided on request by the study investigators. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For the outcome "Grade 3 and 4 adverse events", there is a low risk of bias arising from the randomization process and due to missing outcome data and in the in selection of the reported result. But, there are some concerns for bias due to deviations from intended interventions and in measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Sekine 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomly assigned in a 1:1 ratio to receive two infusions 48 h apart of 300mL of CP plus Standard of Care (SOC) or SOC alone. Randomisation was performed using computer‐generated randomisation with random block sizes of 2 or 4 and stratified according to the unit of hospitalisation on enrolment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information on whether the outcome measure was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized, data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measurement is an appropriate measure and it is unlikely that the measurement differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "Grade 3 and 4 adverse events", there is a low risk of bias for all the domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.4 Grades 3 and 4 adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-85">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-86"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.5 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.5.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bar 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were assigned to treatment or control in a 1:1 ratio using randomization stratified on the use of remdesivir and mechanical ventilation at entry using block randomization with variable block size. There is no information on whether the allocation sequence was concealed. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the statistical analysis plan (SAP). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>Devos 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomised through a computerised system (RedCap®, Vanderbilt University, USA, Version 10.6.13) according to a 2:1 allocation scheme stratified by study site using randomly selected block sizes of 6 or 9, to open‐label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, the serious adverse events are listed in the supplement and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to bias of measurement outcome</p> </td> </tr> <tr class="study-data"> <td> <p>Estcourt 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized via a centralized computer program to each intervention (available locally) starting with balanced assignment. The study will randomly allocate participants to one or more interventions, with each intervention nested within a domain. In this regard, a platform trial is no different to other forms of RCT in that randomization provides the basis for causal inference. However, unlike a conventional RCT, the proportion of participants who are randomized to each available intervention within a domain will not be fixed. Rather, the trial will incorporate RAR. RAR utilizes random allocation with a weighted probability for each intervention, with the weighted probability being proportional to the extent to which similar participants recruited earlier in the trial benefited or not from each particular intervention. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate, the serious adverse events are listed in the supplement and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to bias of measurement outcome</p> </td> </tr> <tr class="study-data"> <td> <p>Koerper 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized using a Web‐based system with a stratified 1:1 allocation ratio between each stratum (Figure 1). Patients were stratified prior to permutated block randomization by presence or absence of ventilation support, ECMO, or ICU treatment. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for (nearly) all participants randomized</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, so the assessment of the outcome could have been influenced by knowledge of intervention received, but it is unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is predefined in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 20.5.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Simonovich 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised through a randomization program (REDCap) in a 2:1 ratio to receive either convalescent plasma or a placebo. The allocation sequence was random and concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>From the 334 participants randomized, data was available for 228 participants in the convalescent plasma group and 105 participants in the placebo group. The data of one participant in control group was missing, due to withdrawal of consent after randomisation and therefore the participant was excluded from the analysis. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome measurement is an appropriate measure and it is unlikely that the measurement differed between intervention groups. The outcome assessors were not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "Serious adverse events", there is a low risk of bias for all the domains. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 20.5 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-86">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-87"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 21.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 21.1.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bennett‐Guerrero 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized 4:1 to CP or SP using permuted block randomization lists generated using SAS software (version 9.4; SAS Institute, Cary NC) and implemented using an interactive web response randomization tool in Research Electronic Data Capture (REDCap). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The individuals who were unblinded were Blood Bank personnel since they needed to label and dispense the masked CP or SP. The bags of CP or SP had an identical label, stating “CP or SP” to preserve blinding. All study personnel who collected data were blinded to study assignment at all times. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol available, but in Supplemental Detailed Methods mentioned</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 21.1.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bajpai 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were block randomized with concealed allocation using the Sequentially Numbered Opaque Sealed Envelopes (SNOSE) method, to receive either convalescent plasma with standard of care or standard plasma (fresh frozen plasma) with standard of care. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants randomized, in total 29 out of 31 participants (2 participants became PCR negative on the day of plasma transfusion). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the trial registration. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "mortality at day 28", there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Baldeon 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This was a random double blinded, non‐convalescent plasma (NCP)‐placebo controlled clinical trial. However, there are no information provided on the concealment of the allocation sequence:"A simple randomization scheme was used to allocate participants in the two treatment groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This study was triple blinded. Hospital personnel at the transfusion medicine services, physicians, and the participants were unaware which plasma was convalescent and which plasma was control. Intention to treat analysis was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for all the 158 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Clinical outcomes were assessed by investigators who were blinded to the treatment groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No protocol was available, but the outcome was pre‐specified in the trial registry.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Some concerns due to bias arising from the randomization process.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 21.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-87">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-88"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 21.2 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 21.2.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>NCT04421404</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Subjects enrolled in the study will be randomized using a web based randomization procedure to receive convalescent plasma versus non‐immune plasma at a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received, there were no deviations from intended interventions and the analysis was appropriate. The nursing staff may be unblinded to the treatment assignment to ensure proper ABO checking of the plasma unit at bedside per standard transfusion procedures. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 34 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The are no information available (as the study still needs to be published in a journal) on whether the measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were blinded to the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 21.2 Clinical worsening: need for invasive mechanical ventilation or death at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-88">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-89"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 21.3 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 21.3.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Bennett‐Guerrero 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Patients were randomized 4:1 to CP or SP using permuted block randomization lists generated using SAS software (version 9.4; SAS Institute, Cary NC) and implemented using an interactive web response randomization tool in Research Electronic Data Capture (REDCap). </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The individuals who were unblinded were Blood Bank personnel since they needed to label and dispense the masked CP or SP. The bags of CP or SP had an identical label, stating “CP or SP” to preserve blinding. All study personnel who collected data were blinded to study assignment at all times. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information available and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome is not pre‐defined in the registry of supplemental material.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr class="study-data"> <td> <p>NCT04421404</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Subjects enrolled in the study will be randomized using a web based randomization procedure to receive convalescent plasma versus non‐immune plasma at a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of intervention received, there were no deviations from intended interventions and the analysis was appropriate. The nursing staff may be unblinded to the treatment assignment to ensure proper ABO checking of the plasma unit at bedside per standard transfusion procedures. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 34 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The are no information available (as the study still needs to be published in a journal) on whether the measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were blinded to the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the predefined outcomes stated in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 21.3 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-89">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-90"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 22.1 All‐cause mortality at up tp day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 22.1.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data that produced this result analysed in accordance with a pre‐specified outcome of the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 22.1.2 Low‐ to middle‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Libster 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomized using an electronic system numbering to receive either convalescent plasma in addition to the standard therapy or standard of care alone and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The participants were unaware of their assigned intervention and those delivering the intervention were aware of intervention assigned during the trial, but there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 160 participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were probably unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome "all‐cause mortality", there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 22.1 All‐cause mortality at up tp day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-90">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-91"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 22.2 Grades 3 and 4 adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 22.2.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is not enough information to judge whether the outcome was measured appropriately.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data that produced this result analysed in accordance with a pre‐specified outcome of the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 22.2 Grades 3 and 4 adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-91">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-92"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 22.3 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 22.3.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Alemany 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a prospective, randomized (1:1), double blind study of Convalescent anti‐SARS‐CoV‐2 MBT Plasma plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID‐19 patients who are non‐hospitalised. However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This outcome was provided on request by the study investgators.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was provided on request.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 22.3 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-92">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-93"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 23.1 All‐cause mortality at up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 23.1.1 High‐income countries</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CoV‐Early</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This trial is a nationwide multicenter, double blind, randomized controlled trial in the Netherlands. Patients will be randomized between the transfusion of 300mL of convP versus regular fresh frozen plasma (FFP). However, there are not enough information avaiable yet on the allocation sequence concealement, as the full text article is not published yet and only the trial registry and requested data are available yet. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and carers and people delivering the intervention were unaware of the assigned intervention received. There is no information available yet ony whether the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial registry does not provide enough information on missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality is an objective outcome measure, appropriately measured and it is unlikely that the measurement differed between intervention groups. The outcome assessors were probably not aware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified outcome in the trial registry. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There are some concerns, as the data was provided on request and the study results are not published yet. </p> </td> </tr> <tr class="study-data"> <td> <p>Sullivan 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants from all sites were randomized by a central web‐based system using blocked assignments to receive ABO compatible control plasma or CCP (both∼250 mL) in a 1:1 ratio. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were blinded, but and those delivering the intervention were aware of intervention received. However, there were no deviations from intended interventions and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified intention‐to‐treat was used, so data for this outcome was available for nearly all participants randomized. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were aware of the intervention received, but it is unlikely that knowledge of the intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There was no information on whether the data that produced this result was analysed in accordance with the predefined outcomes, as there is no protocol available and no information on mortality outcome provided in the trial registry. However, for this mortality outcome, the risk of bias remains still low. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>‐</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 23.1 All‐cause mortality at up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013600.pub6/references#riskOfBias2Table-93">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013600.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013600-note-0027">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013600-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013600-note-0025">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013600-note-0019">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD013600-note-0023">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD013600-note-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013600-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013600\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013600\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013600\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013600\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013600\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013600.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013600.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013600.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013600.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013600.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714894663"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013600.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714894667"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013600.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d79b6add29368',t:'MTc0MDcxNDg5NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 